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Cannabinoid receptors 1 and 2 (CB1 and CB2) belong to the rhodopsin-like family of the G-Protein 
Coupled Receptors (GPCRs). CB1 receptor is highly expressed in the central nervous system, 
while CB2 receptor is expressed mainly in the immune cells and the periphery. Targeting the CB2 
receptor is believed to avoid the psychoactive side effects associated with CB1 receptor. CB2 
receptor has been shown to be involved in several physiological functions as well as diseases, such 
as pain, multiple sclerosis, osteoporosis, and cancer, demonstrating the importance of the CB2 
receptor as a therapeutic target. In the present study, we employed chemistry design and discovery 
to identify novel CB2 ligands, carried out in-vitro functional studies, and evaluated the therapeutic 
potentials. 
Several chemical scaffolds were discovered and evaluated. The di-amide scaffold was 
discovered utilizing pharmacophore drug discovery and molecular docking studies. Several 
derivatives of the di-amide scaffold demonstrated potent and highly selective CB2 inverse agonists 
as well as potent osteoclast (OCL) inhibition capabilities. The di-amide derivatives suffered from 
weak anti-multiple myeloma (MM) properties and poor pharmacokinetic properties. A new 
scaffold was identified utilizing scaffold-hopping and molecular docking studies. However, the 2-
(sulfonylamino)-2-phenylacetamide scaffold demonstrated weak CB2 binding affinity. Due to the 
v 
limitation of the two previous scaffolds, virtual screening and structure-based drug design were 
utilized for scaffold-hopping in order to identify highly potent CB2 specific ligands with new 
scaffolds. A new lead compound was identified and structure activity relationship (SAR) studies 
were conducted on the scaffold 4-(aminomethyl)-N,N-diethylaniline. Several novel compounds 
were discovered with high potency and selectivity towards the CB2 receptor. Cellular function 
assays were applied to characterize the functionality (agonist and inverse agonist) of these 
compounds. Overall, therapeutic studies showed that inverse agonism is essential for the OCL 
inhibition effects while anti-MM experiments showed that CB2 agonists are more effective than 
inverse agonists. 
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1.0  INTRODUCTION 
1.1 THE ENDOCANNABINOID SYSTEM AND THE CANNABINOID RECEPTORS 
1.1.1 THE G-PROTEIN COUPLED RECEPTORS SUPERFAMILY 
The G-protein coupled receptors (GPCRs) represents the largest family of membrane proteins in 
the human genome with more than 800 different GPCRs. GPCRs can be classified based on the 
seven transmembrane (TM) segments into five different subfamilies: Class A – Rhodopsin-like 
family, Class B - Secretin family, Class C -  Glutamate family, Class D - Adhesion family, and 
Class E - Frizzled/taste family [1]. All GPCRs share common structural features and can be divided 
into three parts: the extracellular region, the transmembrane region, and the intracellular region. 
The extracellular region consists of the amino terminus (N'), and extracellular loops (ECL1 – 
ECL3). The transmembrane region consists of seven hydrophobic transmembrane (TM1 – TM7) 
α-helices. And the intracellular region consists of three intracellular loops (ICL1 – ICL3) and a 
carboxyl terminus (C') (Figure 1.1) [2].  
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Figure 1.1. General GPCR structure 
Common structural features of all GPCRs: seven hydrophobic transmembranes (TM1 – TM7), 
three extracellular loops (ECL1 – ECL 3), three intracellular loops (ICL1 – ICL3), extracellular 
amino (N′) terminal, and intracellular carbonyl (C′) terminal 
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GPCRs control several key physiological functions, such as neurotransmission, immune 
responses, cardiac and smooth muscle contraction and blood pressure regulation as well as 
hormone and enzyme regulations. Nevertheless, it has been shown that GPCRs have crucial roles 
in cancer progression and metastasis.  Also, GPCRs represent 50 – 60% of all therapeutic agents 
in the market and it is expected to increase in the following years [3]. 
 
GPCR activation: 
In most GPCRs, the receptor is present in the basal state and different ligand efficiencies alter this 
state. Ligand efficacy is the effect of the ligand on the function of the receptor. Agonists fully 
activate the receptor, partial agonists induce submaximal activation of the G-protein even when 
reaching saturable concentrations, inverse agonists inhibit the basal activity of the receptor, and 
antagonists block competitively the access of other ligands to the receptor.  Upon GPCR activation, 
for example by its endogenous ligand, conformational changes occur within the TM region 
exposing intracellular sites involved in the interaction with the G-protein heterotrimer. G-protein 
heterotrimer contains α, β and γ subunits. Receptor and conformational changes catalyze the 
dissociation of guanosine diphosphate (GDP) bound to the Gα subunit and its replacement with 
guanosine triphosphate (GTP), leading to the dissociation of Gα from the Gβγ subunits. Both 
α•GTP subunits and Gβγ subunit complexes stimulate several downstream effectors, such as ion 
channels or enzymes. Signaling is terminated by the hydrolysis of GTP by the GTPase activity. 
The resulting GDP-bound α-subunit reassociates with the βγ- complex to enter a new cycle [4]. 
The nature of the functionality of GPCRs depends in the numerous subtypes of G-proteins. The α-
subunit can be divided into four families: Gαs, Gαi/ Gαo, Gαq/ Gα11, and Gα12/ Gα13. The α-subunit 
of the Gs protein couples many receptors to adenylate cyclase (AC) and mediates receptor- 
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dependent AC activation resulting in increases in the intracellular cyclic adenosine monophosphate 
(cAMP) concentration. The G proteins of the Gi/Go family are widely expressed and have been 
shown to mediate receptor-dependent inhibition of various types of (AC) resulting in decreases in 
the intracellular cAMP concentrations. The α-subunits of Gq and G11 regulate phospholipase C 
β-isoforms, including β1-, β3-, and β4-isoforms of phospholipase C (PLC). The G proteins G12 
and G13 activate a variety of downstream effectors, such as phospholipase A2, cadherin as well as 
radixin [5].  
 
. 
1.1.2 THE ENDOCANNABINOID SYSTEM 
The endocannabinoid system is composed of cannabinoid receptors and their endogenous 
ligands. A few years after the first isolation and identification of the cannabinoid receptor 1, several 
endogenous ligands were discovered. In 1992, Devane and coworkers first reported the presence 
of a hydrophobic molecule in organic extracts of porcine brain (named anandamide, AEA). Mass 
spectrometry (MS) as well as nuclear magnetic resonance (NMR) studies determined the structure 
of the anandamide and identified it consisting of 20 carbon fatty acid, arachidonic acid, connected 
to ethanolamine through an amide linkage. Anandamide inhibited the specific binding of radio-
labeled cannabinoid ligands in a competitive manner. In addition, anandamide produced a dose-
dependent inhibition of electrically evoked twitch response of the mouse vas deference which 
demonstrates its psychotropic effects [6]. Later, 2-arachidonoylglycerol (2-AG) was discovered 
and characterized as the second endogenous cannabinoid [7].  
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AEA and 2-AG are derivatives of arachidonic acid and are synthesized on demand from 
phospholipids of cell membrane. Both ligands bind, with different affinities, CB1 and CB2 
receptors. It has been shown that 2-AG exhibits high binding efficacy to cannabinoid receptors 
than AEA (Table 1.1) [8]. Several bioactive lipid mediators have been identified as 
endocannabinoids including N-palmitoylethanolamine (PEA), 2-arachidonoyl glycerol ether 
(noladin ether), oleamide, N-arachidonoyl dopamine (NADA), and virodhamine (Figure 1.2).  
6 
 
Figure 1.2. Chemical structures of endocannabinoids 
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These endogenous ligands have been found in the brain, plasma and the periphery with 
varying concentrations. For example, anandamide concentration has been shown to be 200-fold 
lower than 2-AG. However, after receptor stimulation or depolarization, the anandamide 
concentration can rise up to 5-12 folds. Different enzymes and pathways are involved in the distinct 
synthesis of anandamide (and its derivatives, namely N-acylethanolamines) and 2-AG. 
Anandamide is formed by the cleavage of the phospholipid precursor N-arachidonoyl-
phosphatidylethanolamine (NAPE) which is synthesized by the enzyme N-acyltransferase (NAT) 
from phosphatidylethanolamine. NAPE requires the presence of Ca2+ and the regulation by cAMP. 
Finally, phospholipase D (PLD) catalyzes the release of anandamide from NAPE (Figure 1.3) [9]. 
PLD activity is regulated by many receptors, stimuli or neurotransmitters, such as the activation 
of ionotropic glutamate N-methyl-D-Aspartate (NMDA) receptors, nicotinic α7 neuronal 
receptors, dopamine, glutamate, as well as acetylcholine.  
The synthesis of 2-AG includes the cleavage of phosphatidylinositol (PI) to yield 1,2-
diacylglycerol (DAG) which is catalyzed by a phospholipase enzyme, such as phospholipase C 
(PLC). DAG lipase subsequently catalyzes the conversion of DAG to 2-AG (Figure 1.3).  
The degradation of endocannabinoids is mediated by two specific enzymatic systems: the 
fatty acid amide hydrolase (FAAH) for anandamide and related compounds and the 
monoacylglyceride lipase (MAGL) for 2-AG [10, 11].  
Since the discovery and identification of the cannabis active molecule as well as the 
identification of cannabinoid receptors, endocannabinoid research gained a lot of attention to 
understand its physiological roles. It is now understood that endocannabinoids are involved in 
several physiological functions [12, 13]. Endocannabinoids have been shown to regulate cognitive 
functions and emotions in the cortex, hippocampus and amygdale [14].  
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Figure 1.3. Mechanism of anandamide and 2-AG formation 
N-acyltransferase (NAT) catalyzes the formation of N-arachidonoyl-phosphatidylethanolamine 
(NAPE). Subsequently, phospholipase D (PLD) catalyzes the release of anandamide from NAPE. 
Cleavage of phosphatidylinositol by phospholipase C (PLC) releases 1,2-diacylglycerol (DAG) in 
which DAG lipase converts DAG to 2-AG. 
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Endocannabinoids through modulations of the dopaminergic signaling modulate the 
control of movement and posture [15], involved in the regulation of pain perception [16], 
cardiovascular, gastrointestinal and respiratory functions [17, 18].  Endocannabinoids were also 
shown to modulate food intake, pituitary hypothalamus adrenal axis and reproduction [19].  
Under pathological conditions, it has been shown that endocannabinoid levels changes within 
blood and tissues. For example, in neurodegenerative diseases (e.g. Alzheimer’s and Parkinson’s 
diseases), gastrointestinal disorders (e.g. colon inflammation), metabolic disorders (e.g. anorexia 
nervosa) and obesity, higher levels of endocannabinoids have been observed compared to normal 
tissues and states [20]. Importantly, elevated levels of endocannabinoids were observed in many 
tumors, such as colon carcinoma and colon polyps [21], glioblastoma, meningioma [22], prostate 
carcinoma [23], and pituitary adenoma [24]. Furthermore, strong evidence have demonstrated the 
anti-proliferative effects of endocannabinoids in different tumor cells and the involvement of AEA 
as well as 2-AG in the control of cell differentiation, proliferation, and death. Collectively, these 
data suggest critical roles of endocannabinoids as tumor growth modulators [25].   
 
1.1.3 CANNABINOID RECEPTORS 1 (CB1) 
Cannabinoid receptors are members of the Class – A Rhodopsin-like G-protein coupled receptors 
family. Cannabinoid receptor 1 (CB1) was first discovered and isolated in 1990 by Matsuda and 
colleagues from rat cerebral cortex [26]. Further cloning studies by Gerard and coworkers, aided 
the discovery of the CB1 receptors from human brain and testis [27]. The CB1 receptor is a 52.8 
kDa, 472 amino acid polypeptide widely expressed throughout the whole body. It is believed to be 
highly expressed within the brain and the central nervous system (CNS). Specifically, CB1 
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receptor has been isolated from the hippocampus, basal ganglia (striatum, substantia nigra, and 
globus pallidus), cerebral cortex, amygdala, and the cerebellum. In addition, CB1 receptors have 
been found in the periphery, such as the spleen, tonsils, small intestine, and urinary bladder as well 
as low levels in uterus, ovaries, prostate, adrenal gland, and heart [28]. 
The field of cannabinoid research was reinforced with the first cannabinoid drug to reach the 
European market in 2006. SR141716 (commercially known as Rimonabant, developed by Sanofi-
Aventis), a CB1 inverse agonist (Figure 1.9, Table 1.1), was granted an approval in Europe for the 
treatment of obesity by suppressing appetite with potential smoking cessation.  However, the drug 
was withdrawn from the market in 2008 due to the serious side effects including depression and 
suicidal thoughts [29, 30]. 
1.1.4 CANNABINOID RECEPTORS 2 (CB2) 
Cannabinoid receptor 2 (CB2) was cloned from the human promyelocytic leukemia cells (HL-60 
cells) in 1993 by Munro and coworkers [31]. CB2 receptor is a 41 kDa, 360 amino acid polypeptide 
that shares 68% amino acid sequence homology with CB1 receptor within the transmembrane 
region and 44% for the whole protein [31]. Unlike CB1 receptor, CB2 receptors are mainly 
distributed in the periphery with no or limited distribution within the central nervous system. 
Importantly, the CB2 receptor has been found in the marginal zone of the spleen, tonsils, and on 
immune cells such as B-cells, monocytes, and T-cells [28, 31-33]. The high distribution of CB2 
receptors in the periphery and limited distribution in the CNS implies that targeting CB2 receptors 
may avoid any central side effects that may arise from CB1 receptors. Nevertheless, the high 
expression of CB2 receptors on the immune system suggests the involvement of these receptors in 
many pathological and disease states and may serve as a powerful disease target.  
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1.1.5 ORPHAN RECEPTORS 
Sawzdargo and coworkers first identified and cloned the G-protein coupled receptor-55 (GPR55) 
as an orphan receptor in 1999. GPR55 was reported to be highly expressed in the CNS especially 
the striatum [34]. It is also found in the gastrointestinal tract as well as in the adrenal glands [35]. 
In addition, Whyte et al. reported that GPR55 was highly expressed in osteoclasts and osteoblasts 
which played roles in bone regulation and function [36]. GPR55 is classified as a class-A 
rhodopsin-like GPCR with low sequence similarity to CB1 (13.5%) and CB2 (14.4%) receptors 
[1]. Upon activation, GPR55 couples to Gα13 subunit which leads to stimulation of numerous 
GTPases including Ras Homology gene Family (member A: RhoA), Ras-related C3 botulinum 
toxin substrate 1 (rac1), cell division control protein 42 homolog (cdc42) [35, 37].  
Stimulation of GPR55 induces F-actin formation under the control of Gα13, RhoA and Rho-
associated, coiled-coil containing protein kinase (ROCK). GPR55 activation also induces 
intracellular calcium release and activation of the transcription factors nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB), nuclear factor of activated T-cells (NFAT) and 
cAMP response element-binding (CREB) [38]. 
Ligand binding data showed that GPR55 binds to and is activated by the cannabinoid ligand 
CP55,940 (CB1 and CB2 receptor agonist). Furthermore, endocannabinoids including anandamide 
and virodhamine activate [35S]GTPγS binding via GPR55 with nM potencies [35]. Nevertheless, 
there are conflicting data regarding ligands’ binding to GPR55 which hesitated scientists to name 
GPR55 a cannabinoid receptor. Until today, GPR55 classification remains questionable and needs 
further studies [39]. 
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1.1.6 CANNABINOID RECEPTORS SIGNALING 
1.1.6.1 G-protein coupling 
Both receptors couple with high affinity to the G-protein Gαi/o this was analyzed by utilizing the 
[35S]GTPγS binding experiments in rat membrane proteins and in CHO cells expressing 
recombinant human CB2 receptors. Upon the activation of the Gαi/o with cannabinoid agonists, the 
subunit dissociates from the βγ dimer allowing the Gαi/o subunit to associates with its effector 
molecule (i.e. adenylate cyclase) (Figure 1.4). 
It has been shown by Glass and coworker that unlike CB2 receptors, CB1 receptors were able to 
couple to Gs subunit in the absence of a functional Gαi/o protein and in the presence of pertussis 
toxin (PTX). PTX catalyzes ADP-ribosylation which uncouples the receptor from Gi proteins thus 
inactivating the G-protein resulting in high levels of cAMP [40]. 
1.1.6.2 Regulation of adenylate cyclase 
Coupling of CB1 and CB2 receptors to Gαi/o subunit inhibit the production of adenylate cyclase 
(AC) in endogenous expression of these receptors in N18TG2 neuroblastoma cells leading to the 
inhibition of cAMP. As this response was blocked by PTX, it suggests the involvement of Gαi/o 
proteins. Similarly, for CHO transfected with CB1 and CB2 receptors, AC was inhibited leading 
to the inhibition of cAMP production in these cell-lines. AC inhibition or stimulation is critical in 
characterizing the functionality of cannabinoid ligands as the levels of cAMP can aid to distinguish 
between agonists and antagonists/inverse agonists (Figure 1.4). Cannabinoid agonists such as 
anandamide, WIN55212-2, and CP55,940 inhibited AC activity in rat cerebellum and in CHO cells 
transfected with CB1 and CB2 receptors highlighting that these ligands are cannabinoid agonists. 
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Figure 1.4. G-protein coupling and the regulation of adenylate cyclase. 
Cannabinoid activation by agonists promotes the dissociation of GDP bound to the Gα subunit and 
replaces it with GTP. As a result, the Gα subunit dissociates from the Gγβ heterodimer subunit. 
The Gα then inhibits AC, thus inhibiting cAMP formation. 
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On the other hand, antagonist stimulation of CB1 and CB2 receptors inhibits the 
dissociation of the Gαi/o subunit from the βγ dimer blocking the subunit to interact with its effector 
molecule AC and thus stimulating cAMP production. 
1.1.6.3 Ceramide production through sphingomyelin hydrolysis and de novo synthesis 
Ceramide is a lipid second messenger that has been shown to play important roles in the control 
of cell fate. CB1 receptor couple to the hydrolysis sphingomyelin by inducing sphingomyelinases 
in primary astrocytes and glioma cells which in turn increases the levels of ceramide. Increased 
ceramide levels has been shown to link the CB1 receptors to the activation of ERK 1/2 pathway 
through the mobilization of Raf-1. In primary astrocyte cultures, AEA, Δ9–Tetrahydrocannabinol 
(Δ9 –THC, phytocannabinoid), and HU-210 (CB1/CB2 non-selective agonist) induced rapid 
transient elevation of ceramide levels leading to increased glucose metabolism. This effect was 
inhibited by the selective CB1 inverse agonist (SR141716) suggesting a CB1 mechanism [40]. 
Sanchez et al. showed that the sphingomyelinases may be activated in G-protein-independent 
manner through an adaptor protein FAN (factor associated with neutral sphingomyelinase), which 
binds to the CB1 C-terminus leading to the coupling of CB1 receptor to stimulate 
sphingomyelinase activation, release of ceramide, and activation of the Raf-1/MAPK cascade [41]. 
It has been shown that chronic CB1 and CB2 activation in C6 glioma cells were also responsible 
in the de novo ceramide synthesis which activated ERK 1/2 via Raf-1 and subsequently activating 
MAPK leading to the initiation of apoptosis and cell death rather than glucose metabolism [42, 
43].  
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1.1.6.4 Regulation of mitogen-activated protein kinase (MAPK) 
Cellular functions such as cell growth, differentiation, proliferation, apoptosis as well as cell fate 
is controlled via complex signaling pathways. Among the important pathways is the MAPK 
pathway. Several researchers have investigated the relationship between cannabinoids and the 
MAPK signaling pathways. Normally the activation of this pathway is initiated by the activation 
of tyrosine kinase receptors (TYR) leading to the activation of the G protein Ras and thus activating 
MAP kinase kinase (MEK) leading to the phosphorylation and activation of MAPK cascade.  In-
vitro cell-culture studies on the signaling transduction pathways of cannabinoids utilizing WI-38 
fibroblasts, U373MG astrocytic cells, C6 glioma cells, and primary astrocytes expressing 
recombinant CB1 receptors showed p42/p44 MAPK (known as extracellular protein kinase 1 and 
2, ERK 1 and 2) activation which was inhibited by SR141716. As a result of the Gi/o coupling of 
CB1 receptors, the βγ dimer complex serves as a scaffold protein in the MAPK activation. This 
mechanism was blocked by the phosphatidylinositol-3-kinase (PI3K) inhibitors wortmannin and 
LY294002 suggesting the involvement of PI3K activation and the subsequent recruitment of 
protein kinase B (PKB), also known as Akt. The phosphorylation of PKB then phosphorylates and 
activates the three-kinase module of Raf-1, MAPK-ERK (MEK), and p42/p44 MAPK. 
Experiments utilizing WIN55212-2 in N1E-115 neuroblastoma cells and hippocampal 
slice preparations suggested an alternative mechanism for the regulation of p42/p44 MAPK 
activity. The CB1 Gi-mediated inhibition of cAMP production and reduction of PKA would 
promote the dephosphorylation of c-Raf, thus permitting the Raf kinase to activate MEK in the 
p42/p44 MAPK kinase module [44, 45].  
In cells expressing recombinant CB2 receptors (human promyelocytic-HL60 cells and 
CHO cells), phosphorylation of p42/p44 MAPK was observed, however, the PI3K pathway was 
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not involved. Studies on rat RTMGL1 microglial cells expressing CB2 receptors showed that 2-
arachidonylglycerol (2-AG) activated the p42 MAPK activity and promoted cell proliferation [46]. 
In addition, stimulation of CB2 receptors in human prostate epithelial PC3 cells with Δ9-THC or 
methanandamide activated the PI3K/PKB pathway and subsequently translocated Raf-1 to the 
membrane and phosphorylates p42/p44 MAPK. This effect was inhibited by SR144528 (CB2 
inverse agonist) suggesting the involvement of CB2 receptors [47]. 
1.1.6.5 Immediate early genes: Krox 24 and Fos transcriptional factors 
The activation of MAPK can induce the expression of immediate early genes such as Krox 24 (a 
zinc finger-binding transcription factor involved in growth, differentiation, and proliferation of 
cells), and Fos (able to regulate numerous transcriptional genes) in different regions of the brain 
following cannabinoid agonist stimulation. In U373MG human astrocytoma cells, Krox 20, Krox 
24 and Jun B expression was mediated through the CB1 receptors [48], while the CB2 receptors 
mediated the expression of Krox 24 in HL 60 promyelocytes cells with downregulation of Fos [49, 
50]. Cannabinoid agonists activated c-Jun N-terminal kinase (JNK1 and JNK2) in CHO cells 
expressing recombinant CB1 receptors. The mechanism of JNK activation is mediated through 
Gi/o coupling, PI3K, and Ras activation as explained by Rueda and coworkers [51]. 
1.1.6.6 Modulation of ion channels 
CB1 signaling has been shown to inhibit Ca2+ influx by L-, N-, P/Q-, and R-type voltage operated 
calcium channels (VOCCs). The effect was PTX sensitive suggesting the involvement of Gi/o 
protein coupling. As these effects were evident in the central neurons (presynaptic neurons), it 
suggests the involvement of CB1 receptors as these receptors are highly expressed compared to 
CB2 receptors. 
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Cannabinoid agonists WIN55212-2, CP55,940, and anandamide (endocannabinoid) 
inhibited N-type calcium channels via the CB1 receptor leading to a decrease in Ca2+ levels. 
Mackie and coworkers demonstrated that the decrease in Ca2+ levels was cAMP-independent since 
the response was not reversed by the addition of the synthetic cAMP (8-bromo-cAMP) [52]. 
Sugiura and colleagues measured the intracellular Ca2+ levels using fura-2 fluorescence studies in 
high K+ depolarized NG108-15 cells. 2-AG and anandamide inhibited the depolarization-evoked 
Ca2+ concentration and studies have shown that the N-type Ca2+ channel played a role in the 
depolarization since the N-type channel antagonist, ω-conotoxin, blocked this response [53, 54]. 
Utilizing neuronal expression systems, rat cervical ganglion transfected with CB1 receptors 
showed an inhibition in Ca2+ currents when treated with cannabinoid agonists such as WIN55212-
2 and CP55,940. Further studies showed that these effects were PTX and ω-conotoxin sensitive 
confirming that these effects were on N-type Ca2+ channels. Furthermore, utilizing rat striatal 
neurons transfected with CB1 receptors, WIN55212-2 inhibited corticostriatal glutamatergic 
synaptic transmission which was also PTX and SR141716 sensitive and ω-conotoxin reversed this 
inhibition [55, 56]. 
Studies on AtT-20 pituitary tumor cells expressing recombinant CB1 receptors (not CB2 receptors) 
showed that anandamide and WIN55212-2 inhibited the Q-type Ca2+ currents which was PTX 
sensitive [57]. Utilizing fura-2 fluorescence studies in rat cortical and cerebellar brain slices 
showed that the P/Q-type Ca2+ fluxes were inhibited by anandamide and which was mediated 
through the Gi/o protein-couples CB1 receptors as this effect was PTX and SR141716 sensitive 
[58]. 
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CB1 receptors can also regulate the L-type Ca2+ currents. In rat brain arterial smooth muscle cells 
endogenously expressing CB1 receptors, anandamide and WIN55212-2 inhibited the L-type Ca2+ 
currents which was blocked by SR141716 and PTX [59]. 
1.1.6.7 Modulation of intracellular calcium concentration  
Intracellular calcium concentration was increased by 2-AG and WIN55212-2 in NG108-15 
neuroblastoma-glioma hybrid and N18TG2 neuroblastoma cells expressing CB1 receptors as 
determined by fura-2 fluorescence studies [53, 60]. Studies have shown the Ca2+ uptake by CB1 
receptors couples to Gs protein, cAMP production, and protein kinase A (PKA) activation [61]. In 
addition, another mechanism highlights the coupling through Gi/o leading to tyrosine receptor 
kinase transactivation, PKC phosphorylation and the regulation of MAPK activity [62]. 
Interestingly, the phospholipase C (PLC) inhibitor U73122 blocked this response suggesting the 
involvement of an inositol 1,4,5-triphosphate (IP3)-mediated release of Ca
2+ [53, 60]. 
In calf pulmonary endothelial cells expressing CB2 receptors, anandamide increased calcium 
concentration and this effect was blocked by the CB2 inverse agonist SR144528 not the CB1 
inverse agonist SR141716. The mechanism of the increase of Ca2+ levels resulted from the 
activation of phospholipase C [63]. 
1.1.6.8 Modulation of inwardly rectifying K+ channels 
CB1 is coupled to the activation of the inwardly rectifying potassium currents (Kir). In AtT-20 
pituitary tumor cells exogenously expressing CB1 receptors and HEK 293 cells endogenously 
expressing CB1 receptors, anandamide and WIN55212-2 activated the Kir currents. The effect was 
PTX sensitive and was inhibited by AM251 (CB1 inverse agonist) implementing that Gi/o 
involvement in these currents and this phenomena is known as the G-protein coupled inwardly 
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rectifying potassium channels (GIRKs). In addition, cAMP levels and PKA activity were not 
altered suggesting that a direct interaction exists between the G protein subunit and the ion 
channels [57, 64]. Studies in AtT-20 cells expressing CB2 receptors showed that these receptors 
has no effect on the GIRK or calcium channels [57]. 
1.2 CANNABINOID RECEPTOR LIGANDS 
Cannabis sativa is one of the oldest plants to have been used as a medicine for a variety of diseases 
as well as for religious ceremonies and recreationally [65]. The therapeutic indications of cannabis 
stretches back for over 5000 years and many literature reported the use of the plant as an analgesic 
[66, 67], an anesthetic [68], an anti-inflammatory agent [69], for the treatment of hemorrhoids , 
and as an appetite stimulant [70].  Cannabinol (CBN) was the first phytocannabinoid to be isolated 
from cannabis and its structure was elucidated in the early 1930s by Cahn and coworkers 
(Figure 1.5). However, the first synthesis of CBN was achieved by two research groups Adam et 
al. in 1940 [71, 72] as well as by Todd and colleagues. Several derivatives of CBN were 
synthesized, such as Δ6a,10a-tetrahydrocannabinol (Δ6a,10a-THC) and its hexyl analog, synhexyl 
(also known as pyrahexyl or parahexyl) (Figure 1.5).   
 Two additional phytocannabinoids were isolated and identified, (-)-cannabidiol (CBD) and 
cannabidiolic acid by Adams and colleagues (Figure 1.5). Tetrahydrocannabinoids were extracted 
from cannabis and reported to exist as racemic mixtures of Δ9-tetrahydrocannabinol (Δ9-THC) and 
Δ8-tetrahydrocannabinol by Loewe and coworkers. In 1964, Gaoni and Mechoulam isolated and 
characterized the main active constituent of the plant Cannabis sativa, Δ9-THC (Figure 1.5) [70]. 
The activity Δ9-THC was evaluated in a number of animal models including cataleptic reactions 
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in mice, motor activity and gross behavior in mice and rats as well as experiments on rhesus 
monkeys [8, 73, 74].  
In the early 1970s, the cannabis use increased dramatically for recreational purposes in USA and 
UK as well as other Western countries. This potentiated the synthesis and pharmacological studies 
of Δ9-THC. Consequently, experiments focused mainly on determining the active component 
related to the psychoactive properties of cannabis. Utilizing animal as well as human experiments 
on evaluating the effects of Δ9-THC, showed that indeed Δ9-THC is the main psychoactive 
component in cannabis. Following these studies and discoveries, several other constituents of 
cannabis such as cannabigerol, cannabichromene, and cannabicyclol were identified (Figure 1.5) 
[65]. 
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Figure 1.5. Chemical structures of plant cannabinoids (phytocannabinoids) and synthetic 
cannabinoids. 
Chemical structures of phytocannabinoids: cannabinoid, cannabidiol, cannabidiolic acid, Δ9-THC, 
Δ8-THC, cannabigerol, cannabichromene, cannabicyclol as well as chemical structures of 
synthetic cannabinoids: Δ6a,10a-THC and synhexyl. 
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The structural characterization of Δ9-THC paved the path toward cannabinoid research. Several 
research groups focused on cannabinoid research resulting in the design and synthesis of several 
structurally diverse classes of cannabinoid ligands. The cannabinoid receptor ligands can be 
classified into non-selective agonists, selective agonists, and selective antagonists/inverse 
agonists.  
A. Non-selective agonists: 
These ligands can bind and interact with both the CB1 and CB2 receptors with similar potency. 
Non-selective cannabinoid agonists can be classified according to their chemical structure to: 
classical, non-classical, aminoalkylindole, and eicosanoid (Figure 1.6). 
1. Classical cannabinoids: classical cannabinoid ligands contain the dibenzopyran 
pharmacophore in their chemical structures. The classical cannabinoids include Δ9-THC 
(Figure 1.5) and its synthetic analog (6aR)-trans-3-(1,1-dimethylheptyl)-6a,7,10,10a-
tetrahydro-1-hydroxy-6,6-dimethyl-6Hdibenzo[b,d]pyran-9-methanol (HU-210). HU-210 
showed higher affinity to the CB1 and CB2 receptors than Δ9-THC (Table 1.1).  
2. Non-classical cannabinoids: these ligands are analogs of Δ9-THC possessing bicyclic and 
tricyclic rings and lacking the pyran ring of Δ9-THC. The most commonly used chemical 
probe in biochemical assay is (-)-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-
(3-hydroxypropyl)cyclohexanol (CP55,940). CP55,940 showed slight lower CB1 and CB2 
affinity than HU-210 but higher than Δ9-THC (Table 1.1).  
3. Aminoalkylindole: these group of ligands differ significantly from classical and non-
classical cannabinoids. The most common ligand in this group is R-(-)-[2,3-dihydro-5-
methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-
naphthalenylmethanone mesylate (R-(+)-WIN55212-2). The (R)-(+)-isomer exhibits the 
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significant agonist activity while its (S)-(-)-isomer does not show any affinity to the 
cannabinoid receptors.  
4. Eicosanoid: these cannabinoid differ significantly from other groups. Members of this 
group include the endocannabinoids AEA and 2-AG (Figure 1.2). AEA behaves as partial 
agonist with similar affinity to the CB1 receptor as Δ9-THC. All eicosanoid cannabinoids 
showed lower affinity to the CB2 receptor than CB1 receptor (Table 1.1).  
 
 
Figure 1.6. Non-selective CB1 and CB2 agonists. 
Chemical structures of non-selective CB1 and CB2 agonists: HU-210, WIN55212-2 and 
CP55,940. 
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B. Selective CB1 and CB2 agonists: 
1. Selective CB1 agonists: these include the synthetic analogs of AEA: R-(-)-
methanandamide, arachidonyl-2'-chloroethylamide (ACEA), and 
arachidonylcyclopropylamide (ACPA), as well as 2-arachidonyl glyceryl ether (noladin 
ether) (Figure 1.7).  
 
Figure 1.7. Selective CB1 agonists 
Chemical structures of CB1 selective agonists R-(-)-methanandamide, arachidonyl-2'-
chloroethylamide (ACEA), and arachidonylcyclopropylamide (ACPA), as well as 2-arachidonyl 
glyceryl ether (noladin ether) 
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2. Selective CB2 agonists: can be classified according to their chemical structure into: 
classical, non-classical, and aminoalkylindole (Figure 1.8).  
a. Classical: includes the THC derivatives such as (6aR,10aR)-3-(1,1-dimethylbutyl)-
6a,7,10,10a-tetrahydro-6,6,9 trimethyl-6H-dibenzo[b,d]pyran (JWH-133) 
b. Non-classical: {4-[4-(1,1-dimethylheptyl)-2,6-dimethoxy-phenyl]-6,6-
dimethylbicyclo[3.1.1]hept-2-en-2-yl}times-methanol (HU-308) 
c. Aminoalkylindoles: includes (2-methyl-1-propyl-1H-indol-3-yl)-1-
naphthalenylmethanone (JWH-015) and R-3-(2-iodo-5-nitrobenzoyl)-1-methyl-2-
piperidinylmethyl)-1H-indole (AM1241) 
 
Figure 1.8. Selective CB2 agonists 
Chemical structures of the CB2 selective agonists: JWH-133, HU-308, JWH-015, and AM1241 
 
26 
C. Selective CB1 and CB2 inverse agonists/antagonists: 
1. Selective CB1 inverse agonists: 
Include ligands that can block the agonist-induced activation of CB1 receptors in a 
competitive manner and bind with significantly greater affinity to CB1 than CB2 receptors. 
These include the diarylpyrazole Rimonabant (SR141716), N-(piperidin-1-yl)-5-(4-
iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251), 1-
(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-4-morpholinyl-1H-pyrazole-3-
carboxamide (AM281), 4-[[6-methoxy-2-(4-methoxyphenyl)-3-benzofuranyl]carbonyl] 
benzonitrile (LY320135), and taranabant (MK-0364) (Figure 1.9).  
2. Selective CB1 antagonists: 
These are ligands that are able to block the CB1 receptor without any reverse agonism 
effects. Examples of these ligands include: the structural analog of Rimonabant, N-
piperidinyl-[8-chloro-1-(2,4-dichlorophenyl)-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-
c]pyrazole-3-carboxamide] (NESS O327), and (6aR,10aR)-3-(1-methanesulfonylamino-4-
hexyn-6-yl)-6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran (O-2050), 
which is the sulfonamide analog of Δ8-THC with an acetylenic side chain (Figure 1.9).  
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Figure 1.9. Selective CB1 inverse agonists/antagonists. 
 (A) Chemical structures of CB1 inverse agonists SR141716 (Rimonabant), AM251, AM281, MK-
0364 (Taranabant), and LY320135. (B) Chemical structures of CB1 neutral antagonists NESS 
0327, and O-2050. 
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3. Selective CB2 inverse agonists:  
These are ligands that block the agonist-induced CB2 receptor activation in a competitive 
manner, include [6-Iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-
yl](4methoxyphenyl)methanone (6-iodopravadoline) (AM630), the diarylpyrazole N-
[(1S)-endo-1,3,3-trimethyl bicyclo [2.2.1]heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-
methylbenzyl)-pyrazole-3-carboxamide (SR144528), and N-(1,3-benzodioxol-5-
ylmethyl)-1,2- dihydro-7-methoxy-2-oxo-8-(pentyloxy)-3-quinolinecarboxamide (JTE-
907) (Figure 1.10) [75]. 
 
Figure 1.10. Selective CB2 inverse agonists. 
Chemical structure of CB2 inverse agonists SR144528, AM630, and JTE-907 
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Table 1.1. Binding affinities (Ki) of CB1 and CB2 ligands 
Cannabinoid Receptor Ligand 
Binding Affinity (Ki) 
nM Reference 
CB1 CB2 
Non-selective CB1 and CB2 agonists    
 Δ9-THC 41 36 [76] 
 HU-210 0.06 0.17 [39] 
 Anandamide (AEA) 61 279 [39] 
 2-AG 58 145 [77] 
 R-(+)-WIN55212 1.9 0.3 [76] 
 CP55,940 0.5 0.7 [78] 
Selective CB1 agonists    
 R-(-)-methanandamide 17.9 815 [39] 
 ACEA 1.4 195 [39] 
 ACPA 2.2 715 [39] 
 Noladin ether 9.1 480 [79, 80] 
Selective CB2 agonists    
 JWH-133 677 4.0 [81] 
 HU-308 > 10,000 22.7 [82] 
 JWH-015 383 14 [76] 
 AM1241 280 3.4 [83] 
Selective CB1 inverse agonists 
 SR141716 1.8 514 [84] 
 AM251 7.49 2290 [85] 
 AM281 12 4200 [86] 
 MK-0364 0.13 170 [87, 88] 
Selective CB1 antagonists    
 NESS 0327 0.00035 21 [89] 
 O-2050 6.8 250 [39] 
Selective CB2 inverse agonists    
 SR144528 437 0.6 [90] 
 AM630 5152 30 [91] 
 JTE-907 2370 35.9 [92, 93] 
The binding affinities (Ki) were measured by utilizing the radio-ligand displacement assay of labeled 
ligands (CP55940, SR144528, and/or SR141716). Binding affinities are expressed in nM. 
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1.3 THERAPEUTIC SIGNIFICANCE OF CANNABINOIDS 
The endocannabinoid system (cannabinoids, cannabinoid receptors, and the proteins responsible 
for their synthesis, transports, and degradation) are highly expressed in different tissues of the 
body. It has been proven that the endocannabinoid system is involved in different regulatory 
functions such as the control of cardiovascular tone, energy metabolism, in the immune system, as 
well as in the reproductive system [94].  
There are number of cannabinoid drugs that made it to the clinic in the past 30 years. The cannabis 
main active component, Δ9-THC (dronabinol), itself reached the clinic as an anti-emetic drug for 
cancer patients and as an appetite stimulant for patients with AIDS in 1985 and 1992, respectively, 
and was marketed under the name Marinol® (Solvay Pharmaceuticals) [95, 96]. The synthetic 
analog of Δ9-THC, known as nabilone, which is a non-selective CB1/CB2 receptor agonist was 
prescribed for the suppression of nausea and vomiting in chemotherapeutic patients and marketed 
under the name Cesamet® (Meda Pharmaceuticals) in 1981 [95]. Sativex® (GW 
Pharmaceuticals), which is a combination of Δ9-THC and cannabidiol [97]. This drug was licensed 
in Canada in 2005 as an adjunctive treatment for the symptomatic relief of neuropathic pain in 
adults with multiple sclerosis [98, 99] and it is currently in phase III clinical trials for cancer pain 
patients [100].  
As the high expression levels of CB1 receptors in the brain, especially in areas regulating 
appetite/satiety and the presence of these receptors in the gastrointestinal track as well as adipose 
tissues [101], research groups have focused on the potential weight loss mechanism when targeting 
the CB1 receptors [102]. As noted by several researchers, animals treated with cannabinoid 
agonists showed dramatic weight gain and obesity and this effect was not observed in CB1 receptor 
knockdown animals [103]. Based on these observations, possible blocking these receptors maybe 
31 
a new weight loss mechanism. Sanofi-Aventis Pharmaceuticals developed the first CB1 receptor 
inverse agonist for the purposes of appetite suppression and weight loss. The selective CB1 
receptor inverse agonist SR141716, known as rimonabant (Acomplia®), reached the European 
market in 2006 [104, 105]. However, the US Food and Drug Administration (FDA) did not 
approve the marketing of the drug in the US due to some of the psychiatric side effects that were 
found in rimonabant’s clinical trials [29, 30]. Eventually, the drug was withdrawn from the 
European market in 2008 when two patients on rimonabant committed suicide. Yet, CB1 blockade 
may still seem a valuable target in the field of weight regulation, and energy balance. Efforts should 
be focused on delivering such drugs without crossing the blood brain barrier in order to reduce 
psychoactive adverse effects. Furthermore, developing neutral antagonists lacking the CB1 inverse 
agonists’ activities or developing periphery selective agents that do not target the CB1 receptors 
in the brain. The high expression of CB2 receptors in the periphery and immune tissues, however, 
accounts for its promising therapeutic uses without developing serious psychoactive side effects, 
albeit no approved CB2 selective drug has been approved, yet. 
1.3.1 CANNABINOIDS AND TUMOR GROWTH 
Cancer, the uncontrolled differentiation of cells, accounts for more than 14 million new cases and 
approximately 8.2 million deaths in 2012 worldwide, according to the World Health Organization. 
In the United States, there are more than 1.5 million new cases and more than 585 thousand deaths 
occurred due to cancer in 2014. Both sexes showed high mortality rates and new cases of lung 
cancer followed by prostate and breast cancers for men and women, respectively [106]. To date, 
cancer remains an invasive and incurable disease despite the continuous development of new 
treatments and methods.  
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Recently, cannabinoid receptors has been proven to be upregulated in tumor tissues 
compared to normal tissues. Specifically, cannabinoid receptors are highly expressed in different 
cancer tissues such as breast, prostate, and bone cancers suggesting these receptors are valuable 
targets for cancer cell attenuation [107]. Nomura and Thors showed aggressive tumor progression 
was observed associated with the upregulation of endocannabinoid-degrading enzymes in human 
tumor and cancer cell-lines. In mouse xenograft, reduction in the expression of monoacylglycerol 
lipase (the enzyme responsible for the degradation of endocannabinoid) reduced tumor growth and 
progression [108, 109]. Nevertheless, cannabinoids have been shown to play crucial roles as anti-
tumor agents by reducing inflammation, cell proliferation, and cell survival. Munson and 
colleagues reported the first anti-tumor properties of cannabinoids in 1975. They reported the 
administration of Δ9-THC inhibits lung adenocarcinoma growth in-vitro and in-vivo [110]. Since 
then the anti-cancer effects of cannabinoids have been studies extensively in order to understand 
the underlining mechanisms of these effects. 
Anti-cancer signaling of cannabinoids: 
The mechanism of the anti-tumor properties of cannabinoids is not fully illustrated. 
Cannabinoids exhibit anti-tumor activity through modulations of cell growth, cell migration, and 
apoptosis. These mechanisms differ with respect to cancer types and tissues. Figure 1.11 illustrates 
the anti-cancer signaling pathways of CB2 receptors. As previously explained, cannabinoids 
induce the de novo synthesis of ceramides. Ceramide activates the downstream signaling of ERK 
cascade resulting in cell-cycle arrest and apoptosis. Increasing ceramide levels due to cannabinoid 
stimulation, activates the p38-MAPK pathway. Activation of the p38-MAPK pathway leads to 
apoptosis through the activation of cysteine protease (caspases). Ceramide release may also 
activates the release of cytochrome c from the mitochondria to activate caspases leading to 
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apoptosis. Furthermore, increased ceramide levels co-recruits the activating transcription factor 4 
(ATF4), tribbles homolog 3 (TRB3) and C/EBP homologous protein (CHOP) from the 
endoplasmic reticulum, all of which are involved in cellular response to stress stimuli leading to 
the downstream inhibition of protein kinase B (Akt) reducing the phosphorylation of I kappa B 
kinase (IKK) and thus inhibiting the nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-kB) activation and translocation [111]. Cannabinoid are coupled through the Gi/o proteins 
inhibiting adenylate cyclase production, thus reducing the cAMP levels. Reducing cAMP levels 
has been shown to inhibit the downstream protein kinase A (PKA) leading to apoptosis. Sustained 
activation of ERK induces the cyclin kinase inhibitor (p27/KIP1) resulting in cell-cycle arrest and 
apoptosis [107, 112]. CB2 receptor stimulation has been shown to inhibit the production of 
vascular endothelial growth factor (VEGF), thus inhibiting the migration, proliferation, and cell-
survival of cancer cells through inhibiting angiogenesis [111].  
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Figure 1.11. Anti-cancer signaling of CB2 receptors 
Stimulation of CB2 receptor induces a de novo synthesis of ceramide leading to increase 
concentrations of ceramide levels. Ceramide activates ERK cascade leading to cell-cycle arrest 
and apoptosis. In addition, ceramide activates p38-MAPK leading to the activation of caspases and 
apoptosis. Ceramide also activates the release of cytochrome c thus activating caspases and 
apoptosis. Ceramide also induces ER stress activating ATF4, TRB3 and CHOP leading to the 
inhibition of Akt and NF-kB. Inhibition of AC reduces the levels of cAMP leading to the inhibition 
of PKA. CB2 receptor stimulation also inhibit VEGF thus inhibiting migration, survival and 
proliferation. 
 
 
 
 
35 
1.3.1.1 Breast cancer 
Breast cancer accounts for 29% (~232 thousand) of new cancer cases and 15% (~72 
thousand) of cancer deaths in the United States during 2014. Breast cancer is highly invasive and 
can metastasize to other organs such as lymph nodes, lungs, and bones. Studies show that there is 
high expression of CB2 receptors in breast cancer tissues and cell-lines compared to CB1 
receptors. In addition, there is high correlation of the expression of CB2 receptors with known 
breast cancer markers such as estrogen and progesterone receptor levels, as well as the presence 
of the ERBB2/HER-2 oncogene [113]. Recently, the endocannabinoid system was shown to play 
important roles in tumor growth, apoptosis, and angiogenesis of breast cancer. Several breast 
cancer cell-lines were tested for the ability of cannabinoids to attenuate cancer growth. Δ9-THC 
and cannabidiol (CBD) inhibited cell proliferation, induced apoptosis, and reduced migration in 
different breast cancer cell-lines. The mechanism was blocked by SR144528 (CB2 receptor inverse 
agonist) suggesting the roles of CB2 receptors. Qamri and co-workers investigated the effects of 
synthetic cannabinoids on different breast cancer cell-lines. Selective CB2 agonist JWH-133 at a 
dose of 10 µM was able to reduce breast cancer tumor growth, inhibit cancer migration, and induce 
apoptosis by caspase signaling cascade in MDA-MB231 and MDA-MB468 breast cancer cell-
lines. In addition, JWH-133 was able to inhibit angiogenesis in different breast cancer cell-lines 
[114]. Endocannabinoids were also shown to have anti-tumor activity. Anandamide, 2-AG and 
methanandamide inhibited the proliferation, metastasis, and induced apoptosis of breast cancer 
cell-lines. Their underlining mechanism involved the utilization of CB1 and/or CB2 receptors 
[107]. 
In-vivo studies showed the ability of cannabinoids to attenuate tumor growth, migration, 
and angiogenesis. According to Caffarel et al., Δ9-THC was able to inhibit cell proliferation and 
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angiogenesis in metastasis breast cancer animal model. This effect is mediated through the CB2 
receptors, not the CB1 receptors. Further, the CB2 selective agonist JWH-133 was able to decrease 
size and number of tumors, reduces lung metastases, inhibit cell proliferation, and reduce 
angiogenesis in mice injected with different breast cancer cell-lines [114, 115]. In mice injected 
with the breast cancer cell-lines MDA-MB-231 and 4T1, cannabidiol reduced tumor size and 
decreased number of lung metastases [116].  Collectively, these data illustrates the importance of 
the endocannabinoid system in the cancer pathology and suggesting possible new target for future 
drugs targeting the cannabinoid receptors, particularly the CB2 receptors.  
1.3.1.2 Prostate cancer 
Prostate cancer is the tumor of the prostate gland in the male reproductive system. It is 
considered the second most frequently diagnosed tumor in men [117]. In 2014, over 233 thousand 
new cases were diagnosed and over 29 thousand of patients die from prostate cancer in the United 
States [106]. Prostate cancer can metastasize to other parts of the body, particularly the lymph 
nodes and the bones [118, 119]. 
Several studies have explored the involvement of the cannabinoid system in prostate cancer. The 
expression level of cannabinoid receptors in prostate cancer cell-lines were assessed and showed 
upregulated expression of CB1 and CB2 receptors in a wide range of cell-lines such as PC-3, DU-
145, CWR22Rv1, LNCaP, and CA-HPV-10) as well as human prostate cancer tissues [47, 120-
122]. In-vitro studies showed the ability of cannabinoids and endocannabinoids to attenuate 
prostate cancer growth and progression. Velasco and Ruiz demonstrated the anti-proliferative and 
pro-apoptotic effects of Δ9-THC in different prostate cancer cell-lines [123, 124]. Furthermore, 
methanandamide exhibited nanomolar concentrations in the inhibition of prostate cancer 
proliferation and induced apoptosis. Olea-Herreo showed that these effects are mediate by CB2, 
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not CB1 receptors. In addition, the CB2 selective agonist, JWH-015, showed anti-proliferative, 
pro-apoptotic properties which were mediated by the CB2 receptors [125]. Sarfaraz and co-
workers showed that WIN55212-2 inhibited cell growth and induced apoptosis in androgen-
dependent and –independent prostate cancer cell-lines [122].  
In-vivo data by Olea-Herreo and colleagues, showed JWH-015 was able to reduce tumor growth 
in athymic nude male mice injected with PC-3 cells and this effect was blocked by the CB2 
selective inverse agonist SR144528 [125].  
1.3.1.3 Bone cancer 
There are two types of bone cancer: primary bone cancer, which originates from the bone, 
and metastatic bone cancer, which cancer is metastasized from other organs such as breast, lungs, 
or prostate. Primary bone cancer (sarcomas) can be divided into osteosarcoma (which develops in 
new tissues in growing bones) and chondrosarcoma (which develops in the cartilage). 
Osteosarcoma occurs frequently in young people (age 10 – 20) and chondrosarcoma occurs more 
frequently in adults [126]. There are more than 3,000 new cases of sarcoma diagnosed and more 
than 1,400 deaths occurred in the United States during 2014 [106].  
The cannabinoid receptors have been shown to play roles in sarcomas. Khasabova et al., 
and Hald et al., assessed the expression of cannabinoid receptors CB1 and CB2 in NCTC-2472 
sarcoma cells [127, 128]. They showed upregulation of both receptors in these cells suggesting a 
possible role of the cannabinoid system in bone cancer. In-vitro studies examining the roles of 
cannabinoid ligands to attenuate sarcoma progression demonstrates the ability of WIN55212-2 to 
induce apoptosis in the NCTC-2472 sarcoma cell-lines. In addition, the CB2 selective agonist, 
AM-1241, reduced bone loss in mice injected with NCTC-2472 cell-line [129].  
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It is well-established that cannabinoids play critical roles in reducing bone-related pain. CP-55,940 
produced anti-nociceptive effects in mice injected with different cells such as NCTC-2472 and 
B16-F10. It is believed that the anti-nociceptive properties of CP-55,940 is mediated by the CB1, 
but not CB2 receptors [130]. However, the selective CB2 agonist, AM-1241, produced similar 
anti-nociceptive effects that are mediated by the CB2 receptors [129, 131].  
1.3.1.4 Blood cancer 
According the American Cancer Society, there were over 35,000 deaths and more than 
165,000 new cases of blood cancers during 2014 [106]. Several literature reported the involvement 
of the cannabinoid system in the attenuation of different types of blood cancers. McKallip and 
coworkers reported the expression of CB2 receptors in a number of human leukemia and 
lymphoma cell-lines, such as Jurkat, Molt-4, and Sup-T1. Furthermore, the reported the ability of 
THC, HU-210, anandamide, and JWH-015 to induce apoptosis in these cell-lines [132]. 
Gustafsson et al. reported the ability of R-(+)-methanandamide and WIN55212-2 to induce 
apoptosis via ceramide accumulation and p38 activation in mantle cell lymphoma [133] 
Multiple myeloma (MM) is the malignant proliferation of plasma B cells in the bone 
marrow. It is associated with high levels of monoclonal proteins in the blood and/or urine, 
decreased immunoglobulin (Ig) levels and lytic bone diseases [134, 135].In 2013, nearly 22,000 
new cases were diagnosed and more than 10,000 deaths occurred from the disease according to 
the American Cancer Society [136]. The incidence is higher with increasing age (between 60 and 
70 years old) and only 3% of all patients are younger than 40 years old [137, 138].  
The clinical manifestations of MM patients range from bone disease, hypercalcemia, 
hematological abnormalities, renal impairment and peripheral neuropathy. Bone diseases are 
presented in 60% of MM patients. These may include: lytic bone lesions, vertebral fractures and/or 
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osteoporosis. Hypercalcemia is considered the most common metabolic abnormality in MM 
(accounts for more than one-third of patients) [139]. Hypercalcemia results from osteolysis and 
bone resorption caused by secreted cytokines in the bone marrow microenvironment, such as 
receptor activator of nuclear factor-κB ligand (RANKL), macrophage inflammatory protein 
(MIP)-1α, and tumor necrosis factors (TNFs). Bone resorption leads to the efflux of calcium into 
the extracellular fluid [140]. The hematological abnormalities associated with MM include anemia, 
leukopenia and thrombocytopenia. Renal impairment affects more than 20% of MM patients. The 
mechanism of renal impairment in MM is related to the excess accumulation of light chains within 
the distal tubule leading to a condition known as myeloma kidney. Peripheral neuropathy 
represents a significant manifestation in MM patients during diagnosis and as a toxicity limitation 
of various agents used in the treatment of MM [139]. 
MM remains an incurable disease worldwide associated with complicated treatment 
regimens and modalities. Many complex molecular signaling pathways are involved in the MM 
pathogenesis, which accounts for the difficulty in managing the disease. The most important 
pathogenic contributor to the MM pathogenesis is the bone marrow microenvironment (BMME) 
in addition to other signaling pathways that have shown to be crucial in the MM pathogenesis. The 
advances in the understanding of the MM pathogenesis mechanisms aided the discovery of new 
chemical agents. Immunomodulatory drugs (IMiDs) such as thalidomide, lenalidomide and 
recently pomalidomide are used in the clinic to treat MM patients Figure 1.12 [141]. The Ubiquitin 
Proteasome System (UPS) plays a critical role in the MM disease progression. Many cell survival 
and cell growth proteins are regulated via the proteasome pathway. Bortezomib, Figure 1.12, is 
the first discovered proteasome inhibitor used in MM and is considered the first line treatment. 
Although the disease remains incurable, significant advances in the treatment and the development 
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of chemical agents have aided in the understanding of the disease pathogenesis with improved life 
expectancy of patients with median overall survival prolonged to 7 – 8 years [142].  
 
 
Figure 1.12. Chemical structures of anti-MM drugs in the market. 
(A) Immunomodulatory drugs: Thalidomide (Thalomid®), Lenalidomide (Revlimid®, CC-5013) 
and Pomalidomide (Pomalyst®, CC-4047). Thalidomide was the first IMiD introduced in the 
market. Chemical modifications of the phthaloyl ring was performed by adding an amino group 
and removing one of the carbonyl groups to generate lenalidomide. Pomalidomide was derived 
from thalidomide with the addition of an amino group to thalidomide. (B) Proteasome inhibitors: 
Bortezomib, the first proteasome inhibitors approved for MM and carfilzomib the recently 
approved proteasome inhibitor for MM [143].  
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Although significant improvement of the life expectancy of the MM patient, the disease remains 
difficult to cure with current treatment modalities. The urge for discovering new mechanisms and 
targets to eradicate the disease remains a hot area of research. As the MM disease is a cancer of 
the plasma B cells, the cannabinoid receptors are known to be highly expressed in these cells, in 
particular the CB2 receptors. Recently, our lab carried out extensive studies to explore the CB2 
receptors as novel target for MM disease. The expression of CB2 receptors in multiple myeloma 
cell lines were carried out by utilizing RT-PCR and western blot. Unlike CB1 receptors, western 
blot studies of multiple myeloma cell-lines (RPMI8226, U266, H929 and MM.1S) showed high 
expression levels of CB2 receptors Figure 1.13. This was confirmed by measuring the mRNA 
levels of CB2 using RT-PCR utilizing CB2 specific primers. These novel discoveries prompted us 
to carry on medicinal chemistry studies in order to identify novel CB2 ligands and explore the anti-
cancer capabilities, particularly anti-MM properties.  
 
 
 
 
 
 
 
 
 
42 
 
Figure 1.13. Cannabinoid receptors expression in different cell-lines. 
(A) Comparison of the expression level of cannabinoid receptors 1 and 2 in different cancer cell-
lines: MM cell-lines (U266, and MM.1S), pancreatic cancer cell-line (Panc2.039), ovarian cancer 
cell-line (OVCAR3, and SKOV3), as well as normal brain tissues. (B) CB2 receptor expression 
was measured in different MM cell-lines including Jurkat, RPMI8226, U266, H929, MM.1S as 
well as CD139+ [97]. 
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1.3.2 CANNABINOIDS AND BONE HOMEOSTASIS 
Bone remodeling process: 
The bone structure, throughout the lifetime, undergoes substantial changes comprised of three 
phases: 1) rapid skeletal growth phase with increased bone peak; 2) steady state phase where the 
bone mass is constant; 3) age-related bone loss. These changes accounts for the continuous process 
of renewal and repair, known as the bone remodeling. Bone remodeling is highly regulated by 
various hormones, peptides, and cytokines which can be divided into four stages: bone resorption 
phase, reversal phase, bone formation phase, and the quiescence phase. Bone resorption is the 
process of the removal of old bone by osteoclasts (large multinucleated, motile, and highly 
specialized cell derived from monocytes [144]). Several growth factors and cytokines are involved 
in the formation and activity of osteoclasts including the receptor activator of nuclear factor kappa-
B ligand (RANKL), osteoprotegerin (OPG), and macrophage colony forming factor (M-CSF) 
[145-147]. Rapid apoptosis and removal of the osteoclasts by phagocytosis occurs which activates 
the reversal phase.  During this phase, the old bone is coated by a thin layer of a matrix rich in 
glycosaminoglycans, glycoproteins, and acid phosphatases [148]. Osteoblasts (multinucleated 
cells originating from mesenchymal osteoprogenitor cells in the bone marrow [149]) attach to the 
resorbed site by several proteins and growth factors such as the transforming growth factor β (TGF-
β), and type-1 collagen. Parathyroid hormone, estrogen, and vitamin D3 are also known to 
stimulate osteoblast differentiation [150]. Following the bone formation phase is the quiescence 
phase where mature osteoblasts are either buried within the newly matrix as osteocytes or 
converted to lining cells covering the new bone [151].  
Impairment of the bone resorption and bone formation due to local and systemic factors 
accounts for the major causes of bone diseases. Osteoporosis is a common degenerative disease 
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characterized by reduced bone mineral density (BMD) and increased bone fragility and fractures 
[152]. Osteoporosis causes more than 8.9 million fractures every year and it is estimated to affect 
200 million women worldwide. Bone fractures is the main cause of morbidity among osteoporotic 
patients in the elderly. In 2000, there were about 9 million new osteoporotic fractures: 1.6 million 
in the hip, 1.7 million in forearm, and 1.4 million were in the vertebrae [153]. Worldwide incidence 
of hip fractures is projected to increase by 310% and 240% in men and women, respectively, by 
the year 2050 [154]. Primary osteoporosis occurs in women at their postmenopausal period where 
levels of estrogen naturally declines. Decreasing levels of estrogen causes a rapid increase in the 
secretion of several cytokines and growth factors such as interleukin-1 (IL-1), interleukin-6 (IL-6) 
and tumor necrosis factor-alpha (TNF-α) as well as decreases secretions of TGF-β in the bone. 
Elevated levels of these cytokines and growth factors results in increased osteoclast activity 
(osteoclastogenesis) as well as osteoblast activity [155].  In addition, lower levels of estrogen is 
associated with increased levels of RANKL and M-CSF (both stimulate osteoclastogenesis) and 
decreased levels of OPG [156].  
Secondary osteoporosis is caused by the long-term treatment with glucocorticoids (GCs). 
Glucocorticoids are class of steroid hormones that has many uses as immunosuppressive agent 
with a common bone loss side effect. Long-term GC treatment is associated with decreased bone 
formation and osteonecrosis (collapse of large joints). GCs regulate osteoblast production and 
promote the apoptosis of osteoblasts (inhibit osteoblastogenesis) and regulate osteoclasts by 
inhibiting osteoclast formation. GCs inhibit the synthesis of osteoclastogenesis promoters such as 
IL-1 and TNFs. In addition, GSs play important roles in reducing the metabolic and proliferative 
activity of osteoblasts. For example, GCs have been shown to inhibit the synthesis of collagenase-
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3, reduce the expression of insulin-like growth factor 1 and 2 (IGF-1, -2), and decreased TGF-β1 
activity [157]. 
Roles of Cannabinoids in the bone remodeling process: 
Endocannabinoids and their metabolizing enzymes have been reported, recently, in the skeleton. 
The endogenous cannabinoids AEA and 2-AG were found in high concentration in the bone 
marrow. In addition, osteoclasts and osteoblasts are able to produce AEA and 2-AG. Osteoclasts, 
osteoblasts, stromal cells, osteocytes, and adipocytes are capable to express the endocannabinoid 
metabolizing enzymes, such as NAPE-phospholipase D, FAAH, and DAGLs α and β. 
Furthermore, several studies demonstrated the expression of the cannabinoid receptors 1 and as 
well as GPR55 and TRPV1 in the skeleton. Specifically, CB1 receptors are expressed in low levels 
in osteoblasts and the mouse bone marrow-derived stromal cells. In contrast, CB2 receptors are 
highly expressed in osteoclasts, osteoblasts, and osteocytes.  
Following estrogen-deficiency in mice, CB1 and CB2 expression were highly upregulated in 
osteoclasts and osteoclasts bone-marrow precursor cells. CB1 selective inverse agonist, AM251, 
and CB2 selective inverse agonist, AM630, inhibited osteoclast formation, fusion, polarization, 
and activity [158]. However, there are conflicting data on the effect cannabinoid agonists of 
osteoclasts and osteoblasts. Endocannabinoids (AEA, 2-AG), synthetic cannabinoids CP55940, 
JWH133 and HU308 increased osteoclast number, size, and stimulated bone resorption. Other 
research groups demonstrated that the CB2 selective agonist HU308 inhibited osteoclast formation 
[158-160]. These data suggest the importance of the cannabinoid system in the regulation of bone 
mass and that the development of CB2 selective inverse agonist show a promising new class in the 
treatment of osteoporosis.  
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The bone marrow microenvironment (BMME) plays a critical role in the progression of 
MM. In fact, MM cells stimulate osteoclastogenesis by the increasing levels of RANKL and 
decreasing OPG levels.  In addition, MM cells block the differentiation and activity of osteoblasts. 
Adhesion molecules, such as the vascular cell adhesion molecule 1 (VCAM-1) is highly expressed 
and produced from MM and BM cells. Adhesion molecules have been demonstrated to upregulate 
RANKL expression and downregulate OPG levels. Furthermore, the interaction of MM cells to 
the bone marrow has been reported to produce several cytokines and growth factors that are anti-
apoptotic and promote osteoclastogenesis. Examples of these cytokines are IL-6, IGF-1, stromal 
cell-derived factor 1 (SDF-1α), and VEGF. 
Osteoclasts produced from the BM interaction with MM cells enhance the MM growth and 
survival. In addition, osteoclasts protect the MM cell from apoptosis and play roles in the resistant 
mechanisms of MM to anti-cancer drugs [161].  
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2.0  RECENT DEVELOPMENT OF CANNABINOID RECEPTOR 2 LIGANDS  
Since the isolation and discovery of the main active constituent of Cannabis sativa, Δ9-THC, 
cannabinoid research gained a lot of attention. This was reinforced by the discovery and isolation 
of the two main cannabinoid receptors 1 and 2.  Several chemotype compounds were developed 
with different potency and selectivity properties. As we have shown in Chapter 1 the critical roles 
of the cannabinoid system in several physiological and disease state, the development of 
cannabinoid ligands has gained a lot of attention. Specifically, CB2 selective ligand discovery is 
of highest demands as the expression of this receptor is higher in the periphery and the immune 
system. Furthermore, the recent withdrawal of the CB1 selective inverse agonist, Rimonabant, 
from the European market highlighted the complex signaling pathways involved in the 
cannabinoid system.  
In the past decade, over 400 CB2 chemical patents, and over 1500 new chemical ligands 
have been developed. Due to the lack of a high-resolution X-ray crystal structure of the CB2 
receptor, several chemical discovery and development methods were employed, such as 
pharmacophore drug discovery, high-throughput screening methods (computational and 
biochemical), molecular docking studies, and fragment-based drug discovery. This chapter will 
highlight the recent advances in the development of selective CB2 ligands and demonstrating the 
different scaffold and strategies employed in the development of these ligands. 
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2.1 TETRAHYDROCANNABIOID DERIVATIVES 
Since the discovery of the Δ9-THC, several tetrahydrocannabinol derivatives have been developed 
with high potency and selectivity. Huffman and coworkers explored the different modifications on 
the classical THC chemical scaffold. As have been shown previously, the removal of the phenolic 
hydroxyl group from Δ8-THC led to the discovery of JWH-133 (section 1.2) which was evaluated 
in several disease states, such as inflammatory pain, hepatic injury, and colitis as well as anti-
tumor properties. Recently, Huffman developed new bromo-Δ8-THC by replacing the phenolic 
hydroxyl to aryl bromide which resulted in the discovery of novel ligands with high CB2 potency 
and selectivity (Compound 2.1, CB2 Ki = 28 nM, Figure 2.1).  
Burdick and coworkers reported the synthesis of novel Δ9-THC derivatives as selective 
CB2 ligands. The chemistry focused on the conversion of the phenol of Δ9-THC to other 
functionality through palladium catalyzed reactions. Two analogs with sub 100 nM affinity for the 
CB1 and CB2 receptors were discovered (compounds 2.2 and 2.3, Figure 2.1) [162].  
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Figure 2.1. Chemical structures of THC derivatives 
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2.2 PURINE DERIVATIVES 
Hollinshead et al. at Eli Lilly performed medium throughput screening of a GPCR focused library 
of 130 K compounds utilizing competition-binding assay for hCB2 and hCB1 receptors. 
Subsequently the hit compounds were tested for their functionality by utilizing the [35S]-GTPγS 
hCB2 assay in CHO cells. The lead compound 2.4, a thienopyrimidine derivative, was identified 
which possessed moderate CB2 selectivity (hCB2 Ki = 16 nM) and behaved as a full agonist (CB2 
EC50 = 24.8 nM) (Figure 2.2). Compound 2.4 also suffered from poor metabolic stability in-vitro 
as well as rapid in-vivo clearance. Subsequently, it was subjected to chemical modification to 
improve its potency, selectivity and physicochemical properties. The replacement of the 
thienopyrimidine core with a purine core, moderately improved the potency as well as 
physicochemical properties (compound 2.5). With further optimizations and modification, 
compound 2.6 was discovered with high potency, selectivity as well as improved metabolic and 
physicochemical properties (Figure 2.2) [163]. 
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Figure 2.2. Chemical structures of purine derivatives 
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2.3 PYRIDINE DERIVATIVES 
Scientists at GlaxoSmithKline carried out a research to discover novel CB2 selective agonist with 
the aim at improving in-vitro metabolic stability as well as CB2 selectivity. High-throughput 
screening identified aminopyridine, compound 2.7 (Figure 2.3), which was subjected to chemical 
modifications to overcome the metabolic instability. The SAR studies included: 1) to replace the 
lipophilic azepane ring, 2) to reduce the electron density of the aminopyridine core by introducing 
ring substitutions, and 3) to replace the dichlorophenyl with less lipophilic heterocycles. Initial 
SAR study led to the identification of 2.8 by replacing the azepane ring with a morpholine. 
Compound 2.8 showed good CB2 potency but relatively high in vitro clearance. Keeping the 
morpholine group as the amine substituent, SAR studies were carried out to investigate the 
replacement of the dichlorophenyl with different groups and fragments, to introduce electron 
withdrawing substituents into the core, and to lower the lipophilicity by introducing another 
pyridyl ring to the core. As a result several analogs were synthesized and biologically evaluated 
yielding varying potencies and metabolic stabilities, for example compound 2.9 [164]. Further 
SAR studies were carried out on the three positions of the lead compound led to the discovery of 
2.10 which showed high CB2 potency and good pharmacokinetic profile as well as its ability as 
an anti-inflammatory agent after oral administration (Figure 2.3) [165]. 
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Figure 2.3. Chemical structures of aminopyridines 
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A research group led by Bartolozzi et al. patented over 150 pyridine derivatives. Among 
those derivatives, 126 compounds exhibited high CB2 affinity. Importantly, compound 2.11, 
showed the highest CB2 affinity with CB2 EC50 of 0.093 nM. In-vitro studies demonstrated the 
ability of these pyridine derivatives to reduce inflammatory pain (Figure 2.4) [166]. 
Chu et al. aimed on the discovery of pyridine derivatives by chemical modifications of a 
series of (morpholinomethyl)aniline carboxamides (exemplified by compound 2.12). The 
replacement of a phenyl ring with a pyridine led to the discovery of a novel chemical series of CB2 
ligands. Compound 2.14 demonstrated the highest CB2 affinity and selectivity among those new 
series (CB2 Ki = 24 nM, CB1 Ki = 3800 nM, Figure 2.4). Moreover, this compound showed good 
efficacy in-vivo after oral administration in a neuropathic pain rat model [167]. 
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Figure 2.4. Chemical structures of pyridine derivatives 
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Merck scientist performed compound screening followed by small optimization campaign 
that resulted in the identification a series of 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione 
derivatives. The initial hit compound 2.15, possessed high CB2 affinity (CB2 EC50 = 2.5 nM) with 
more than 1000-fold selectivity over CB1 receptors. The hit compound however showed low oral 
bioavailability with some affinity for the hERG ion channel. Chemical modification of the hit 
compound led to the discovery of compound 2.16, which demonstrated high CB2 affinity (CB2 
EC50 = 10 nM) and selectivity (SI >1000) and behaved as an agonist with high bioavailability 
(Figure 2.4) [168].  
2.4 PYRIMIDINE CARBOXAMIDES DERIVATIVES 
A group of scientists at GlaxoSmithKline initiated a program to discover selective CB2 agonists 
with the aim to treat chronic pain, since CB2 agonists were shown to reduce inflammatory pain in 
the carrageenan model [169]. Pharmacophore drug discovery approach was utilized by collecting 
the structures of known cannabinoid ligands to generate the pharmacophore model. Subsequently, 
about 1000 compounds were selected and tested for their CB2 and CB1 affinity by utilizing the 
[35S]-GTPγS assay. The hit compound 2.17, a trifluoromethyl substituted pyrimidine ester showed 
high CB2 affinity with no affinity towards the CB1 (CB2 EC50 = 630 nM, CB1 EC50 > 10,000 
nM). Lead optimization and chemical modifications were carried out and compound 2.18 was 
identified. Compound 2.18 showed high CB2 affinity (CB2 EC50 = 63 nM) and selectivity with an 
oral ED50 of 0.1 mg/kg in the rat FCA model of inflammatory pain. Currently, this compound is 
known as GW 842166X and is in clinical trial for the treatment of inflammatory pain (Figure 2.5) 
[170]. 
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GW 833972A was also identified at GlaxoSmithKline (data unpublished) as a selective CB2 full 
agonist (CB2 EC50 = 50 nM). In addition, GW 833972A was tested on human and on guinea-pig 
sensory nerves in the airways and showed its ability in the treatment of chronic cough (Figure 2.5) 
[171]. 
 
 
 
Figure 2.5. Pyrimidine carboxamides derivatives 
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2.5 DIHYDROQUINOLINE-3-CARBOXAMIDES AND 1,8-NAPHTHYRIDINONE 
Researchers at the University of Lille first reported the discovery and identification of 4-oxo-1,4-
dihydroquinoline-3-carboxamide derivatives as a novel class of CB2 receptor agonists. Their 
design and synthesis approach was based on other known cannabinoid pharmacophores by 
modifying two positions on the 4-oxo-1,4-dihydroquinoline-3-carboxamide scaffold. At the R1, 
they introduced different alkyl or benzyl groups, while at position 3 they tested different aliphatic 
or aromatic carboxamide groups. Four derivatives exhibited high CB2 affinity and selectivity 
based on competition-binding experiments utilizing [3H]-CP-55940 on CB1 and CB2 receptors 
(CB2 Ki < 38 nM, SI > 150). Moreover, in the [
35S]-GTPγS binding assay, these derivatives were 
shown to behave as CB2 agonists. Particularly, compound 2.19 bearing a 1-(3,5-
dimethyl)adamantyl at the R1 position, hydrogen on the R2 position, and n-pentyl at the R3 
position displayed the highest CB2 potency with a CB2 Ki of 15.8 nM (Figure 2.6) [172, 173]. 
Manera et al. explored different substitution on the 4-oxo-1,4-dihydroquinoline core at the R4 
position and reported a series of substituted 4-oxo-1,4-dihydroquinoline-3-carboxamide 
derivatives. Two compounds demonstrated high CB2 affinity and selectivity with CB2 Ki = 4.8 
and 3.3 nM for compounds 2.20 and 2.21, respectively, and both compounds behaved as CB2 
agonists (Figure 2.6) [174]. 
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Figure 2.6. 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives 
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In addition, Manera et al. reported new 4-oxo-1,4-dihydroquinoline-3-carboxamide 
derivatives with substitutions on the 4-oxo-1,4-dihydroquinoline core, namely the 1,8-
naphthyridin-4(1H)-on-3-carboxamide scaffold. Molecular docking studies were carried out on 
the designed derivatives to illustrate the interactions of the ligands with the constructed CB1 and 
CB2 homology models. Compound 2.22 (also known as CB13), showed a CB2 Ki of 50 nM with 
a selectivity of over 50 and behaved as a CB2 agonist (Figure 2.7) [174]. Cinachi et al. reported 
that CB13 induced apoptosis in 2 human cancer cell-lines by increasing ceramide levels. In 
addition CB13 demonstrated the ability to slow the growth of a mouse model of colon cancer 
[175].  
 
 
 
Figure 2.7. 1,8-naphthyridin-4(1H)-on-3-carboxamide derivatives 
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Following the discovery and identification of the 1,8-naphthyridin-4(1H)-on-3-
carboxamide, Manera et al. investigated another modification on the 1,8-naphthyridin-4(1H)-on-
3-carboxamide central core and synthesized a series of 1,8-naphthyridin-2(1H)-on-3-carboxamide. 
Compounds 2.23 and 2.24 showed the highest CB2 binding affinity of 0.9 and 5.8 nM with 
selectivity indices of 286 and 262, respectively. Interestingly, these two compounds were 13-fold 
and 7-fold more potent than the corresponding trans-isoforms for compounds 2.23 and 2.24, 
respectively (Figure 2.8) [176]. 
 
 
Figure 2.8. 1,8-naphthyridin-2(1H)-on-3-carboxamide derivatives 
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Research group at the University of Siena explored different substitutions on the quinolone 
core of the 4-oxo-1,4-dihydroquinoline-3- carboxamide scaffold. They tested various substitutions 
such as halides, aryl, alkyl, alkoxy, and aryloxy groups differing steric/electrostatic properties. 
Moreover, The N-1 pentyl chain and adamantyl group were either retained or replaced with other 
lipophilic groups, such as prop-1-en-3-yl, but-1-en-4-yl, pent-1-en-5-yl, or (R)-1-phenylethyl. 
Several ligands were shown to possess high CB2 affinity and selectivity. Specifically, compounds 
2.25 and 2.26 exhibited CB2 binding affinity of 6.3 and 3.8 nM with a selectivity index of 194 and 
> 2666, respectively (Figure 2.9). Importantly, compound 2.25 showed analgesic activity in the 
formalin test of acute peripheral and inflammatory pain in mice [177]. Moreover, compound 2.26 
exhibited anti-nociceptive properties. These two compounds differed in their cellular functionality 
as demonstrated by the [35S]-GTPγS binding assay which showed compound 2.25 behaved as an 
agonist while compound 2.26 is an inverse agonist and that both CB2 agonists and inverse agonists 
show anti-inflammatory properties. It is believed that the aliphatic substitutions at the R2 position 
influenced the agonism property while aryl substitution influenced the inverse agonism property 
[178].  
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Figure 2.9. Recent 4-oxo-1,4-dihydroquinoline-3- carboxamide  derivatives 
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El Bakali et al. investigated the replacement of the 1,4-dihydroquinoline moiety with 1,4-
dihydropyridine moiety. In addition, replacement of the 4-oxo- moiety with 4-thioxo- was studied. 
Several selective CB2 ligands were reported and compound 2.27 exhibited the highest affinity 
(CB2 Ki = 4 nM, SI > 148, Figure 2.10). Importantly, they reported that the functionality of this 
series is controlled by its C-6 substituent (R3) where agonists bear a methyl or a tert-butyl group 
and inverse agonists bear a phenyl or 4-chlorophenyl group [179].  
 
 
 
Figure 2.10. 4-oxo-1,4-dihydropyridine-3-carboxamide derivatives 
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By the utilization of the three-dimensional quantitative structure activity relationship (3D-
QSAR) studies, Brogi et al. generated a three-dimensional computational model by using the Phase 
software which was utilized for the design and synthesis of new CB2 selective ligands. As a result, 
this computational model aided in the discovery and identification of compound 2.28 which is a 
structural derivative from 4-quinolone-3-carbaxamide with the insertion of a methyl group at the 
8-position which potentiated the CB2 affinity dramatically (Figure 2.11) [180]. Structural 
modification carried out on the compound 2.28 lead by Pasquini and coworkers, they replaced the 
8-methyl with 8-methoxy, compound 2.29 which showed high affinity and selectivity towards the 
CB2 receptor (CB2 Ki = 0.6 nM, CB1 Ki > 10000, SI > 16666, Figure 2.11). Functional studies 
demonstrated that this compound behaved as an inverse agonist with anti-nociceptive effects in 
the formalin test [181].  
 
 
Figure 2.11. Chemical structures of N-(adamantan-1-yl)-4-oxo-8-methyl-1-pentyl-1,4- 
dihydroquinoline-3-carboxamide and N-(adamantan-1-yl)-4-oxo-8-methoxy-1-pentyl-1,4- 
dihydroquinoline-3-carboxamide 
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Due to the low solubility profile of the dihydroquinoline-3-carboxamide derivatives, 
bioisosteric replacement of the amide by heterocyclic moieties was utilized to improve the 
physicochemical and pharmacodynamic properties in a series developed by Mugnaini and 
colleagues. They reported a new series of 1,6-disubstituted-4-quinolone-3-carboxamide 
derivatives with high CB2 potency and selectivity. Among the series of derivatives, the triazole 
derivative, compound 2.30, displayed highest affinity with improved physicochemical and 
pharmacodynamic properties (CB2 Ki = 1.2 nM, CB1 Ki > 10000, SI > 8620). Furthermore, 
compound 2.30, was shown to behave as an inverse agonist and demonstrated its ability as an anti-
nociceptive agent (Figure 2.11) [182]. In another attempt to explore different substitutions on the 
4-quinolone-3-carboxamide, Pasquini et al. reported the synthesis and pharmacology of 7-
substituted quinolone-3-carboxamides. Varying affinities for both CB1 and CB2 receptors were 
observed. The N-(3,4-dichlorobenzyl) amide derivatives, compounds 2.31 and 2.32, displayed 
high affinity toward the CB1 receptor. While the N-fencylamide derivative, compound 2.33, 
displayed high CB2 affinity (Figure 2.12). All three ligands demonstrated as partial agonists with 
very low permeability in blood brain barrier (BBB) model. Due to their low penetration to the 
BBB, these ligands may serve as a starting point to develop cannabinoid ligands with low CNS 
distribution [183]. 
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Figure 2.12. Chemical structures of 1,6-disubstituted-4-quinolone-3-carboxamide 
and 7-substituted quinolone-3-carboxamides derivatives 
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Recently, several nitrogen heterocyclic derivatives were synthesized and tested for their 
affinity on human CB1 and CB2 receptors. Replacement of the 1,8-naphthyridinone core with 2-
pyridine, as in compound 2.34, reduced the CB2 affinity albeit its improved solubility. On the 
other hand, the 1,8-naphthrydinone-3-carboxamide compound 2.35, showed high affinity and 
selectivity properties. Furthermore, these two compounds were evaluated for their anti-
proliferative properties by utilizing different cancer cell-lines. They both inhibited the proliferation 
of the cancer cells, in particular, the DU-145 prostate cancer cell-line [184].  
 
 
 
Figure 2.13. Chemical structures of 2.34 and 2.35 
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Baraldi et al. at the University of Ferrara reported a series of 7-oxo-[1,4]oxazole[2,3,4-
ij]quinoline-6-carboxamides derivatives as selective CB2 ligands [185]. Their design was based 
on hybrid ligand design which incorporates structural features of known cannabinoid ligands. The 
design of compound 2.37 was based on the quinolone compound 2.36 and the known cannabinoid 
ligand WIN55212-2. Further exploration led to the identification of compounds 2.38 and 2.39, 
which displayed high affinity and selectivity (Figure 2.14).  
 
 
 
Figure 2.14. Development of 7-oxo-[1,4]oxazole[2,3,4-ij]quinoline-6-carboxamides 
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Tabrizi and co-workers [186] demonstrated the discovery of a new class of selective CB2 
derivatives, heteroaryl-4-oxopyridine / 7-oxopyrimidine series, by pharmacophore analysis and 
structural modifications based on previously discovered CB2 selective ligands and the known CB2 
agonists (HU-210, JWH-133, CP55940, HU-308, R-(+)-WIN55212, JWH-015, AM1241, AM630, 
as well as SR144528). They depicted several pharmacophoric properties into their chemistry 
designs in order to discover novel CB2 selective agonists. As a result, four scaffolds were designed 
and several substitution at different positions were evaluated. Subsequently, four compounds 
showed the highest CB2 affinity and selectivity and exhibited varying functionalities, Table 2.1. 
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Table 2.1. Chemical structures of selective CB2 ligands developed by Tabrizi et al. 
Entry Chemical Structure hCB2 Ki (nM) Functional Class 
1.40 
 
9.51 Partial agonist 
1.41 
 
21 Full agonist 
1.42 
 
1.12 Inverse agonist 
1.43 
 
20 Partial agonist 
CB2 affinity was calculated by using [3H]CP-55,940 as radioligand calculated on human CB2 CHO 
membranes. 
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2.6 INDOLE-BASED DERIVATIVES 
The indole moiety is present in many known cannabinoid ligands, as shown previously, such as 
WIN55212-2, JWH-015, and AM1241. Researchers at Merck Laboratories extended the 
development of indole derivatives based on GW405833 (CB2 Ki = 10 nM, CB1 Ki = 2000 nM) by 
replacing the indole moiety with imidazopyridine core giving three varying scaffolds (Figure 2.15) 
[187]. The imidazopyridines were shown to be potent CB2 agonists with adjustable CNS 
penetration properties. SAR studies performed on the three imidazopyridine scaffold led to the 
production of several CB2 selective agonists with analgesic effects. Compounds 2.44, 2.45, 2.46, 
2.47, and 2.48 are reported to exhibit the highest CB2 affinity and selectivity with hCB2 cAMP 
IC50 of 5, 0.7, 7, 33, and 36 nM, respectively (Figure 2.15).  
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Figure 2.15. Chemical structures of imidazopyridine 
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2.7 BENZIMIDAZOLE DERIVATIVES 
Johnson and Johnson developed 5-sulfonyl-benzimidazoles as potent and selective CB2 agonists. 
Their studies was initiated by a high-throughput screening and identified compound 2.49 with a 
CB2 EC50 of 25 nM and SI = 354. Initial SAR studies aided in the discovery and synthesis of 
compound 2.50 which is an ortho-substituted pyridylsulfone analog with high selectivity with 
acceptable drug-like properties.  However, compound 2.50 suffered from low solubility and 
inhibited CYP-450 isoforms which limited its in-vivo activity [188]. Further SAR studies identified 
compounds 2.51 and 2.52 displaying high CB2 affinity and selectivity with CB2 EC50 of 8.2 and 
7.7 nM and CB1 EC50 of > 10000 and 3428 nM, respectively (Figure 2.16). Although both 
compounds show comparable CB2 affinity and selectivity, only compound 2.51 displayed good, 
sustained activity in a chronic model of neuropathic pain. This may be attributed of the good 
solubility observed in compound 2.51 but not 2.52. Furthermore, both compounds, 2.51 and 2.52, 
delayed the onset of clinical symptoms in an experimental model for multiple sclerosis which is 
attributed for their agonism properties [189]. 
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Figure 2.16. Chemical structures of the benzimidazoles 2.49 - 2.52 
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Yu et al. at AstraZeneca produced a peripherally restricted cannabinoid receptor agonist 
on the CB1 receptor and a partial agonist of the CB2 receptor, compound 2.53 (also known as 
AZ11713908) (Figure 2.17). This compound exhibited poor BBB penetration which potentiated 
its peripheral analgesic properties in inflammatory and neuropathic pain animal models [190]. A 
research group in Pfizer led by Watson and coworkers reported a series of benzimidazoles as 
analgesics based on their previously reported benzimidazole CB2 agonist (compound 2.54 CB2 
EC50 = 12 nM, CB1 EC50 > 19400 nM). Due to its high in-vivo clearance (Cl 75 mL/min/kg) and 
the modest oral bioavailability, SAR studies were carried out based on molecular docking 
simulation studies. Compound 2.55 was synthesized and reported to have high CB2 affinity (CB2 
EC50 = 3.2 nM) and selectivity (CB1 Ki > 10000 nM) with improved CNS penetrative properties. 
Further optimization led to the discovery of compound 2.56 with high CB2 affinity and selectivity, 
the highest CNS penetration properties as well as reduced hERG activity (Figure 2.17) [191].   
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Figure 2.17. Chemical structures of the benzimidazoles 2.53 – 2.56 
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2.8 IMIDAZOLES 
Cara Therapeutics, Inc. reported the identification of more than 600 substituted 
imidazoheterocyclic compounds with different CB2 and CB1 receptors affinities. The magnitude 
of binding ranged from 0.1 nM to 10000 nM. Among the 600 compounds, compound 2.57 showed 
high affinity and selectivity with CB2 EC50 < 0.1 – 10 nM and CB1 EC50 > 10000 nM (Figure 2.18) 
[192].  
Lang and coworkers at Solvay Pharmaceuticals reported the synthesis and SAR study of 
novel imidazole derivatives with varying affinities and functionalities. Their strategy was to design 
CB2 inverse agonist based on the CB1 receptor inverse agonist SR141716 (Rimonabant) 
pharmacophore properties. Compound 2.58 exhibited the highest CB2 receptor affinity (Ki = 1.03 
nM) and the highest selectivity (SI > 9708) (Figure 2.18) [193].  
 
 
 
 
 
 
 
 
 
 
 
 
79 
 
 
 
 
Figure 2.18. Chemical structures imidazole derivatives 
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Merck laboratories performed high-throughput screening to identify novel CB2 
chemotype. Compound 2.59 was identified and exhibited high CB2 affinity (CB2 Ki = 42 nM) 
with moderate selectivity. Moreover, compound 2.59 was shown to behave as an agonist as 
demonstrated by the cAMP assay. Subsequently, a series of 2,4-diphenyl-1H-imidazole scaffold 
were synthesized and SAR as well as pharmacokinetic data were studied. Compounds 2.60 and 
2.61 displayed the highest CB2 affinity, CB2 EC50 = 5 nM and 10 nM, respectively. In addition 
the selectivity indices were 510 and 245 for compound 2.60 and 2.61, respectively (Figure 2.19) 
[194].  
 
 
Figure 2.19. Chemical structures of 2,4-diphenyl-1H-imidazole 
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2.9 THIOPHENE AMIDE DERIVATIVES 
Nelson and coworkers at Abbott identified several thiophene bisamide compounds utilizing high-
throughput screening of the Abbott compound collection. SAR studies of the thiophene bisamide 
scaffold produced several CB2 selective agonists. Importantly, compounds 2.62, 2.63, and 2.64 
showed the highest CB2 affinity and selectivity and behaved as agonists (Figure 2.20). Compound 
2.62, effectively produced analgesia in behavioral models of neuropathic, inflammatory, and 
postsurgical pain as well as demonstrating excellent bioavailability properties [195]. Nycomed 
Pharma performed high-throughput screening of ~300,000 compounds and identified the hit 
compound 2.65 with CB2 EC50 = 10 nM and CB1 EC50 = 251 nM. Extensive SAR studies on the 
hit compound aided in the synthesis of compounds 2.66 and 2.67 with high affinity and selectivity 
(Figure 2.20). Compound 2.66 produced analgesia after oral administration in inflammatory pain 
models of writhing and carrageenan-induced allodynia [196].  
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Figure 2.20. Thiophene amide derivatives 
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2.10 SULFONAMIDE DERIVATIVES 
Scientists at Boehringer Ingelheim Pharma led by Berry and coworkers identified 192 sulfonyl 
carboxamide compounds exhibiting CB2 modulatory activity [197]. About 80 compounds 
demonstrated CB2 agonism and were evaluated for their pharmaceutical uses. Among those 80 
compounds, compound 2.68 which showed high CB2 affinity (CB2 EC50 = 0.04 nM) and as an 
anti-inflammatory agent (Figure 2.21). Two years later, another series of compounds was patented 
by Boehringer Ingelheim Pharma and reported the identification of a series of heterocyclic sulfone 
compounds with CB2 agonism properties. The new series of heterocyclic sulfone scaffold 
demonstrated anti-inflammatory as well as analgesic properties [198]. Compound 2.69 
demonstrated the highest CB2 affinity among those series with CB2 Ki of 25 nM and behaved as 
an agonist (Figure 2.21).  
Since the first identification of the triaryl bis-sulfones scaffold and the discovery of 
compound 2.70 (also known as Sch.225336, Figure 2.21) as selective CB2 inverse agonist by the 
Schering-Plough Research Institute in 2003, several SAR studies were carried out to optimize 
affinity, selectivity as well pharmacokinetic/pharmacodynamic properties. Shankar et al. studied 
the variations of the substitution pattern on the aromatic rings and the linkers (L1 and L2) of the 
aromatic rings (Figure 2.21). Changes at L2 were not tolerated, and sulfone was determined to be 
the best overall for L1 and L2. Substitution on the phenyl rings showed a preference for a small 
group at the 2-position of the C-ring and a small alkyl or halogen at the 4-position of the B-ring as 
in compound 2.71 (known as Sch.356036, Figure 2.21) [199]. Gilbrt et al. modified compound 
2.71 by converting the aryl A-ring to a piperidine ring. The piperidine ring was further replaced to 
a spirocyclopropyl piperidine moiety. Such modification led to the identification of compound 
2.72 with improved CB2 potency and selectivity (CB2 Ki = 0.9 nM, SI > 1000, Figure 2.21) [200]. 
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Another SAR study of compound 2.71 was carried out by Lavey and coworkers. The changes to 
compound 2.71 include the addition of polar groups to the 2-fluorophenyl ring, replacement of the 
fluorophenyl ring with heterocycles and other groups, and changing the NHSO2CH3 group into a 
NHSO2CF3 to allow the formation of salts to improve solubility. Compound 2.73 (also known as 
Sch.414319, Figure 2.21) was identified with high CB2 affinity and selectivity (CB2 Ki = 2 nM, 
SI = 3393) as well as improved pharmacokinetic properties [201]. 
Merck laboratories led by Tong et al. expanded the SAR of 2.73 identified another highly potent 
and selective CB2 inverse agonist, compound 2.74, with CB2 Ki of 0.4 nM and SI of 3500, 
Figure 2.21) [202]. 
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Figure 2.21. Sulfonamide derivatives 
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2.11 CONCLUSION 
The involvement of the cannabinoid system in different physiological and disease states 
potentiated the high demand for developing cannabinoid ligands. It is now well appreciated that 
with CNS limitations accompanied with CB1 targeting, developing selective CB2 ligands is more 
promising. In fact, several CB2 selective ligands have undergone or are currently in clinical trials 
for different diseases. For example, cannabinor (PRS-211375, compound 2.75, Figure 2.22) was 
evaluated by Pharmos Corporation in Phase II clinical trials as an anti-nociceptive agent. 
Furthermore, Glenmark Pharmaceuticals conducted a Phase I clinical trial to evaluate the selective 
CB2 agonist tedalinab (GRC-10693, compound 2.76, Figure 2.22) for the treatment of 
osteoarthritis and neuropathic pain. Clinical studies demonstrated the ability of tedalinab to reduce 
bone pain in osteoarthritis and neuropathic patients [203]. In addition, Kyowa Hakko Kirin 
reported the testing of the CB2 agonist KHK-6188 (no structural data reported) in clinical trials 
for pain in Phase II clinical study for postherpetic neuralgia [204]. Shinogi Pharmaceuticals 
reported the discovery of 3-carbamoyl-2-pyridone based CB2 agonist, namely S-7774698 
(compound 2.77, Figure 2.22) with promising antipruritic effects [205]. S-7774698 was evaluated 
in a Phase II randomized and double-blind clinical study to evaluate its efficacy in patients with 
atopic dermatitis with no published data yet [206]. 
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Figure 2.22. Chemical structures of selective CB2 ligands in clinical trials 
 
To date, the 3D X-ray crystal structure of CB2 receptor has not been resolved demanding 
different methods of ligand discovery. As demonstrated in this chapter, many ligand discovery 
tools were employed such as computer-aided drug discovery (molecular docking, QSAR/CoMFA, 
and pharmacophore modeling), high-throughput screening as well as mutational studies. Also, 
many selective CB2 ligands have been discovered and yet a lot of ligands will be discovered due 
to the different functions of the cannabinoid system and the therapeutic potentials CB2 ligands 
hold. Several novel CB2 chemotype were reported suggesting the variety of the CB2 ligands and 
the potential of different other chemical moieties to be developed. More structural modifications 
to improve efficacy, physicochemical properties, and pharmacokinetic properties will advance the 
use of CB2 ligands into the clinic.  
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3.0  GENERAL METHODS AND MATERIAL 
3.1 COMPUTER MODELING 
All molecular docking studies, pharmacophore modeling, Quantitative Structure Activity 
Relationship (QSAR)/Comparative Molecular Field Analysis (CoMFA) and virtual screening 
procedures were performed using SYBYL X 1.3 (Tripos, Inc.). Molecular docking studies were 
performed using the Surflex-Dock GemXTM module in the SYBYL software. The docking 
interactions were analyzed based on the FlexX-Pharm Docking/CScore [207]. Pharmacophore 
studies were performed using the GALAHADTM module (Tripos, Inc.) to generate pharmacophore 
models. QSAR/CoMFA was performed using the QSAR module (Tripos, Inc.). Our CB2 
homology model [208] was utilized for the docking and virtual screening procedures. Refined 
figures and contours were obtained using PyMol 1.7 (Schrödinger®, LCC) platform.  
3.2 CHEMISTRY 
All reagents were purchased from commercial suppliers and used without further purification. 
Analytical thin-layer chromatography (TLC) was performed on SiO2 plates 250 µm on Alumina 
from Whatman. Visualization was accomplished by ultra-violet (UV) irradiation at 254 nm. The 
purification experiments were conducted using Preparative Silica gel TLC plates (1000 µm. 20 cm 
× 20 cm) or Flash chromatography (Biotage, Isolera Inc.), where indicated.  Flash column 
chromatography was performed using the Biotage Isolera flash purification system with SiO2 60 
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(particle size 0.040−0.055 mm, 230−400 mesh). Proton and carbon NMR were determined on 
Bruker 400 MHz or Bruker 600 MHz NMR spectrometer, where indicated. Chemical shifts are 
reported as delta (δ) values in parts per million (ppm) as referenced to residual solvent. 1H NMR 
spectra are reported as follows: chemical shift, number of protons, multiplicity (s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet, br = broad peak), and coupling constant. Chemical 
shifts are reported relative to that of tetramethylsilane at 0.00 ppm. Compound purity of at least 
95% was confirmed by HPLC. LC-MS analysis was recorded on a Shimadzu HPLC instrument 
with a Hamilton reversed phase column (HxSil, C18, 3 μm, 2.1 mm × 50 mm (H2)); eluent A 
consisting of 5% CH3CN in H2O; eluent B consisting of 90% CH3CN in H2O; flow rate of 0.2 mL/ 
min; UV detection, 254 and 214 nm. HPLC coupled to electrospray ionization-mass spectrometry 
(ESI-MS) Quadrupole-time-of-flight (QTOF) tandem mass spectrometry QSTAR Elite (Applied 
Biosystems). 
3.3 CANNABINOID RECEPTORS MEMBRANE PROTEIN PREPARATIONS 
Membranes are isolated from Chinese Hamster Ovary (CHO) cells stably expressing both CB1 
and CB2 receptors. These cells were cultured in 50:50 mixtures of DMEM and Ham’s F-12 with 
the supplementation with antibiotics. The cells were harvested in phosphate-buffered saline 
containing 0.4% EDTA. The membrane proteins were prepared by homogenization of cells in 50 
mM Tris buffer with 10% sucrose. Centrifugation was performed and the supernatant was 
collected. The supernatant was ultra-centrifuged at 50,000 x g for 45 minutes at 4°C and the 
membranes were stored at -80 °C. 
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3.4 RADIO-LIGAND COMPETITION BINDING ASSAYS 
3.4.1 Saturation Binding Assay 
Saturation binding experiment is initially performed in order to characterize the membrane 
receptor preparation. The experiment is carried out as previously described [209]. It measures the 
total and non-specific binding at various concentrations of the radioligand. Two values are 
measured; Kd (equilibrium dissociation constant) and Bmax (receptor density). Briefly, the 
membrane fractions (20 μg) were incubated with increasing concentrations of [3H] H](−)-cis-3-[2-
hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl) cyclohexanol (CP55,940) 
(0.01–5nM) in 96-well plates at 30 °C with slow shaking for 1 h. The incubation buffer was 
composed of 50 mM Tris–HCl (pH 7.4), 5 mM MgCl2, 2.5 mM EGTA and 0.1% (w/v) fatty acid 
free BSA. Hot ligand was diluted in incubation buffer supplemented with 10% dimethyl sulfoxide 
and 0.4% methylcellulose. Non-specific binding was determined in the presence of 1:1000 
unlabeled CP-55,940 (5000 nM) in excess. The reaction was terminated by rapid filtration through 
Unifilter GF/C filter plates using a Unifilter Cell Harvester (PerkinElmer). After the plate was 
allowed to dry overnight, 30 μL MicroScint-20 cocktail (PerkinElmer) was added to each well and 
the radioactivity was counted using a PerkinElmer TopCounter. 
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Figure 3.1. Saturation binding assay of CB2 and CB1 membrane preparations. 
Saturation binding assay was performed with membrane proteins preparations harvested from 
CHO cells stably expressing either CB1 or CB2 receptors by increasing the concentration of hot 
ligand, [3H]-CP55,940, using a fixed amount of target protein. A 1:1000 excess of cold CP55,940 
was added in the reaction mixture to account for non-specific binding. Total (●) and non-specific 
(■) binding was measured and the deduced specific binding saturation isotherm (▲) was obtained 
as the difference between total and nonspecific binding. (A) Cannabinoid receptor 2 saturation 
binding curve (CB2); (B) Cannabinoid receptor 1 saturation binding curve (CB1). Assay was 
performed in triplicate. Data presented as mean ± SEM.  
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The assay provides the Kd (equilibrium dissociation constant) and Bmax (receptor density) 
that provides information on the membrane preparation. Total binding (receptor + radioligand), 
non-specific binding (receptor + radioligand + excess cold ligand) and specific binding of the 
radioligand (total minus non-specific) were plotted versus the free concentration of the radioligand. 
The Kd is determined using non-linear regression analysis using GraphPad Prism as: Bound = Bmax 
* [L] / ([L] + Kd), where [L] is the hot ligand concentration (Figure 3.1). 
3.4.2 Radio-Ligand Competition Binding Assay 
The competitive radio-ligand binding assays for CB1 and CB2 receptors were performed as 
described previously using a Perkin Elmer 96-well Top Counter to determine the cannabinoid 
receptor binding affinity (Ki) for CB1 or CB2 ligands by displacing [
3H]-CP55,940. [209]. Briefly, 
the compounds to be tested are diluted in binding buffer (50 mM Tris-HCl (pH 7.4), 5 mM MgCl2, 
2.5 mM EGTA, and 0.1% (w/v) fatty acid free BSA), supplemented with 10% dimethyl sulfoxide 
and 0.4% methylcellulose. Each assay plate well contains a total of 200 μL of reaction mixture 
comprising 5 μg of CB1 (or CB2) membrane protein, labeled [
3H]-CP55,940 at a final 
concentration of 3 nM, and the unlabeled ligand at its varying dilutions. Plates were incubated at 
30 °C for 1 h with gentle shaking. The reaction was terminated by rapid filtration through Unifilter 
GF/B filter plates using a UniFilter cell harvester (PerkinElmer). After the plate was allowed to 
dry overnight, 30 μL MicroScint-0 cocktail (PerkinElmer) was added to each well and the 
radioactivity was counted by using a PerkinElmer TopCount. All assays were performed in 
triplicate and data points represented as mean ± S.E.M. The Ki was calculated by using nonlinear 
regression analysis (Prism 5, GraphPad) utilizing the Cheng-Prusoff equation: Ki = IC50 / 1 + 
([L]/Kd), with the Kd values determined from saturation binding experiments (Figure 3.2). 
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Figure 3.2. Competition binding profiles for SR141716 and SR144528. 
Competition binding experiments were performed on membrane proteins harvested from CHO 
cells stably expressing CB1 or CB2 receptors. Competitive displacement of the [3H]-CP55,940 
was obtained by using an increased amount of cold ligands (A) Competition binding profile of 
cannabinoid receptor 1 selective ligand, SR141716, Ki = 3.12 nM. (B) Competition binding profile 
of cannabinoid receptor 2 selective ligand, SR144528, Ki = 1.55 nM. Assay was performed in 
triplicate. Data represented as mean ± SEM. 
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3.5 CYCLIC ADENOSINE MONOPHOSPHATE (CAMP) ASSAY 
Cellular cyclic adenosine monophosphate (cAMP) levels were measured according to the reported 
method using LANCE cAMP 384 kits (PerkinElmer) [210]. This assay determines the 
functionality of the synthesized derivatives (agonist, antagonist/inverse agonist) by measuring the 
cAMP accumulation. The assay is a time-resolved fluorescence resonance energy transfer (TR-
FRET) immunoassay designed to measure cAMP produced upon modulation of adenyl cyclase 
(AC) activity by GPCRs. The assay is based on the competition between the europium-labeled 
cAMP tracer complex and total cAMP for binding sites on cAMP-specific antibodies. The anti-
bodies are labeled with Alexa Fluor dye that is sensitive to energy emissions. The fluorescence 
intensity decreases in the presence cAMP from the tested samples.  
CB2 receptor transfected CHO cells were seeded in a 384-well white ProxiPlates with a density of 
2000 cells per well in 5 μL of RPMI-1640 medium containing 1% dialyzed FBS, 25 mM HEPES, 
100 μg/mL penicillin, 100 U/mL streptomycin and 200 μg/mL of G-418. After culture overnight 
at 37 ºC and 5% CO2, 2.5 μL of cAMP antibody and RO20-1724 (final concentration 50 μM) in 
stimulation buffer (DPBS 1x, containing 0.1% BSA) were added to each well, followed by the 
addition of 2.5 μL compound with forskolin (final 5 μM) for agonist-inhibited adenylate cyclase 
(AC) activity assay. After incubation at room temperature for 45 min, 10 μL of detection reagent 
was added into each well. The plate was then incubated for 1 h at room temperature and measured 
in Synergy H1 hybrid reader (BioTek) with excitation at 340 nm and emission at 665 nm. Each 
cAMP determination was made via at least two independent experiments, each in triplicate. EC50 
values were determined by nonlinear regression, dose–response curves (GraphPad Prism 5).  
Figure 3.3 illustrates the cAMP assay of two known CB2 ligands; HU-308 (CB2 agonist), and 
SR144528 (CB2 inverse agonist). 
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Figure 3.3. LANCE cAMP signal profiles for reference CB2 ligands HU-308 and 
SR144528 
Comparisons of the LANCE signal of two CB2 receptor ligands in stably transfected CHO cells 
expressing human CB2 receptors in a concentration-dependent manner. (A) LANCE signal profile 
of a cannabinoid receptor 2 agonist, HU-308. (B) LANCE signal profile of a cannabinoid receptor 
2 inverse agonist, SR144528. Assay was performed in triplicate. Data represented as mean ± SEM. 
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3.6 CELL-VIABILITY ASSAY 
The purpose of the cell-viability assay can be divided to: A) to test the anti-proliferation properties 
of our synthesized derivatives on MM cell-lines, and B) to test the cytotoxicity effects of the 
derivatives. The synthesized CB2 ligands are tested for anti-cancer (anti-proliferation) activity and 
cytotoxicity effects using MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
colorimetric cell viability assay as described in the literature [211]. The anti-MM properties were 
examined on two MM cell-line: RPMI8226 and MM1.S. For the cytotoxicity assay, two cell-lines 
were utilized: the osteoclast precursor RAW 267.7 cell-lines and bone marrow macrophages 
(BMM) derived cell-lines. The principle of the MTT assay is that the mitochondrial activity for 
most viable cells is constant. Thus, an increase or decrease in the number of viable cells is linearly 
related to mitochondrial activity. The mitochondrial activity of the cells is reflected by the 
conversion of the tetrazolium salt MTT into insoluble formazan crystals (dark purple) by cellular 
reductase, which can be solubilized for measurement. Thus, measuring the formazan concentration 
by optical density (OD) will reflect any increase or decrease in cell viability. A plate 
spectrophotometer reader was used to measure the OD at 570 nm. Briefly, MTT stock was 
prepared by dissolving 500 mg MTT (Sigma, St. Louis, USA) in 10 mL PBS. Continuous stirring 
for 1 hour in the dark, filtered and stored at – 20 ºC. Cells were seeded in a 96-well at a cell number 
of 1.5 × 103 – 3 × 103 cells per well in RPMI-1640 medium containing 5% FCS to a volume of 
100 μL. Divide the well into: blank, control and treatment groups in triplicates. The blank wells 
contains only the assay media, while the control wells contain only the assay media plus ≤ 0.1% 
DMSO with no drug. Add the synthesized derivatives into the wells after dilution with DMSO and 
incubate for 48 hours at 37 C 5% CO2. MTT (20 μL) solution is added to each well, shaking 150 
rpm for 5 minutes, and then incubated for 2-5 hours at 37 C 5% CO2. The metabolism product 
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(formazan) was dissolved in 200 μL DMSO and the plate was shaken at 150 rpm for 5 minutes. 
Optical density was then read at 540 nm and subtracted from the background at 720 nm. 
In order to generate BMM, first the L-929 (murine fibroblast cell-line that secrets M-CSF) 
supplemented media is generated according to the following: L-929 cell-lines are seeded at a 
density of 7 × 106 cells/plate in α-MEM media supplemented with 10% FBS, 100 U/mL penicillin, 
and 100 µg/mL streptomycin. The plates were incubated for 3 – 5 days at 37 ºC and 5% CO2, then 
the L-929 supernatant were collected. α-MEM media was mixed with 10% FBS, 10 – 30% L-929 
supernatant, 2-5% β-mercaptoethanol and penicillin/streptomycin  (L-929 conditioned media, 
stored at -20 ºC). Bone marrow cells harvested from the femur and tibia of 4- to 6-week-old 
C57/BL6 mice were plated at density of 7 × 106 cells/plate in 10 mL L-929 conditioned media and 
incubated at 37 ºC and 5% CO2 for 7 – 10 days, changing media every 3 days. After incubation, 
the BMM were harvested and ready to use. For the cell-viability assay, the same procedure of MTT 
assay described above is used. 
3.7 OSTEOCLAST FORMATION ASSAY 
Mouse osteoclast formation assay was performed as previously described [212, 213]. Bone 
marrow cells were harvested from the femur and tibia of 4- to 6-week-old C57/BL6 mice washed 
with α-MEM filtered through a 70 mm cell strainer, and seeded in a 96-well plate at a density of 2 
× 105 cells per well (50 μL). To examine the effect of our synthesized CB2 ligands on the formation 
of osteoclast cells, ligands were diluted to the desired concentrations in DMSO and added to each 
well in the presence of 30 ng/mL receptor activator of nuclear factor kappa-B ligand (RANKL) 
(ProSpec, NJ) and 15 ng/mL macrophage colony-stimulating factor (M-CSF) (R&D Systems) to 
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a total volume of 50 μL. Plates were incubated at 37 C 5% CO2 changing half media every 3 days 
with or without treatment. After 7 – 10 days, cells were fixed and stained for tartrate-resistant acid 
phosphate (TRAP) (Sigma) activity according to the recommendation of the manufacturer. TRAP+ 
multinucleated cells with more than three nuclei were counted as osteoclasts. 
3.8 STATISTICAL ANALYSIS 
Radioligand binding assays as well as the CB2 functional assays (cAMP) were performed in 
triplicates and expressed as the mean ± SEM. Cell viability assay and the osteoclast formation 
assay were performed in triplicates and the data are expressed as the mean ± SD. Comparisons 
between the groups were made with unpaired Student’s t test. Statistical differences were as 
follows: no significance (NS) P>0.05, *P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001 
compared with the control groups. 
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4.0  DESIGN, SYNTHESIS, AND BIOLOGICAL EVALUATIONS OF DI-AMIDE 
DERIVATIVES AS SELECTIVE CB 2 INVERSE AGONISTS 
4.1 INTRODUCTION 
4.1.1 Discovery of Cannabinoid Receptor 2 (CB2) Ligands 
To develop potent and selective cannabinoid receptor 2 ligands, 3D pharmacophore modeling and 
in-silico virtual screening studies were carried out. The 3D-QSAR studies of CB2 bioactive 
antagonists were utilized using the genetic algorithm based pharmacophore alignment method 
(GALAHAD, Tripos, Inc.). The training set consisted of 20 known active CB2 ligands and 980 
random compounds to ensure the liability of the generated pharmacophore models. The resulted 
pharmacophore and virtual screening studies lead to the discovery of a novel CB2 scaffold, XIE-
35 (Figure 4.1) [214]. The hit compound was subjected to radio-ligand competition binding assay 
in order to validate its potency and selectivity towards the CB2 receptor (Figure 4.2). XIE-35 
showed high potency and selectivity towards the CB2 receptor (CB2 Ki = 31.7 nM, CB1 Ki = 4185 
nM, SI = 132).  
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Figure 4.1. Chemical structure of XIE-35 
The hit compound, XIE-35, showed a novel CB2 chemical structure consisting of a carbon center, 
an amidine group, an azo- group (R-N=N-R) and three benzyl rings. 
 
 
Figure 4.2. Competition binding profile for XIE-35 
Competition binding experiments were performed on membrane proteins harvested from CHO 
cells stably expressing CB1 or CB2 receptors. Competitive displacement of the [3H]-CP55,940 
was obtained by using an increased amount of cold ligands. (A) Competition binding profile of 
XIE-35 utilizing CB2 membrane proteins, Ki = 31.7 nM. (B) Competition binding profile of XIE-
35 utilizing CB1 membrane proteins, Ki = 4185 nM. 
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 To further test the hit compound, XIE-35, for functionality, LANCE cyclic adenosine 
monophosphate (cAMP) assay was carried out to determine its agonism, antagonism or inverse 
agonism profile. cAMP is a secondary messenger that can be measured using cell-based assay  in 
GPCR’s to determine the ligand’s functionality. The assay was carried out as described in Chapter 
3. CB2 receptors are Gαi/o-Protein Coupled Receptors which an agonist will inhibit the forskolin-
induced cAMP production, resulting in an increase of the LANCE signal. An antagonist or an 
inverse agonist, on the other hand, decreases the LANCE signal toward forskolin-induced cAMP 
accumulation. As shown in Figure 4.3, increasing concentrations of compounds SR144528 and 
XIE-35 caused reductions of the LANCE signal indicating that these compounds are inverse 
agonist. However, increasing concentrations of compound CP-55,940 caused an increase in the 
LANCE signal which is exhibited by CB2 agonists. These results indicate that XIE-35 is a 
selective CB2 receptor inverse agonist. 
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Figure 4.3. LANCE cAMP signal of XIE-35 and known CB2 ligands 
Stably transfected CHO cells expressing human CB2 receptors was utilized in LANCE cAMP 
assay. CP-55,940 is a known CB2 agonist, while SR 144528 is a known CB2 inverse agonist. 
Assay was performed in triplicate. Data represented as mean ± SEM 
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4.1.2 Scaffold Hopping and Lead Optimization  
Although XIE-35 showed high potency and selectivity towards the CB2 receptor, the chemical 
structure has limitations that require chemical modifications. The amidine scaffold is an 
unfavorable drug moiety as it will cause poor solubility and bioavailability. In addition the azo- 
group is known to be a toxic moiety that requires modifications to replace it. As a result, scaffold 
hopping was performed utilizing pharmacophore and molecular docking studies. The 
pharmacophore alignment studies were performed using GALAHAD module (Tripos, Inc.) 
utilizing four known CB2 inverse agonists (SR144528, AM630, JTE-907, and Sch.225336) as well 
as XIE-35, and the molecular docking was performed using Surflex-Dock module (Tripos, Inc.). 
The 3D pharmacophore model suggested four hydrophobic (light blue), one hydrogen bond 
acceptor (green), and one hydrogen bond donor (pink) features (Figure 4.4). Utilizing the 
pharmacophore model, we carried out a 3D database screening via the UNITY pharmacophore 
search program (SYBYL X1.3). As a result, compound 4.1 (N,N′-((4-
(dimethylamino)phenyl)methylene)-bis(2-phenylacetamide)) was discovered and identified with 
novel chemotype (Figure 4.5). Structural analysis of 4.1 shows the replacement of the amidine 
group with an amide moiety which retains the hydrogen bonding feature. Furthermore, the azo- 
group was removed, yet retaining the hydrophobic property of ring B. Finally, molecular docking 
was performed using Surflex-Sim module (Tripos, Inc.), which suggested that adding bulky groups 
on ring B may help in improving the binding affinity.  
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Figure 4.4. Pharmacophore model 
The pharmacophore alignment model was generated using GALAHAD module (Tripos, Inc.). (A) 
Pharmacophore properties of XIE-35. (B) Pharmacophore model utilizing four known CB2 
inverse agonists (SR144528, AM630, JTE-907, and Sch.225336) as well as XIE-35.  
 
 
                                             
                               XIE-35                   Compound 4.1 
 
Figure 4.5. Scaffold hopping and lead optimization of XIE-35. 
The hit compound, XIE-35, was subjected to chemical modifications and optimizations based of 
pharmacophore alignment and docking studies to identify 4.1. The amidine group and the adjacent 
amide moiety was replaced with a di-amide backbone. The azo- group was replaced and the 
distance between ring B and the di-amide backbone was reduced.  
Lead 
optimization 
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The modified hit compound, 4.1, represents a novel CB2 structure. The important features of 4.1 
are: (i) di-amide scaffold; (ii) two un-substituted benzyl rings (ring A); (iii) a p-substituted benzyl 
ring (ring B) attached with dimethyl amine. The binding affinities of 4.1 towards the CB2 and CB1 
are illustrated in Figure 4.6.  
 
Figure 4.6. Competition binding profile for compound 4.1. 
Competition binding experiments were performed on membrane proteins harvested from CHO 
cells stably expressing CB1 or CB2 receptors. Competitive displacement of the [3H]-CP55,940 
was obtained by using an increased amount of cold ligands. (A) Competition binding profile of 4.1 
utilizing CB2 membrane proteins, Ki = 777 nM. (B) Competition binding profile of 4.1 utilizing 
CB1 membrane proteins, Ki > 20,000 nM. 
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The goal of the lead optimization is to obtain highly potent and selective CB2 ligands that 
will be further tested for OCL formation experiments as well as anti-MM activity. Thus, the lead 
modification strategy was to perform a structure activity relationship (SAR) studies in order to 
develop selective ligands. The SAR plan included: preserving the aromatic moiety of ring A and 
to add small substitutions on the ring, such as Cl, CF3, etc. Also, to introduce bulky groups on ring 
B in order to preserve the hydrophobic hollow in the CB2 binding pocket. 
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4.2 RESULTS AND DISCUSSION 
4.2.1 Chemistry Synthesis 
 The chemistry synthesis routes for the di-amide derivatives are illustrated in Scheme 1. The 
commercially available 2-phenylacetonitrile was treated with concentrated H2SO4 to give 2-
phenylacetamide. 2-Phenylacetamide was reacted with substituted aldehyde in the presence of 
either trimethylsilyl chloride (TMSCI) or trimethylsilyl trifluoromethanesulfonate (F3CSO3SiMe3) 
(compounds 4.1 – 4.22 and 4.42 – 4.43). Similarly, when the building block 2-(4-
Chlorophenyl)acetamide and (4-(trifluoromethyl)phenyl)acetamide were reacted with substituted 
aldehyde in the presence of TMSCl yielded the corresponding compounds 4.23 – 4.31 and 4.32 – 
4.38. Furthermore, when the commercially available amide building blocks benzamide, 3-
phenylpropanamide, cinnamamide, isobutyramide, pivalamide, pentanamide, hexanamide, 
octanamide, and decanamide reacted with substituted aldehyde yielded the corresponding 
compounds 4.39, 4.40, 4.41, 4.44, 4.45, 4.46, 4.47, 4.48, and 4.49. For compound 4.20, N, N'-((4-
nitrophenyl)methylene)bis(2-phenylacetamide) was subjected to nitro reduction when treated with 
palladium and hydrazine. The intermediate was then subjected alkylation utilizing benzyl bromide. 
The target compounds were purified by flash chromatography or preparative TLC where indicated 
and confirmed by NMR as well as LC-MS. 
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Scheme 1. Synthesis routes of di-amide derivatives. 
R1: H, -Cl, -CF3, R2: substituted aldehydes, and R3: phenyl.  Reagents and conditions: (a) 
concentrated H2SO4, 0 °C, 12 h. (b) Method 1: substituted aldehyde, anhydrous dichloroethane, 
TMSCl, 70 °C, 3 – 12 h. (c) Method 2: substituted aldehyde, anhydrous dichloroethane, 
F3CSO3SiMe3, rt, 12 h. (d) 4-nitrobenzaldehyde, anhydrous dichloroethane, TMSCl, 70 °C, 3 – 12 
h. (e) ethanol, palladium (10%), hydrazine, 70 °C, 3 h. (f) substituted bromide, DMF, K2CO3, rt, 
12 h. 
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4.2.2 Structure Activity Relationship Analysis 
In light of the lead optimization strategy, medicinal chemistry modifications were carried out and 
synthesized 49 di-amide derivatives. The SAR study was carried out on the basis of CB1 and CB2 
binding affinities and selectivities. The radio-ligand binding affinities were carried by performing 
[3H]-CP55,940 radio-ligand displacement assay utilizing membrane protein preparations of CHO 
cells stably expressing human CB1 and CB2 receptors. CB1 selective ligand (SR141716) was used 
as a positive control along with the tested compounds. CB2 selective ligand (SR144528) was used 
as a positive control with the tested compounds. The chemical structures, physicochemical 
properties, binding affinities, and selectivity indices are tabulated in Table 4.1 - Table 4.4. 
The first SAR study was focused on the different substitutions on ring B while keeping 
ring A without substitutions. Ring B was modified with substitutions varying in size, electron 
character and position. Twenty-one compounds were synthesized (4.2 – 4.22, Table 4.1). 
Compared to compound 4.1, the removal of the p-dimethylamino group significantly decreased 
the CB2 binding activity (compound 4.2, CB2 Ki = 9930 nM). The CB2 binding affinity was 
reduced upon introducing fluorine atoms to different positions of ring B (ortho, meta, and para 
positions) (compounds 4.3, 4.4, and 4.5, CB2 Ki 35330, 12670, and 10900, respectively). The 
binding affinities of the F-substituted compounds towards the CB2 receptor was in the order of p-
F > m-F > o-F. Similarly, introducing p-trifluoromethyl to ring B showed improved CB2 binding 
affinity (compound 4.14, CB2 Ki = 596 nM) while o-trifluoromethyl substitution on ring B showed 
significant binding activity reduction (compound 4.13, CB2 Ki = 11780 nM). Furthermore, 
replacing the p-fluorine with chlorine (compound 4.6) or bromine (compound 4.7) showed weak 
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binding affinities. We concluded from these results that substitution at the para position of ring B 
may play an essential role in the CB2 binding affinity. In addition, introducing p-methyl to ring B 
(compound 4.8) improved the CB2 binding affinity, however compound 4.8 showed high CB1 
affinity (compound 4.8, CB2 Ki = 494 nM, CB1 Ki = 109 nM). Introducing bioisostere isopropyl 
(compound 4.9) instead of the p-diethylamino significantly improved the binding affinity as well 
as selectivity (CB2 Ki = 85 nM, CB1 Ki > 20,000 nM, selectivity index > 235).  
Next, we further investigated para substitutions on ring B by introducing different alkoxy 
groups.  Three alkoxy groups were tested varying in size, methoxy (4.10), ethoxy (4.11), and 
isopropoxy (4.12). Compound 4.10 with methoxy group showed similar activity and selectivity 
compared to the parent compound (4.10, CB2 Ki = 783 nM, CB1 Ki > 20000 nM, selectivity index 
> 235). Compound 4.11 with ethoxy group showed slight decrease in binding activity (4.11, CB2 
Ki = 1500 nM). Compound 4.12 with the isopropoxy group showed slight increase in the binding 
activity (4.12, CB2 Ki = 313 nM, CB1 Ki > 20000, selectivity index > 64). These results indicate 
that the size of the alkoxy group influence the binding affinity and selectivity. 
In order to explore the electronic and steric effects on the binding affinity and selectivity, 
we introduced a p-NO2 group to ring B (compound 4.15). However, 4.15 completely lost the CB2 
binding affinity. When reducing the nitro group to the corresponding amine (compound 4.16), the 
CB2 binding activity was restored but remained weak (4.16, CB2 Ki = 12550 nM). When replacing 
the p-amino with p-diethylamine group, the CB2 binding affinity and selectivity was significantly 
improved (compound 4.17, CB2 Ki = 64 nM, CB1 Ki > 20000, selectivity index >313). Compound 
4.17 was identified to be more potent and selective that the lead compound 4.1. As the introduction 
of the p-diethylamine to ring B resulted in a potent and selective compound, we tested different 
substituted amino groups on ring B. As a result, a number of potent compounds were identified 
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bearing p-dipropylamino, p-dibutylamino, p-dibenzylamino. p-pyrrolidinyl, and p-piperidyl 
(compounds 4.18, 4.19, 4.20, 4.21, and 4.22, respectively). These five amino substituted 
compounds showed high potency and selectivity compared to the lead compound 4.1. Comparing 
to compound 4.17 with the p-diethylamino on ring B, compound 4.18 with a p-dipropylamino 
group showed the highest activity and selectivity (CB2 Ki = 22 nM, selectivity index > 909). 
Increasing the size of the para substituted amine on ring B more than three carbons (compound 
4.19 bearing p-dibutylamino) slightly reduced the binding affinity compared to compound 4.17 
(4.19, CB2 Ki = 221 nM, selectivity index > 90). To further confirm the importance of the size of 
para substituted amine on ring B, compound 4.21 bearing a pyrrolidinyl group on ring B showed 
a similar activity (CB2 Ki = 71 nM, selectivity index > 281). While compound 4.20 with p-
dibenzylamino on ring B and compound 4.22 with a p-piperidylamino showed reduced CB2 
activities.  Thus, these results showed that the size of the para substituted amine at the para position 
on ring B play crucial roles in the binding activity. 
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Table 4.1. Radioligand competition binding affinity and physicochemical properties of di-
amide derivatives on ring B 
 
 
Entry R MW cLogP Ki (CB2), nM  Ki (CB1), nM SI 
4.1 p-(CH3)2N- 401.50 4.04 777 > 20,000 > 26 
4.2 H 358.43 3.93 9930 NT - 
4.3 o-F- 376.42 4.08 35330 NT - 
4.4 m-F- 376.42 4.08 12670 NT - 
4.5 p-F- 376.42 4.08 10900 NT - 
4.6 p-Cl- 392.88 4.54 3081 NT - 
4.7 p-Br- 437.33 4.70 2226 NT - 
4.8 p-CH3- 372.46 4.45 494 109 - 
4.9 p-i-C3H7- 400.51 5.18 85 > 20,000 > 235 
4.10 p-CH3O- 388.46 3.78 783 > 20,000 > 26 
4.11 p-C2H5O- 402.49 4.13 1500 NT - 
4.12 p-i-C3H7O- 416.51 4.55 313 > 20,000 > 64 
4.13 o-CF3- 426.43 4.81 11780 NT - 
4.14 p-CF3- 426.43 4.81 596 > 20,000 > 34 
4.15 p-NO2- 403.43 3.87 NB NT - 
4.16 p-H2N- 373.45 2.51 12550 NT - 
4.17 p-(C2H5)2N- 429.55 4.76 64 > 20,000 > 313 
4.18 p-(C3H7)2N- 457.61 5.80 22 > 20,000 > 909 
4.19 p-(C4H9)2N- 485.66 6.69 221 > 20,000 > 90 
4.20 p-(benzyl)2N- 553.69 7.33 203 > 20,000 > 99 
4.21 p-pyrrolidinyl- 427.53 4.45 71 > 20,000 > 281 
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4.22 p-piperidyl- 441.56 4.89 595 > 20,000 > 34 
SR144528    2.1 NT - 
SR141716    NT 10.6 - 
Binding affinities of compounds for CB1 and CB2 receptor were evaluated using [3H]CP-55,940 
radioligand competition binding assay. NB: no binding, Ki > 20000 nM. NT: not tested. SI: selectivity index 
for CB2, calculated as Ki(CB1)/Ki(CB2) ratio. The binding affinities of reference compounds were 
evaluated in parallel with tested compounds. CB2 reference compound SR144528 and CB1 reference 
compound SR141716. 
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Further, we explored the effect of variations on ring A by introducing Cl or CF3. Two series 
of compounds were synthesized: 4.23 – 4.31 (Table 4.2) and 4.32 – 4.38 (Table 4.3). The first 
series included compounds with p-Cl substitution on ring A and the substitutions on ring B were 
tested. Among the nine compounds, five compounds (4.26 – 4.30) showed improved binding 
activity to CB2. Comparing compound 4.26 with p-Cl on ring B and ring A (CB2 Ki = 154, 
selectivity index >130) with compound 4.6 with un-substituted rings A and p-Cl on ring B (CB2 
Ki = 3081 nM), the chlorine substitutions on rings A improved the binding affinity and selectivity. 
Same results were observed when comparing compounds 4.27 with 4.8, 4.28 with 4.10, 4.29 with 
4.22 and 4.30 with 4.14. The second series of compounds (4.32 – 4.38) with –CF3 substitution on 
rings A showed completely no binding to the CB2 receptors. These results indicated that the p-Cl 
substitution on rings A is better than –CF3 and H. 
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Table 4.2. Radioligand competition binding affinity and physicochemical properties of di-
amide derivatives with substituted chloride on ring A 
 
Entry R MW cLogP Ki (CB2), nM  Ki (CB1), nM SI 
4.23 H 427.32 5.14 NB NT - 
4.24 o-F- 445.31 5.29 10850 NT - 
4.25 p-F- 445.31 5.29 NB NT - 
4.26 p-Cl- 461.77 5.75 154 > 20,000 > 130 
4.27 p-CH3- 441.35 5.66 462 > 20,000 > 43 
4.28 p-CH3O- 457.35 4.98 310 > 20,000 > 65 
4.29 o-CF3- 495.32 6.02 158 > 20,000 > 127 
4.30 p-CF3- 495.32 6.02 101 > 20,000 > 198 
4.31 p-NO2- 472.32 5.08 NB NT - 
SR144528    2.1 NT - 
SR141716    NT 10.6 - 
Binding affinities of compounds for CB1 and CB2 receptor were evaluated using [3H]CP-55,940 
radioligand competition binding assay. NB: no binding, Ki > 20000 nM. NT: not tested. SI: selectivity index 
for CB2, calculated as Ki(CB1)/Ki(CB2) ratio. The binding affinities of reference compounds were 
evaluated in parallel with tested compounds. CB2 reference compound SR144528 and CB1 reference 
compound SR141716. 
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Table 4.3. Radioligand competition binding affinity and physicochemical properties of di-
amide derivatives with substituted trifluoromethyl (-CF3) on ring A 
 
Entry R MW cLogP Ki (CB2), nM  Ki (CB1), nM SI 
4.32 H 494.43 5.69 NB NT - 
4.33 o-F- 512.42 5.83 NB NT - 
4.34 p-F- 512.42 5.83 NB NT - 
4.35 p-Cl- 528.87 6.29 NB NT - 
4.36 p-CH3- 508.46 6.20 NB NT - 
4.37 p-CH3O- 524.45 5.53 NB NT - 
4.38 o-CF3- 562.43 6.57 NB NT - 
SR144528    2.1 NT - 
SR141716    NT 10.6 - 
Binding affinities of compounds for CB1 and CB2 receptor were evaluated using [3H]CP-55,940 
radioligand competition binding assay. NB: no binding, Ki > 20000 nM. NT: not tested. SI: selectivity index 
for CB2, calculated as Ki(CB1)/Ki(CB2) ratio. The binding affinities of reference compounds were 
evaluated in parallel with tested compounds. CB2 reference compound SR144528 and CB1 reference 
compound SR141716. 
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Next, we studied the importance of the distance from ring A to the amide group 
(compounds 4.39 – 4.41, Table 4.4). Reducing or increasing the distance between ring A and the 
amide group of compound 4.17 by removing CH2 (compound 4.39), inserting -CH2CH2- 
(compound 4.40), or inserting –CH=CH- (compound 4.41) retained the CB2 binding affinity and 
selectivity with minimal decrease.  
To explore the importance of the aromatic property of ring B on the CB2 binding affinity 
and selectivity, we explored the effects of removing the aromatic ring B of compound 4.17 and 
replacing it with various alkyl chains varying in length (compounds 4.42 and 4.43, Table 4.4). 
Replacing ring B with butyl alky chain (4.42) or pentyl (4.43) resulted in complete loss of binding 
activity. These results indicate that aromatic property of ring B plays crucial roles in the CB2 
binding affinity.  
We further studied the importance of ring A by replacing the aromatic rings with different 
alkyl chains while retaining ring B with p-diethylamino group (compounds 4.44 – 4.49, Table 4.4). 
Replacing the benzyl groups with a branched chain isopropyl (compound 4.44) or tert-butyl group 
(compound 4.45) significantly decreased the CB2 binding affinity. However, replacing the benzyl 
group with a butyl alkyl chain (compound 4.46) showed a slight decrease in binding activity. 
Importantly, replacing the benzyl group with a pentyl alkyl chain showed a remarkable CB2 
binding affinity and selectivity (compound 4.47, CB2 Ki = 25 nM, CB1 Ki > 20000, selectivity 
index > 800). Compared to compound 4.47, increasing the length of the alkyl chain with n-C7H15 
(compound 4.48) or n-C9H19 (compound 4.49) showed a slight decrease in binding activity with 
CB2 Ki of 146 nM, selectivity index > 136 and CB2 Ki = 160 nM, selectivity index > 125, 
respectively. From these results, we conclude that distance between the ring A and the amide group 
play a slight role and the –CH2 is optimal. Also, ring B is important for retaining the CB2 binding 
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activity. Finally, aromatic rings A may be replaced with alkyl chains and the pentyl group in 
optimal for binding activity. 
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Table 4.4. Radioligand competition binding affinity and physicochemical properties of di-
amide derivatives with varying substitutions 
   
Entry R1 R2 R3 R4 MW cLogP 
K
i
 (CB2), 
nM  
K
i
 (CB1), 
nM 
SI 
4.39 - - 
 
N,N-
diethylaniline 
401.50 4.80 688 > 20,000 > 29 
4.40 - - 
 
N,N-
diethylaniline 
457.61 5.64 213 > 20,000 > 93 
4.41 - - 
 
N,N-
diethylaniline 
453.58 5.80 167 > 20,000 >119 
4.42 H H 
 
-C4H9 338.44 3.75 35970 NT - 
4.43 H H 
 
-C5H11 352.47 4.19 18200 > 20,000 - 
4.44 H -CH3 -CH3 
N,N-
diethylaniline 
333.46 3.57 2636 NB - 
4.45 -CH3 -CH3 -CH3 
N,N-
diethylaniline 
361.52 4.69 3553 NB - 
4.46 H H -C3H7 
N,N-
diethylaniline 
361.52 4.27 182 > 20,000 >109 
4.47 H H -C4H9 
N,N-
diethylaniline 
389.57 5.16 25 > 20,000 >800 
4.48 H H -C6H13 
N,N-
diethylaniline 
445.68 7.9 146 > 20,000 >136 
4.49 H H -C8H17 
N,N-
diethylaniline 
501.79 10.0 160 > 20,000 >125 
SR144528       2.1 NT -- 
SR141716       NT 10.6 -- 
Binding affinities of compounds for CB1 and CB2 receptor were evaluated using [3H]CP-55,940 
radioligand competition binding assay. NB: no binding, Ki > 20000 nM. NT: not tested. SI: selectivity index 
for CB2, calculated as Ki(CB1)/Ki(CB2) ratio. The binding affinities of reference compounds were 
evaluated in parallel with tested compounds. CB2 reference compound SR144528 and CB1 reference 
compound SR141716. 
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4.2.3 In-Vitro Functional Assay  
To determine the functionality (agonist or antagonist functions) of the synthesized CB2 ligands, 
ligands that exhibited high potency and selectivity were subjected to LANCE cAMP assay. The 
assay was carried out as stated in Chapter 3. Six compounds (4.1, 4.9, 4.17, 4.18, 4.21, and 4.47) 
were chosen for the assay utilizing CB2 cells harvested from CHO cells stably expressing CB2 
receptors. CB2 receptors are Gαi-coupled receptors in which an agonist will inhibit the forskolin-
induced cAMP production resulting in an increase of the LANCE signal. An antagonist or an 
inverse agonist will induce the cAMP formation resulting in a decrease of the LANCE signal. 
Thus, LANCE signal is inversely proportional to cAMP level. As illustrated in Figure 4.7, 
increasing concentrations of compounds 4.1, 4.9, 4.17, 4.18, 4.21, 4.47 as well as SR144528 (CB2 
inverse agonist) led to reductions of the LANCE cAMP signal. These results indicate that these 
ligands are inverse agonists. This behavior was not seen with CB2 agonists CP-55,940 and HU-
308 as they inhibited cAMP production.  
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Figure 4.7. LANCE cAMP signal of the di-amide derivatives 
Stably transfected CHO cells expressing human CB2 receptors were utilized in LANCE cAMP 
assay. HU-308 and CP-55,940 are known CB2 agonist, while SR 144528 is a known CB2 inverse 
agonist. Compounds 4.1, 4.9, 4.17, 4.18, 4.21, and 4.47 as well as SR144528 inhibited the cAMP 
production with an EC50 value of 159 ± 8.68, 4.11 ± 3.66, 5.73 ± 6.37, 28.33 ± 2.54, 17.08 ± 2.11, 
13.42 ± 2.07, and 13.7 ± 2.81 nM, respectively. Data represented as the mean ± SEM of one 
representative experiment of three experiments carried out in triplicates. 
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4.2.4 CB2 Inverse Agonist as Osteoclast Inhibitors 
As the cannabinoid receptors and the endocannabinoid systems have been proven to have roles in 
bone remodeling and homeostasis, we tested several synthesized ligands for their anti-
osteoclastogenesis activities. The assay is based on the OCL formation after receptor activator of 
nuclear factor kappa-B ligand (RANKL) induction. Non-adherent mononuclear bone marrow cells 
were seeded at a density of 2 × 105 cells/well in a 96- well plate. Test wells were treated with the 
highly potent and selective CB2 derivatives (4.9, 4.12, and 4.17). In addition, the known CB2 
inverse agonist, SR144528, was used as a positive control and compound 4.1 was also tested for 
comparison reasons. Plates were incubated for 3 weeks in the presence of RANKL (50 ng/mL) 
and M-CSF (10 ng/mL). The detailed experimental protocol was outlined in Chapter 3. All 
compounds were tested in concentrations of 10 µM, 1 µM, and 0.1 µM. Control groups included 
wells treated with RANKL, wells without RANKL, and wells treated with SR144528.  
All tested ligands exhibited a concentration-dependent inhibition of osteoclastogenesis. 
The synthesized ligands exhibited even more inhibition activity than the known CB2 inverse 
agonist (SR144528). As illustrated in Figure 4.8, compound 4.17 showed the strongest inhibition 
activity with inhibition rates of 72%, 79% and 84% at 0.1, 1 and 10 µM, respectively. In addition, 
compound 4.17 was more potent in inhibiting the OCL than the lead compound 4.1, as it showed 
and inhibition rate of 75%, 77% and 82% at 0.1, 1 and 10 µM, respectively. Overall, these data 
suggest that our medicinal chemistry design and synthesis were successful in improving CB2 
binding level as well as the therapeutic level. 
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Figure 4.8. Osteoclast inhibition activity by di-amide derivatives. 
Inhibition of human osteoclastogenesis by the di-amide derivatives. Human-bone-marrow-derived 
mononuclear cells (2 × 105 cells/well) were seeded in a 96- well plate for 3 weeks in the presence 
of RANKL (50 ng/mL) and M-CSF (10 ng/mL). Control group were divided into RANKL positive 
and RANKL negative. Cultures were stained with TRAP staining kit (Sigma). TRAP positive 
OCLs containing three or more nuclei were counted as OCL. Results represented as the mean ± 
SD of three experiments carried out in triplicates. Statistical differences are as follows: *P<0.05, 
**P<0.01, ***P<0.001, and ****P<0.0001 compared with the control (RANKL +). 
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4.2.5 Multiple Myeloma Anti-Proliferation Studies 
To test whether our newly synthesized compounds possesses anti-proliferation effects on MM cell-
lines, we first analyzed the proliferation activity of the known selective CB2 ligands including, 
SR144825 and CP-55,940. As illustrated in Figure 4.9, the CB2 inverse agonist, SR144528, 
exhibited low anti-proliferative effects on MM cell-lines with IC50 of 19.4 µM and 25 µM for 
RPMI8226 and MM1.S cell-lines, respectively. On the other hand, the CB2 agonist, CP55940, 
showed good anti-proliferative effects on MM cell-lines with an IC50 of 2.76 µM and 2.17 µM for 
RPMI8226 and MM1.S, respectively. These data suggest that CB2 agonist may play crucial roles 
as anti-MM.  
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Figure 4.9. IC50 of known CB2 ligands on MM cell-lines 
IC50 was measured by utilizing the MTT-colorimetric assay. MM cell-lines RPMI8226 and 
MM1.S were seeded at a density of 3 × 103 / well and treated with varying concentrations of the 
compounds. (A) IC50 of SR144528 = 19.4 µM and 25 µM for RPMI8226 and MM1.S cell-lines, 
respectively. (B) IC50 of CP55,940 = 2.76 µM and 2.17 µM for RPMI8226 and MM1.S cell-lines, 
respectively. Data is the mean ± SD of three experiments carried out in triplicates. 
125 
For our newly synthesized CB2 ligands, we utilized the MTT assay to screen our 
compounds for their anti-MM activity using 10 µM concentration of the compounds. Four 
compounds with high CB2 affinity and selectivity were utilized in the MTT screening studies. As 
shown in Figure 4.10, nearly all the derivatives exhibited low inhibition rates on the MM cell-lines 
RPMI8226 and MM1.S. As expected, these results indicates that developing selective CB2 
agonists is more promising as anti-MM agents. 
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Figure 4.10. Cell viability screening of the di-amide derivatives on MM cell-lines 
Two multiple myeloma cell-lines (MM1.S and RPMI8226) were utilized to study the anti-
proliferation effects of the synthesized derivatives. Cells were plated at density of 3 × 103/well in 
96-well plates. Cells were incubated with 10 µM concentration of the tested derivatives for 3 days. 
The cell viability was determined with the MTT assay. All of the compounds demonstrated no 
significant (NS) inhibition rates (NS = P >0.05 compared with the control which was defined as 
100%). Data is the mean ± SD of three experiments carried out in triplicates.
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4.2.6 Stability and Pharmacokinetic Studies 
As the excellent in-vitro activity profiles of several of the newly discovered novel CB2 ligands, 
we utilized compound 4.17 as a representative compounds of the di-amide CB2 scaffold to carry 
out in-vivo pharmacokinetic (PK) studies and to establish PK profile in rats. After oral 
administration of compound 4.17, the maximal plasma concentration was 8 µg/L (Cmax), plasma 
exposure of 23.46 µg/L*h (AUC0-∞), an elimination half-life (t1/2) of 2.69 hours, and a clearance 
of 1649.1 L/h/kg.  
 
Table 4.5. Oral pharmacokinetic properties of 4.17 
Parameter Unit No.1 No.2 No.3 Mean 
AUC(0-t) µg/L*h 14.20 28.08 28.10 23.46 
AUC(0-∞) µg/L*h 16.47 28.10 28.19 24.25 
λ 1/h 0.23 0.32 0.24 0.26 
C µg/L 0.52 0.01 0.02 0.18 
t1/2 h 3.04 2.20 2.84 2.69 
Tmax h 0.17 0.17 1.00 0.44 
Vd L/kg 5326 2260 2908 3498 
CL L/h/kg 1214 712 709 879 
Cmax µg/L 8 11 4 8 
AUC, area under the concentration−time curve; Cmax, peak plasma concentration of a drug after 
administration; CL, clearance; Tmax, time to reach Cmax; t1/2, elimination half-life; Vd, volume of 
distribution.  
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The poor PK profile of 4.17 (and other di-amide derivatives) may be attributed to the di-
amide scaffold as in acidic conditions, the di-amide is subjected hydrolysis in which the ligand 
will break down into 2-phenylacetamide and (Z)-N-(4-(diethylamino)benzylidene)-2-
phenylacetamide. Figure 4.11 illustrates the possible instability mechanism due to the di-amide 
scaffold. Nevertheless, intravenous (IV) PK studies were not conducted due to the instability and 
poor water solubility of the di-amide scaffold. 
 
 
Figure 4.11. Compound 4.17 acidic instability. 
In acidic conditions (i.e. gastric acid), the di-amide scaffold of compound 4.17 is subjected to 
hydrolysis resulting in the breakdown of the compound. The possible byproducts are 2-
phenylacetamide and (Z)-N-(4-(diethylamino)benzylidene)-2-phenylacetamide. As a result, poor 
pharmacokinetic properties were observed. 
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4.3 CONCLUSION 
In this chapter, we utilized ligand discovery tools in order to discover and identify novel CB2 
chemotype including pharmacophore modeling as well as high-throughput screening 
methodologies. 3D-QSAR studies were carried out to identify XIE-35 as a new CB2 selective 
inverse agonist with CB2 Ki = 31.7 nM, CB1 Ki = 4185, and SI of > 132. Due to the structural 
limitations of XIE-35, lead optimization was carried out by utilizing pharmacophore model 
generation followed by virtual screening to identify compound 4.1. Compound 4.1 was identified 
as a novel CB2 chemotype with the di-amide scaffold and was subjected to SAR studies to identify 
and explore different structural modifications on the di-amide scaffold.  
In the SAR studies, we designed and synthesized 49 di-amide derivatives with variations 
on the aromatic rings A and B. The SAR studies revealed: (1) the para-substituted amino group on 
ring B plays crucial roles in the CB2 receptor binding affinity and selectivity, different functional 
groups were tolerated and the p-dipropylamino group is optimal, (2) small group substitutions on 
ring A showed that p-Cl is better substituent than –CF3 and H, (3) the aromatic ring B is essential 
to retain potency toward the CB2 receptor. Our results and findings are consistent with the 
pharmacophore findings where aromatic ring B is necessary for CB2 affinity. Among the 49 di-
amide derivatives, five compounds 4.9, 4.17 4.18, 4.21, and 4.47 exhibited high potency and 
selectivity toward the CB2 receptor (CB2 Ki < 90 nM, CB1 Ki > 20000 nM). Furthermore, 
functional assay (cAMP assay) confirmed that these five compounds are selective CB2 inverse 
agonists.  
Importantly, osteoclast formation assay utilizing human bone marrow cells confirmed that 
the top novel di-amide CB2 inverse agonists inhibited the osteoclast formation at low doses. 
Compound 4.17 demonstrated the highest inhibition rate of 72% at low concentration (0.1 µM) 
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suggesting important roles for selective CB2 inverse agonists as anti-osteoclastogenesis and 
ultimately for treating osteoporosis. On the other hand, anti-proliferation studies on MM cell-lines 
showed low inhibitory effects of our newly discovered compounds and that developing CB2 
agonists rather than inverse agonists may play key roles as anti-MM agents as demonstrated by 
the inhibition abilities of CP-55,940 on MM cell-lines. In addition, pharmacokinetic studies of the 
di-amide scaffold were conducted and demonstrated moderate elimination half-life, plasma 
exposure as well as clearance properties. Furthermore, i.v. PK studies were not conducted due to 
the limited stability and solubility of the compounds. Albeit the limitations of the di-amide 
scaffold, our novel selective CB2 inverse agonists represent a novel class of CB2 ligands that can 
be further optimized as anti-osteoclastogenesis agents with improved pharmacokinetic properties. 
Nevertheless, the newly discovered selective ligands represent a new chemotype that can be 
utilized as chemical probes in different biochemical assays. 
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4.4 EXPERIMENTAL 
4.4.1 Pharmacophore Modeling and Virtual Screening 
Genetic algorithm-based pharmacophore alignment (GALAHAD™, Tripos Inc.) approach was 
used to derive a 3D pharmacophore model based on known CB2 inverse agonists including 
SR144528, AM630, JTE-907, Sch.225336 and XIE-35. The derived pharmacophore model was 
then examined and refined using our in-house training database which contained a mixture of 
random molecules and known CB2 ligands. The derived pharmacophore model was subsequently 
used as a query in the UNITY (Tripos Inc.) program to perform virtual screening on a structurally 
diverse representative compound database [132]. Top ranked screened compounds from the 
pharmacophore search were obtained commercially or via material transfer agreement (MTA) to 
be experimentally validated for CB2 binding activity and selectivity. 
4.4.2 Chemistry 
4.4.2.1 General synthesis procedure of 2-Phenylacetamide building blocks 
2-Phenylacetamide.  
Benzyl cyanide (5 g, 42.7 mmol) was added slowly to concentrated sulfuric 
acid (20 mL) cooled by a water-ice bath. The solution was stirred overnight. 
The reaction mixture was poured into ice-water and neutralized with 20% NaOH. The aqueous 
phase was extracted by ethyl acetate (3 × 15 mL). The combined organic layer was washed with 
water (3 × 10 mL) and brine (3 × 10 mL), dried over anhydrous MgSO4, filtered, concentrated 
under reduced pressure, and the residue was recrystallized from ethyl acetate and hexane to give 
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the desired compound. (4.5 g, yield: 78%). 1H NMR (400 MHz, DMSO-d6) δ7.54 (s, 1H), 
7.20−7.32 (m, 5H), 6.87 (s, 1H), 3.38 (s, 2H). 
2-(4-Chlorophenyl)acetamide.  
Yield: 65%. 1H NMR (400 MHz, DMSO-d6) δ 7.49 (s, 1H), 7.34−7.35 (m, 
2H), 7.26−7.27 (m, 2H), 6.92 (s, 1H), 3.34−3.37 (m, 2H). 
(4-(Trifluoromethyl)phenyl)acetamide.  
Yield: 80%. 1H NMR (400 MHz, DMSO-d6) δ 7.65 (d, J = 8.0 Hz, 2H), 7.58 
(s, 1H), 7.49 (d, J = 8.0 Hz, 2H), 7.00 (s, 1H), 3.51 (s, 2H). 
4.4.2.2 General synthesis procedure for the coupling reaction between amide and aldehyde 
General Method 1 [215]:  
N,N′-((4- (dimethylamino)phenyl)methylene)bis(2-phenylacetamide) (4.1). To a suspension of 
4-(dimethylamino)benzaldehyde (149 mg, 1 mmol) and 2-
phenylacetamide (270 mg, 2 mmol) in anhydrous 
dichloroethane (2 mL) was added TMSCl (216 mg, 2 mmol) . 
The mixture was heated at 70 °C for 12 h, then cooled to room 
temperature and the crude product precipitated from the solution. The crude product was 
recrystallized with methanol and hexane to give the final product. Off-white solid (140 mg, yield: 
35%).1H NMR (400 MHz, DMSO-d6) δ 8.89 (d, J = 8.0 Hz, 2H), 7.59 (s, 2H), 7.41 (d, J = 8.8 Hz, 
2H), 7.21−7.32 (m, 10H), 6.54 (t, J = 8.0 Hz, 1H), 3.52 (dd, J = 14.0, 15.6 Hz, 4H), 3.06 (s, 6H). 
LC−MS (ESI): m/z 402.1 (M + H)+. 
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N,N′-(phenylmethylene)bis(2-phenylacetamide) (4.2). Compound 4.2 was prepared from 2-
phenylacetamide and benzaldehyde using method 1. White 
solid (240 mg, yield: 67%).1H NMR (400 MHz, DMSO-d6) δ 
8.78 (d, J = 7.2Hz, 2H), 7.21−7.35 (m, 15H), 6.55 (t, J = 7.8 Hz, 
1H), 3.50 (dd, J = 13.8, 20.4 Hz, 4H). LC−MS (ESI): m/z 359.3 (M + H)+. 
N,N′-((2-fluorophenyl)methylene)bis(2-phenylacetamide) (4.3). Compound 4.3 was prepared 
from 2-phenylacetamide and 2-fluorobenzaldehyde using method 1. 
White sold (240 mg, yield: 64%). 1H NMR (400 MHz, DMSO-d6) δ 
8.87 (d, J = 7.8 Hz, 2H), 7.44 (t, J = 7.8 Hz, 1H), 7.36 (q, J = 6.6 Hz, 
1H), 7.17−7.29 (m, 12H), 6.74 (t, J = 7.8 Hz, 1H), 3.48 (dd, J = 14.4, 
24.0 Hz, 4H). LC−MS (ESI): m/z 377.2 (M + H)+. 
N,N′-((4-fluorophenyl)methylene)bis(2-phenylacetamide) (4.5). Compound 4.5 was prepared 
from 2-phenylacetamide and 4-fluorobenzaldehyde using 
method 1. White solid (271 mg, yield: 72%). 1H NMR (400 
MHz, DMSO-d6) δ 8.79 (d, J = 8.0 Hz, 2H), 7.16−7.36 (m, 
14H), 6.54 (t, J = 8.0 Hz, 1H), 3.52 (dd, J = 14.4, 15.6 Hz, 4H). 
LC−MS (ESI): m/z 377.2 (M + H)+. 
N,N′-((4-chlorophenyl)methylene)bis(2-phenylacetamide) (4.6). Compound 4.6 was prepared 
from 2-phenylacetamide and 4-chlorobenzaldehyde using 
method 1. White solid (279 mg, yield: 71%). 1H NMR (400 
MHz, DMSO-d6) δ 8.83 (d, J = 7.8 Hz, 2H), 7.41 (d, J = 7.8 Hz, 
2H), 7.21−7.32 (m, 12H), 6.51 (t, J = 7.8 Hz, 1H), 3.50 (dd, J = 
14.4, 17.4 Hz, 4H). LC−MS (ESI): m/z 393.2 (M + H)+. 
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N,N′-(p-tolylmethylene)bis(2-phenylacetamide) (4.8). Compound 4.8 was prepared from 2-
phenylacetamide and 4-methylbenzaldehyde using method 1. 
White solid (260 mg, yield: 70%). 1H NMR (400 MHz, DMSO-
d6) δ 8.71 (d, J = 8.0 Hz, 2H), 7.13−7.32 (m, 14H), 6.52 (t, J = 
8.0 Hz, 1H), 3.51 (dd, J = 14.4, 15.6 Hz, 4H), 2.29 (s, 3H). 
LC−MS (ESI): m/z 373.1 (M +H)+. 
N,N′-((4-methoxyphenyl)methylene)bis(2-phenylacetamide) (4.10). Compound 4.10 was 
prepared from 2-phenylacetamide and 4-methoxybenzaldehyde 
using method 1. White solid (240 mg, yield: 62%). 1H NMR 
(400 MHz, DMSO-d6) δ 8.70 (d, J = 7.6 Hz, 2H), 7.21−7.31 (m, 
12H), 6.89 (d, J = 8.8 Hz, 2H), 6.51 (t, J = 8.0 Hz, 1H), 3.74 (s, 
3H), 3.50 (dd, J = 14.0, 17.2 Hz, 4H). LC−MS (ESI): m/z 389.1 (M + H)+. 
N,N′-((2-(trifluoromethyl)phenyl)methylene)bis(2-phenylacetamide) (4.13). Compound 4.13 
was prepared from 2-phenylacetamide and 2-
(trifluoromethyl)benzaldehyde using method 1. White solid (299 mg, 
yield: 70%). 1H NMR (400 MHz, DMSO-d6) δ 8.87 (d, J = 7.2 Hz, 2H), 
7.78 (d, J = 7.6 Hz, 1H), 7.68−7.73 (m, 2H), 7.54 (t, J = 7.6 Hz, 1H), 
7.19−7.30 (m, 10H), 6.83 (t, J = 6.8 Hz, 1H), 3.46 (dd, J = 14.0, 17.6 
Hz, 4H). LC−MS (ESI): m/z 427.0 (M + H)+. 
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N,N′-((4-(trifluoromethyl)phenyl)methylene)bis(2-phenylacetamide) (4.14). Compound 4.14 
was prepared from 2-phenylacetamide and 4-
(trifluoromethyl)benzaldehyde using method 1. White solid 
(320 mg, yield: 75%). 1H NMR (400 MHz, DMSO-d6) δ 8.89 
(d, J = 7.6 Hz, 2H), 7.72 (d, J = 7.6 Hz, 2H), 7.51 (d, J = 7.6 Hz, 
2H), 7.25−7.30 (m, 10H), 6.58 (t, J = 7.2 Hz, 1H), 3.53 (s, 4H). LC−MS (ESI): m/z 427.2 (M + 
H)+. 
N,N′-((4-nitrophenyl)methylene)bis(2-phenylacetamide) (4.15). Compound 4.15 was prepared 
from 2-phenylacetamide and 4-nitrobenzaldehyde using 
method 1. White solid (339 mg, yield: 84%). 1H NMR (400 
MHz, DMSO-d6) δ 8.98 (d, J = 7.6 Hz, 2H), 8.20−8.23 (m, 2H), 
7.56 (d, J = 8.4 Hz, 2H), 7.23−7.32 (m, 10H), 6.58 (t, J = 7.6 
Hz, 1H), 3.53 (s, 4H). LC−MS (ESI): m/z 404.1 (M + H)+. 
N,N′-((4-(dipropylamino)phenyl)methylene)bis(2-phenylacetamide) (4.18). Compound 4.18 
was prepared from 2-phenylacetamide and 4-
(dipropylamino)benzaldehyde using method 1. White solid (70 
mg, yield: 15%). 1H NMR (400 MHz, CD3OD) δ 7.25−7.30 (m, 
10H), 7.10 (d, J = 8.8 Hz, 2H), 6.62 (d, J = 8.8 Hz, 2H), 6.57 (s, 
1H), 3.56 (s, 4H), 3.24−3.26 (m, 4H), 1.54−1.64 (m, 4H), 0.93 (t, J = 7.6 Hz, 6H). LC−MS (ESI): 
m/z 458.2 (M + H)+.  
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N,N′-((4-(pyrrolidin-1-yl)phenyl)methylene)bis(2-phenylacetamide) (4.21). Compound 4.21 
was prepared from 2-phenylacetamide and 4-(pyrrolidin-1-
yl)benzaldehyde using method 1. White solid (52 mg, yield: 
12%). 1H NMR (400 MHz, DMSO-d6) δ 8.58 (d, J = 8.0 Hz, 
2H), 7.20−7.31 (m, 10H), 7.08 (d, J = 8.4 Hz, 2H), 6.42−6.49 
(m, 3H), 3.44−3.45 (m, 4H), 3.18− 3.20 (m, 4H), 1.93−1.96 (m, 4H). LC−MS (ESI): m/z 428.2 (M 
+H)+.  
N,N′-(phenylmethylene)bis(2-(4-chlorophenyl)acetamide) (4.23). Compound 4.23 was 
prepared from 2-(4-chlorophenyl)acetamide and 
benzaldehyde using method 1. White solid (222 mg, 
yield: 52%). 1H NMR (400 MHz, DMSO-d6) δ 8.88 (d, 
J = 7.8 Hz, 2H), 7.25−7.41 (m, 13H), 6.52 (t, J = 7.8 Hz, 1H), 3.50 (s, 4H). LC−MS (ESI): m/z 
427.1 (M + H)+. 
N,N′-((2-fluorophenyl)methylene)bis(2-(4-chlorophenyl)-acetamide) (4.24). Compound 4.24 
was prepared from 2-(4-chlorophenyl)acetamide and 2-
fluorobenzaldehyde using method 1. White solid (280 mg, yield: 
63%). 1H NMR (400 MHz, DMSO-d6) δ 8.93 (d, J = 7.2 Hz, 2H), 
7.45 (t, J = 7.2 Hz, 1H), 7.33−7.37 (m, 5H), 7.25−7.26 (m, 4H), 
7.18− 7.21 (m, 2H), 6.73 (t, J = 7.2 Hz, 1H), 3.48 (s, 4H). LC−MS 
(ESI): m/z 445.0 (M + H)+. 
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N,N′-((4-fluorophenyl)methylene)bis(2-(4-chlorophenyl)-acetamide) (4.25). Compound 4.25 
was prepared from 2-(4-chlorophenyl)acetamide and 4-
fluorobenzaldehyde using method 1. White solid (300 
mg, yield: 67%). 1H NMR (400 MHz, DMSO-d6) δ 
8.82 (d, J = 7.6 Hz, 2H), 7.34−7.37 (m, 6H), 7.27 (d, J 
= 8.4 Hz, 4H), 7.19 (t, J = 8.8 Hz, 2H), 6.51 (t, J = 8.0 Hz, 1H), 3.51 (s, 4H). LC−MS (ESI): m/z 
444.9 (M +H)+. 
N,N′-((4-chlorophenyl)methylene)bis(2-(4-chlorophenyl)-acetamide) (4.26). Compound 4.26 
was prepared from 2-(4chlorophenyl)acetamide and 4-
chlorobenzaldehyde using method 1. White solid (323 
mg, yield: 70%). 1H NMR (400 MHz, DMSO-d6) δ 8.88 
(d, J = 7.8 Hz, 2H), 7.42 (d, J = 8.4 Hz, 2H), 7.31−7.35 (m, 6H), 7.26 (d, J = 8.4 Hz, 4H), 6.47 (t, 
J = 7.8 Hz, 1H), 3.50 (s, 4H). LC−MS (ESI): m/z 460.8 (M +H)+. 
N,N′-(p-tolylmethylene)bis(2-(4-chlorophenyl)acetamide) (4.27). Compound 4.27 was 
prepared from 2-(4-chlorophenyl)acetamide and 4-
methylbenzaldehyde using method 1. White solid (388 
mg, yield: 88%). 1H NMR (400 MHz, DMSO-d6) δ 8.76 
(d, J = 8.0 Hz, 2H), 7.34 (d, J = 8.4 Hz, 4H), 7.28 (d, J = 8.4 Hz, 4H), 7.17 (q, J = 8.0 Hz, 4H), 
6.50 (t, J = 7.6 Hz, 1H), 3.51 (s, 4H), 2.29 (s, 3H). LC−MS (ESI): m/z 441.3 (M + H)+. 
N,N′-((4-methoxyphenyl)methylene)bis(2-(4-chlorophenyl)-acetamide) (4.28). Compound 
4.28 was prepared from 2-(4-chlorophenyl)acetamide 
and 4-methoxybenzaldehyde using method 1. White 
solid (416 mg, yield: 91%). 1H NMR (400 MHz, 
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DMSO-d6) δ 8.73 (d, J = 7.6 Hz, 2H), 7.34 (d, J = 8.8 Hz, 4H), 7.26 (d, J = 8.4 Hz, 4H), 7.21 (d, 
J = 8.8 Hz,2H), 6.90 (d, J = 8.8 Hz, 2H), 6.46 (t, J = 8.0 Hz, 1H), 3.74 (s, 3H), 3.49 (s, 4H). 
LC−MS (ESI): m/z 457.2 (M + H)+. 
N,N′-((2-(trifluoromethyl)phenyl)methylene)bis(2-(4-chlorophenyl)acetamide) (4.29). 
Compound 4.29 was prepared from 2-(4-chlorophenyl)acetamide 
and 2-(trifluoromethyl)benzaldehyde using method 1. White solid 
(406 mg, yield: 82%). 1H NMR (400 MHz, DMSO-d6) δ 8.04 (d, J 
= 6.0 Hz, 2H), 7.81 (d, J = 7.8 Hz, 1H), 7.72 (d, J = 7.8 Hz, 1H), 
7.62 (t, J = 7.8 Hz, 1H), 7.52 (t, J = 7.8 Hz, 1H), 7.27−7.30 (m, 
8H), 7.06 (t, J = 7.2 Hz, 1H), 3.52 (s, 4H). LC−MS (ESI): m/z 495.0 (M + H)+. 
N,N′-((4-(trifluoromethyl)phenyl)methylene)bis(2-(4-chlorophenyl)acetamide) (4.30). 
Compound 4.30 was prepared from 2-(4-
chlorophenyl)acetamide and 4-
(trifluoromethyl)benzaldehyde using method 1. White 
solid (421 mg, yield: 85%). 1H NMR(400 MHz, 
DMSO-d6) δ 8.96 (d, J = 7.6 Hz, 2H), 7.73 (d, J = 8.4 Hz, 2H), 7.54 (d, J = 8.4 Hz, 2H), 7.35 (d, 
J = 8.4 Hz, 4H), 7.28 (d, J = 8.4 Hz, 4H), 6.57 (t, J = 7.6 Hz, 1H), 3.54 (s, 4H). LC−MS (ESI): m/z 
495.2 (M + H)+. 
N,N′-((4-nitrophenyl)methylene)bis(2-(4-chlorophenyl)-acetamide) (4.31). Compound 4.31 
was prepared from 2-(4-chlorophenyl)acetamide and 4-
nitrobenzaldehyde using method 1. Off-white solid 
(425 mg, yield: 90%). 1H NMR (400 MHz, DMSO-d6) 
δ 9.02 (d, J = 8.0 Hz, 2H), 8.24−8.25 (m, 2H), 
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7.56−7.58 (m, 2H), 7.34−7.37 (m, 4H), 7.26−7.29 (m, 4H), 6.55 (t, J = 8.0 Hz, 1H), 3.53 (s, 4H). 
LC−MS (ESI): m/z 472.0 (M + H)+. 
N,N′-(phenylmethylene)bis(2-(4-(trifluoromethyl)phenyl)- acetamide) (4.32). Compound 4.32 
was prepared from 2-(4-
(trifluoromethyl)phenyl)acetamide and 
benzaldehyde using method 1. White solid (410 mg, 
yield: 83%). 1H NMR (400 MHz, DMSO-d6) δ 8.94 (d, J = 7.8 Hz, 2H), 7.63 (d, J = 7.8 Hz, 4H), 
7.48 (d, J = 8.4 Hz, 4H), 7.29−7.37 (m, 5H), 6.55 (t, J = 7.8 Hz, 1H), 3.63 (s, 4H). LC−MS (ESI): 
m/z 495.1 (M + H)+. 
N,N′-((2-fluorophenyl)methylene)bis(2-(4-(trifluoromethyl)-phenyl)acetamide) (4.33). 
Compound 4.33 was prepared from 2-(4-
(trifluoromethyl)phenyl)acetamide and 2-fluorobenzaldehyde 
using method 1. White solid (440 mg, yield: 86%). 1H NMR (400 
MHz, DMSO-d6) δ 8.99 (d, J = 7.2 Hz, 2H), 7.63 (d, J = 7.8 Hz, 
4H), 7.46 (d, J = 7.8 Hz, 5H), 7.36−7.40 (m, 1H), 7.21 (t, J = 7.8 
Hz, 2H), 6.74 (t, J = 7.8 Hz, 1H), 3.60 (s, 4H). LC−MS (ESI): 
m/z 513.0 (M + H)+. 
N,N′-((4-fluorophenyl)methylene)bis(2-(4-(trifluoromethyl)-phenyl)acetamide) (4.34). 
Compound 4.34 was prepared from 2-(4-
(trifluoromethyl)phenyl)acetamide and 4-
fluorobenzaldehyde using method 1. White solid 
(460mg, yield: 90%). 1H NMR (400 MHz, DMSO-
d6) δ 8.95 (d, J = 8.4 Hz, 2H), 7.63 (d, J = 8.4 Hz, 4H), 7.47 d, J = 8.4 Hz, 4H), 7.37 (dd, J = 5.4, 
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8.4 Hz, 2H), 7.19 (t, J = 8.4 Hz, 2H), 6.51 (t, J = 7.8 Hz, 1H), 3.62 (s, 4H). LC−MS (ESI): m/z 
513.2 (M + H)+. 
N,N′-((4-chlorophenyl)methylene)bis(2-(4-(trifluoromethyl)-phenyl)acetamide) (4.35). 
Compound 4.35 was prepared from 2-(4-
(trifluoromethyl)phenyl)acetamide and 4-
chlorobenzaldehyde using method 1. White solid 
(450 mg, yield: 85%). 1H NMR(400 MHz, DMSO-d6) δ 8.96 (d, J = 7.8 Hz, 2H), 7.63 (d, J = 7.2 
Hz, 4H), 7.46 (d, J = 7.8 Hz, 4H), 7.43 (dd, J = 1.8, 8.4 Hz, 2H), 7.34−7.35 (m, 2H), 6.50 (t, J = 
7.2 Hz, 1H), 3.62 (s, 4H). LC−MS (ESI): m/z 529.0 (M + H)+. 
N,N′-(p-tolylmethylene)bis(2-(4-(trifluoromethyl)phenyl)-acetamide) (4.36). Compound 4.36 
was prepared from 2-(4-
(trifluoromethyl)phenyl)acetamide and 4-
methylbenzaldehyde using method 1. White solid 
(412 mg, yield: 81%). 1HNMR(400 MHz, DMSO-
d6) δ 8.87 (d, J = 8.4 Hz, 2H), 7.63 (d, J = 7.8 Hz, 4H), 7.47 (d, J = 8.4 Hz, 4H), 7.20 (d, J = 8.4 
Hz, 2H), 7.15 (d, J = 7.8 Hz, 2H), 6.49 (t, J = 7.8 Hz, 1H), 3.61 (s, 4H), 2.28 (s, 3H). LC−MS 
(ESI): m/z 509.1 (M + H)+. 
N,N′-((4-methoxyphenyl)methylene)bis(2-(4-(trifluoromethyl)-phenyl)acetamide) (4.37). 
Compound 4.37 was prepared from 2-(4-
(trifluoromethyl)phenyl)acetamide and 4-
methoxybenzaldehyde using method 1. White solid 
(450 mg, yield: 86%). 1H NMR(400 MHz, DMSO-
d6) δ 8.85 (d, J = 7.8 Hz, 2H), 7.63 (d, J = 7.8 Hz, 4H), 7.47 (d, J = 7.8 Hz, 4H),7.24 (d, J = 9.0 
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Hz, 2H), 6.91 (d, J = 8.4 Hz, 2H), 6.48 (t, J = 7.8 Hz, 1H), 3.74 (s, 3H), 3.61(s, 4H). LC−MS (ESI): 
m/z 525.1 (M + H)+. 
N,N′-((4-(trifluoromethyl)phenyl)methylene)bis(2-(4-(trifluoromethyl)phenyl)acetamide) 
(4.38). Compound 4.38 was prepared from 2-(4-
(trifluoromethyl)phenyl)acetamide and 4-
(trifluoromethyl)-benzaldehyde using method 1. 
White solid (415 mg, yield: 74%). 1H NMR (400 
MHz, DMSO-d6) δ 9.08 (d, J = 7.2 Hz, 2H), 7.73 (d, J = 7.8 Hz, 2H), 7.63 (d, J = 7.8 Hz, 4H), 
7.56 (d, J = 7.8 Hz, 2H), 7.48 (d, J = 7.8 Hz, 4H), 6.60 (t, J = 7.8 Hz, 1H), 3.35−3.43 (m, 4H). 
LC−MS (ESI): m/z 562.9 (M + H)+. 
 N,N′-((4-(diethylamino)phenyl)methylene)dibenzamide (4.39). Compound 4.39 was prepared 
from benzamide and 4-(diethylamino)-benzaldehyde using method 1. 
White solid (293 mg, yield: 73%). 1H NMR (400 MHz, CD3OD) δ 
9.24 (d, J = 7.6 Hz, 1H), 7.88−7.93 (m, 4H), 7.81 (d, J = 8.8 Hz, 2H), 
7.46−7.65 (m, 9H), 7.20 (m, 1H), 3.70−3.81 (m, 4H), 1.17 (t, J = 7.2 
Hz, 6H). LC−MS (ESI): m/z 402.2 (M + H)+. 
N,N′-((4-(diethylamino)phenyl)methylene)bis(3-phenylpropanamide) (4.40). Compound 4.40 
was prepared from 3-phenylpropanamide and 4-
(diethylamino)benzaldehyde using method 1. White solid 
(302 mg, yield: 66%). 1H NMR (400 MHz, CD3OD) δ 
8.29−8.30 (m, 2H), 7.17−7.29 (m, 10H), 6.92 (d, J = 8.4 
Hz, 2H), 6.56 (d, J = 8.4 Hz, 2H), 6.46 (t, J = 8.0 Hz, 1H), 2.82 (t, J = 7.6 Hz, 4H), 2.42−2.47 (m, 
4H), 1.07 (t, J = 6.8 Hz, 6H). LC−MS (ESI): m/z 458.2 (M + H)+.  
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N,N′-((4-(diethylamino)phenyl)methylene)bis(3-phenylacrylamide) (4.41). Compound 4.41 
was prepared from cinnamamide and 4-
(diethylamino)benzaldehyde using method 1. Off-white 
solid (309 mg, yield: 68%). 1H NMR (400 MHz, CD3OD) 
δ 8.68−8.70 (m, 2H), 7.38−7.58 (m, 12H), 7.19 (d, J = 8.8 
Hz, 2H), 6.79 (d, J = 16.0 Hz, 2H), 6.66−6.68 (m, 3H), 3.29−3.35 (m, 4H), 1.08 (t, J = 7.2 Hz, 
6H). LC−MS (ESI): m/z 454.2 (M + H)+.  
N,N′-((4-(diethylamino)phenyl)methylene)bis(2-methylpropanamide) (4.44). Compound 4.44 
was prepared from isobutyramide and 4-(diethylamino)benzaldehyde 
using method 1. White solid (267 mg, yield: 80%). 1H NMR (400 MHz, 
CD3OD) δ 7.18 (d, J = 8.4 Hz, 2H), 6.70−6.73 (m, 2H), 6.56 (s, 1H), 
3.35−3.50 (m, 2H), 2.47−2.54 (m, 4H), 1.13−1.16 (m, 12H). LC−MS 
(ESI): m/z 334.2 (M + H)+.  
N,N′-((4-(diethylamino)phenyl)methylene)bis(2,2-dimethylpropanamide) (4.45). Compound 
4.45 was prepared from pivalamide and 4-(diethylamino)benzaldehyde 
using method 1. White solid (278 mg, yield: 77%). 1H NMR (400 MHz, 
DMSO-d6) δ 7.70 (d, J = 8.8 Hz, 2H), 7.03 (d, J = 8.8 Hz, 2H), 6.62 (d, J 
= 8.8 Hz, 2H), 6.52 (t, J = 8.4 Hz, 1H), 3.30−3.33 (m, 4H), 1.12 (s, 18H), 
1.05−1.08 (m, 6H). LC−MS (ESI): m/z 362.2 (M +H)+. 
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N,N′-((4-(diethylamino)phenyl)methylene)dipentanamide (4.46). Compound 4.46 was 
prepared from pentanamide and 4-(diethylamino)-benzaldehyde 
using method 1. White solid (250 mg, yield: 69%). 1H NMR 
(400 MHz, CD3OD) δ 7.18 (d, J = 8.8 Hz, 2H), 6.71 (d, J = 8.8 
Hz, 2H), 6.58 (t, J = 8.4 Hz, 1H), 3.33−3.41 (m, 4H), 2.25 (t, J 
= 7.2 Hz, 4H), 1.58−1.66 (m, 4H), 1.33−1.43 (m, 4H), 1.14 (t, J = 7.2 Hz, 6H), 0.95 (t, J = 2.8 Hz, 
6H). LC−MS (ESI): m/z 362.2 (M + H)+. 
N,N′-((4-(diethylamino)phenyl)methylene)dihexanamide (4.47). Compound 4.47 was prepared 
from hexanamide and 4-(diethylamino)-benzaldehyde 
using method 1. White solid (297 mg,  yield: 76%). 1H 
NMR (400 MHz, CD3OD) δ 7.19 (d, J = 8.8 Hz, 2H), 6.71 
(d, J = 8.8 Hz, 2H), 6.58 (t, J = 8.4 Hz, 1H), 3.35−3.41 (m, 
4H), 2.19−2.26 (m, 4H), 1.61−1.68 (m, 4H), 1.32−1.35 (m, 8H), 1.14 (t, J = 6.8 Hz, 6H), 0.94 (t, 
J = 2.8 Hz, 6H). LC−MS (ESI): m/z 390.3 (M + H)+.  
N,N′-((4-(diethylamino)phenyl)methylene)dioctanamide (4.48). Compound 4.48 was prepared 
from octanamide and 4-(diethylamino)-benzaldehyde using method 
1. White solid (308 mg, yield: 68%). 1H NMR (400 MHz, DMSO-
d6) δ 8.21 (d, J = 8.0 Hz, 2H), 7.07 (d, J = 8.8 Hz, 2H), 6.61 (d, J = 
8.8 Hz, 2H), 6.42 (t, J = 8.0 Hz, 1H), 3.29−3.31 (m, 4H), 2.06−2.14 
(m, 4H), 1.47−1.50 (m, 4H), 1.08−1.24 (m, 16H), 1.06 (t, J = 7.2 Hz, 6H), 0.94 (t, J = 7.2 Hz, 6H). 
LC−MS (ESI): m/z 446.3 (M + H)+. 
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N,N′-((4-(diethylamino)phenyl)methylene)bis(decanamide) (4.49). Compound 4.49 was 
prepared from decanamide and 4-(diethylamino)-benzaldehyde 
using method 1. White solid (281 mg, yield: 56%). 1H NMR 
(400 MHz, DMSO-d6) δ 8.99 (d, J = 9.6 Hz, 1H), 8.38 (d, J = 
8.8 Hz, 1H), 6.99 (d, J = 8.8 Hz, 2H), 6.58 (d, J = 8.4 Hz, 2H), 
5.84 (d, J = 8.4 Hz, 1H), 3.27−3.30 (m, 4H), 2.33 (t, J = 7.2 Hz, 4H), 2.14 (t, J = 7.2 Hz, 4H), 
1.50−1.55 (m, 4H), 1.24−1.28 (m, 24H), 1.06 (t, J = 7.2 Hz, 6H), 0.87 (t, J = 7.2 Hz, 6H). LC−MS 
(ESI): m/z 502.4 (M + H)+. 
General Method 2 [216]: 
N,N′-((3-fluorophenyl)methylene)bis(2-phenylacetamide) (4.4). To a suspension of 2-
phenylacetamide (540 mg, 4 mmol) in dry dichloromethane (2 
mL) was added 3-fluorobenzaldehyde (250 mg, 2 mmol) and 
trimethylsilyltrifluoromethane sulfonate (22 mg, 0.1 mmol). 
The mixture was vigorously stirred for 12 h at room temperature, diluted with toluene (4 mL), and 
filtered. The precipitate was washed several times with toluene which was recrystallized with 
methanol and hexane to give the final product as white solid (290 mg, yield: 77%). 1H NMR (400 
MHz, DMSO-d6) δ 8.83 (d, J = 8.0 Hz, 2H), 7.06−7.42 (m, 14H), 6.53 (t, J = 7.6 Hz, 1H), 
3.47−3.55 (m, 4H). LC−MS (ESI): m/z 377.2 (M + H)+. 
N,N′-((4-bromophenyl)methylene)bis(2-phenylacetamide) (4.7). Compound 4.7 was prepared 
from 2-phenylacetamide and 4-bromobenzaldehyde using 
method 2. White solid (390 mg, yield: 89%). 1H NMR (400 
MHz, DMSO-d6) δ 8.82 (d, J = 7.6 Hz, 2H), 7.53−7.56 (m, 2H), 
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7.21−7.33 (m, 12H), 6.48 (t, J = 7.6 Hz, 1H), 3.46−3.54 (m, 4H). LC−MS (ESI): m/z 437.0 (M + 
H)+. 
N,N′-((4-isopropylphenyl)methylene)bis(2-phenylacetamide) (4.9). Compound 4.9 was 
prepared from 2-phenylacetamide and 4-
isopropylbenzaldehyde using method 2. Off-white solid (260 
mg, yield: 65%). 1H NMR (400 MHz, DMSO-d6) δ 8.73 (d, J = 
8.0 Hz, 2H), 7.20−7.32 (m, 14H), 6.51 (t, J = 8.0 Hz, 1H), 
3.46−3.54 (m, 4H), 2.85−2.89 (m, 1H), 1.19 (d, J = 6.8 Hz, 6H). LC−MS (ESI): m/z 401.2 (M + 
H)+.  
N,N′-((4-ethoxyphenyl)methylene)bis(2-phenylacetamide) (4.11). Compound 4.11 was 
prepared from 2-phenylacetamide and 4-ethoxybenzaldehyde 
using method 2. White solid (280 mg, yield: 70%). 1H NMR 
(400 MHz, DMSO-d6) δ 8.69 (d, J = 8.0 Hz, 2H), 7.18−7.31 (m, 
10H), 6.88 (d, J = 6.4 Hz, 2H), 6.48 (t, J = 8.0 Hz, 1H), 
3.98−4.03 (m, 2H), 3.45− 3.52 (m, 4H), 1.31 (t, J = 6.8 Hz, 3H). LC−MS (ESI): m/z 403.1 (M + 
H)+. 
N,N′-((4-isopropoxyphenyl)methylene)bis(2-phenylacetamide) (4.12). Compound 4.12 was 
prepared from 2-phenylacetamide and 4-
isopropoxybenzaldehyde using method 2. White solid (335 mg, 
yield: 81%). 1H NMR (400 MHz, DMSO-d6) δ 8.69 (d, J = 7.6 
Hz, 2H), 7.18−7.13 (m, 12H), 6.87 (d, J = 6.8 Hz, 2H), 6.48 (t, 
J = 8.0 Hz, 1H), 4.58−4.61 (m, 1H), 3.45− 3.53 (m, 4H), 1.25 (d, J = 6.0 Hz, 6H). LC−MS (ESI): 
m/z 417.2 (M + H)+. 
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N,N′-((4-(diethylamino)phenyl)methylene)bis(2-phenylacetamide) (4.17). Compound 4.17 
was prepared from 2-phenylacetamide and 4-
(diethylamino)benzaldehyde using method 2. White solid (335 
mg, yield: 78%). 1H NMR (400 MHz, DMSO-d6) δ 8.60 (d, J = 
8.0 Hz, 2H), 7.21−7.31 (m, 10H), 7.07 (d, J = 8.4 Hz, 2H), 6.60 
(d, J = 8.8 Hz, 2H), 6.43 (t, J = 8.0 Hz, 1H), 3,44−3.52 (m, 4H), 3.29−3.34 (m, 4H), 1.06 (t, J = 
7.6 Hz, 6H). LC−MS (ESI): m/z 430.3 (M + H)+.  
N,N′-((4-(dibutylamino)phenyl)methylene)bis(2-phenylacetamide) (4.19). Compound 4.19 
was prepared from 2-phenylacetamide and 4-
(dibutylamino)benzaldehyde using method 2. Yellow solid (410 
mg, yield: 85%). 1H NMR (400 MHz, DMSO-d6) δ 8.58 (d, J = 
8.0 Hz, 2H), 7.20−7.31 (m, 10H), 7.06 (d, J = 8.8 Hz, 2H), 6.57 
(d, J = 8.8 Hz, 2H), 6.41 (t, J = 8.0 Hz, 1H), 3.47−3.48 (m, 4H), 3.22−3.26 (m, 4H), 1.43−1.50 (m, 
4H), 1.26−1.35 (m, 4H), 0.91 (t, J = 7.6 Hz, 6H). LC−MS (ESI): m/z 486.2 (M + H)+. 
N,N′-((4-(piperidin-1-yl)phenyl)methylene)bis(2-phenylacetamide) (4.22). Compound 4.22 
was prepared from 2-phenylacetamide and 4- (piperidin-1-
yl)benzaldehyde using method 2. Red solid (375 mg, yield: 
85%). 1H NMR (400 MHz, DMSO-d6) δ 8.80 (d, J = 8.0 Hz, 
2H), 7.15−7.32 (m, 14H), 6.51 (t, J = 8.0 Hz, 1H), 3.37−3.52 
(m, 8H), 1.61−1.83 (m, 6H). LC− MS (ESI): m/z 442.3 (M + 
H)+. 
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N,N′-(pentane-1,1-diyl)bis(2-phenylacetamide) (4.42). Compound 4.42 was prepared from 2-
phenylacetamide and pentanal using method 2. White solid (280 
mg, yield: 83%). 1H NMR (400 MHz, DMSO-d6) δ 8.25 (d, J = 
8.0 Hz, 2H), 7.19−7.30 (m, 8H), 5.30 (t, J = 7.6 Hz, 1H), 
3.36−3.44 (m, 4H), 1.56−1.62 (m, 2H), 1.14−1.26 (m, 4H), 0.81 (t, J = 7.2 Hz, 3H). LC−MS (ESI): 
m/z 339.1 (M + H)+. 
N,N′-(hexane-1,1-diyl)bis(2-phenylacetamide) (4.43). Compound 4.43 was prepared from 2-
phenylacetamide and hexanal using method 2. White solid (327 
mg, yield: 93%). 1H NMR (400 MHz, DMSO-d6) δ 8.25 (d, J = 
8.0 Hz, 2H), 7.19−7.30 (m, 8H), 5.29 (t, J = 7.6 Hz, 1H), 3.39−3.44 
(m, 4H), 1.57−1.59 (m, 2H), 1.18−1.23 (m, 6H), 0.82 (t, J = 6.8 Hz, 3H). LC− MS (ESI): m/z 353.3 
(M + H)+. 
4.4.2.3 General Method of Reduction 
 N,N′-((4-aminophenyl)-methylene)bis(2-phenylacetamide) (4.16). To a suspension of N,N′-
((4-nitrophenyl)methylene)bis(2-phenylacetamide) (4.15) (403 
mg, 1 mmol) in ethanol (2 mL) was added the palladium (10%, 
3.0 mg) and hydrazine (0.05 mL, 1.5 mmol). The mixture was 
stirred for 3 h at 70 °C. After filtration, the filtrate was 
evaporated to dryness on a rotary evaporator. The crude compound was further purified by 
recrystallization from ethanol. After the sample was dried in a vacuum at room temperature, 4.16 
was obtained as a yellow solid (370 mg, yield: 99%). 1H NMR (400 MHz, DMSO-d6) δ 8.54 (d, J 
= 8.0 Hz, 2H), 7.20−7.31 (m, 10H), 6.92 (d, J = 8.4 Hz, 2H), 6.49 (d, J = 8.4 Hz, 2H), 6.39 (t, J = 
8.0 Hz, 1H), 5.04 (bs, 2H), 3.43−3.53 (m, 4H). LC−MS (ESI): m/z 374.1 (M + H)+. 
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4.4.2.4 General Method of Alkylation 
N,N′-((4-(dibenzylamino)-phenyl)methylene)bis(2-phenylacetamide) (4.20). Compound 4.16 
(373 mg, 1 mmol), K2CO3 (0.27 g, 1.95 mmol), and DMF (10 
mL) were placed in a flask equipped with a condenser and a 
magnetic stirrer. Benzyl bromide (376 mg, 2.2 mmol) was 
added, and the mixture was stirred at room temperature for 12 
h. The reaction solution was poured into water and extracted with EA. The combined organic 
layers were washed with water and brine and then dried over Na2SO4. The mixture was filtered, 
and the solvent was evaporated in vacuum. The residue was purified by flash chromatography on 
silica gel to obtain 4.20 as an off-white solid (282 mg, yield: 51%). 1H NMR (400 MHz, DMSO-
d6) δ 8.50 (s, 2H), 7.18−7.35 (m, 20H), 7.01 (d, J = 8.8 Hz, 2H), 6.62 (d, J = 8.8 Hz, 2H), 6.39 (t, 
J = 8.0 Hz, 1H), 4.70 (s, 4H), 3.44−3.45 (m, 4H). LC−MS (ESI): m/z 554.2(M + H)+. 
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5.0  DESIGN, SYNTHESIS, AND BIOLOGICAL EVALUATION OF SUBSTITUTED 2-
(SULFONYLAMINO)-2-PHENYLACETAMIDE DERIVATIVES 
5.1 INTRODUCTION 
Although the di-amide scaffold yielded novel, highly potent, and selective CB2 chemotype 
ligands, the scaffold suffered some limitations that require chemical modifications. As highlighted 
in Chapter 4, compound 4.17 showed several pharmacokinetic limitations including low 
elimination half-life after oral administration. This limitation is mainly due to the di-amide 
backbone. The di-amide backbone had to be modified in order to overcome these issues. Scaffold 
hopping was carried out based on molecular docking interactions and structural features. As 
highlighted in Figure 5.1, the di-amide backbone was replaced with an amide and sulfonamide 
backbone with three varying positions (R1, R2, and R3). Based on the previous pharmacophore 
model in Chapter 4, three hydrophobic groups were utilized on the R groups with different 
substitutions, length and size as well as charge. Hydrogen bond acceptors and donors were 
preserved in the new scaffold (two hydrogen bond donors and three hydrogen bond acceptors). We 
hypothesized that these modifications will yield ligands with good CB2 affinity and selectivity as 
well as overcoming PK limitations associated with the di-amide scaffold derivatives. 
The new scaffold, 2-(sulfonylamino)-2-phenylacetamide, holds three R positions, R1: 
connect with different substituted phenyl amines, R2: connect with different substituted 
sulfonamides and R3: connect with either aliphatic or aromatic groups (Figure 5.1).  
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Figure 5.1. 2-(sulfonylamino)-2-phenylacetamide scaffold hopping and chemistry 
optimization strategy 
The di-amide scaffold was subjected to scaffold hopping and modification based on molecular 
docking and chemical features studies. (A) di-amide scaffold and the amide-sulfonamide scaffold. 
(B) The chemistry optimizations strategies. (C) The final structure of the 2-(sulfonylamino)-2-
phenylacetamide scaffold 
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5.2 RESULTS AND DISCUSSION 
5.2.1 Chemistry Synthesis 
The chemistry synthesis routes of 2-(sulfonylamino)-2-phenylacetamide derivatives are illustrated 
in Scheme 2. The commercially available methyl (R)-2-amino-2-phenylacetate was reacted with 
different substituted sulfonyl chloride to give the intermediate methyl (R)-2-(sulfonamido)-2-
phenylacetate (intermediate-1). When methyl (R)-2-amino-2-phenylacetate was reacted with 4-
methoxybenzenesulfonyl chloride, 4-isopropoxybenzenesulfonyl chloride, benzenesulfonyl 
chloride, [1,1'-biphenyl]-4-sulfonyl chloride, naphthalene-2-sulfonyl chloride, and pentane-1-
sulfonyl chloride, compounds 5.1 – 5.6 were obtained, respectively. Intermediate-1 was then 
treated with different reaction conditions to yield the final products. Intermediate-1 was reacted 
with different substituted amines to yield compounds 5.8, 5.9, 5.11, and 5.25 (method 1). When 
intermediate-1 was reacted with substituted amines in the presence of toluene, the corresponding 
compounds were obtained 5.10, 5.12 – 5.14, 5.16, 5.23, 5.26, and 5.27 (Method 2). In another 
method, intermediate-1 was subjected to ester hydrolysis in order to obtain the corresponding 
carboxylic acid. This was achieved by treating intermediate-1 with lithium hydroxide to yield 
intermediate-2 (compounds 5.7, and 5.32). Intermediate-2 was subjected to acylation in order to 
achieve acyl chlorides. Acylation was achieved by treating intermediate-2 with thionyl chloride. 
Acyl chloride derivatives were then reacted with substituted amines to yield compounds 5.15, 5.24, 
and 5.29 (method 3). In method 4, intermediate-2 was subjected to amine coupling utilizing 
coupling reagents (HOBt/EDCI) to yield the target compounds 5.18 – 5.22, 5.28, 5.30, and 5.31. 
All final products were purified by flash chromatography or preparative TLC where indicated and 
confirmed with NMR and LC-MS. 
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Scheme 2. Synthesis routes of 2-(sulfonylamino)-2-phenylacetamide derivatives. 
Reagents and conditions: (a) substituted sulfonyl chloride (R1), TEA, DCM, rt, 12 hr. (b) 
substituted amine (R2), MeOH, 70 °C, 12 h. (c) substituted amine (R2), toluene, 125 °C, 12 h. (d) 
LiOH, THF:H2O, 4 °C, 12 h. (e) Thionyl chloride, EA, 80 °C, 2 h. (f) substituted amine (R2), TEA, 
EA, rt, 12 h. (g) substituted amine (R2), HOBt/EDCI, rt, TEA, THF, 12 h. 
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5.2.2 Structure Activity Relationship Analysis 
Radioligand-competition binding experiments were carried out as described in Chapter 3 
(materials and method) utilizing membrane protein preparations stably expressing human CB2 and 
CB1 receptors. CB2 selective ligand SR144528 was used as positive control in binding 
experiments. Similarly, the CB1 selective ligand SR141728 was utilized as a positive control in 
binding experiments. Different sulfonyl amide intermediates were explored for the CB2 receptor 
binding affinity. Compounds with different substituted sulfonyl amide groups yielded varying CB2 
receptor affinity. Compound 5.1 with p-methoxyphenyl group displayed a CB2 Ki of 1050 nM. 
Compound 5.2 with isopropoxybenzene showed a CB2 Ki of 7640 nM. Compound 5.3 with a 
phenyl group showed no CB2 affinity (CB2 Ki > 20000 nM). Compound 5.4 bearing a bi-phenyl 
group showed a CB2 Ki = 2650 nM. Compound 5.5 with a naphthalene group displayed a CB2 Ki 
of 1080 nM. Finally, compound 5.6 with an aliphatic chain (pentane) showed no CB2 receptor 
binding affinity (CB2 Ki > 20000 nM). The highly-to-moderately potent intermediates were chosen 
for further SAR studies. CB2 binding affinities of the phenylacetamide intermediates are shown 
in Table 5.1. Intermediates 5.1 and 5.5 were chosen for further SAR studies (CB2 Ki < 1100 nM). 
Other intermediates (5.2 – 5.4, and 5.6) were ignored due to their low CB2 receptor binding affinity 
(CB2 Ki > 2000 nM). 
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Table 5.1. Chemical structures, physicochemical properties and radioligand competition 
binding affinity for 2-(sulfonylamino)-2-phenylacetamide scaffold intermediates 
 
 
Entry R MW cLogP Ki (CB2), µM 
5.1 
 
335.37 2.71 1.05 
5.2 
 
363.43 3.55 7.64  
5.3 
 
305.35 2.44 NB 
5.4 
 
381.44 4.32 2.65 
5.5 
 
355.41 3.61 1.08 
5.6  299.39 2.94 NB  
Binding affinity for CB2 receptor were evaluated using [3H]CP-55,940 radioligand competition binding 
assay. NB: no binding, Ki > 20000 nM. CB2 reference compound SR144528.  
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The first SAR study was carried out on the intermediate bearing p-methoxyphenyl 
fragment connected to the sulfone group. This intermediate showed moderate CB2 binding affinity 
(compound 5.1, CB2 Ki = 1.05 µM, Table 5.1). By keeping the p-methoxyphenyl connecting to 
the sulfone group we introduced several fragments connected to the amide groups varying in size, 
property, and charge and synthesized 18 derivatives (Table 5.2).   
Compared to compound 5.1, converting the methoxy group adjacent to the amide group to 
hydroxide by ester hydrolysis resulted in complete loss of the CB2 receptor binding affinity 
(compound 5.7). By the aim of having three phenyl (hydrophobic) rings, we introduced several 
substituted phenyls to compound 5.1. Un-substituted phenyl ring showed loss of the CB2 binding 
affinity (compound 5.15, CB2 Ki = 13700 nM). Increasing the distance between the phenyl ring 
and the amide group showed minimal effects of the CB2 binding affinity (compound 5.9, CB2 Ki 
= 15000 nM) compared to 5.15. We then tested different substitutions on the phenyl ring varying 
in size and position. Introducing p-Cl on the phenyl ring showed weak CB2 binding affinity 
(compound 5.11, CB2 Ki = 9500 nM). However, introducing 1,2-dichlorophenyl showed improved 
CB2 binding affinity compared to p-Cl (compound 5.12, CB2 Ki = 3490 nM). Further, introducing 
p-diethylamine on the phenyl ring showed improved CB2 receptor binding affinity and selectivity 
(CB2 Ki = 586 nM, CB1 Ki > 20000 nM, SI, 34). Reducing the size of the diethylamine with 
dimethylamine showed weak CB2 binding affinity (compound 5.23, Ki = 4260 nM). This shows 
that the diethylamine moiety is important in CB2 binding affinity. Replacing the diethylamine with 
a hydroxyl group abolished the CB2 binding affinity and selectivity (compound 5.22, CB2 Ki = 
6920 nM). Also, when the aromatic property was replaced with cyclohexylmethanamine or 
cycloheptylmethanamine, the CB2 binding affinity was reduced (compounds 5.10, and 5.24, CB2 
Ki = 5200 nM, and 7020 nM, respectively).  
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Next we wanted to explore the effects of replacing the phenyl group connected with the 
amide with different heterocyclic groups.  Introducing 2-methylthiophene (compound 5.18), 2-
methylfuran (compound 5.19), and a morpholine group (compound 5.21) abolished the CB2 
receptor binding affinity (CB2 Ki > 14000 nM). In addition, we explored introducing bulky groups 
such as adamantine and bicyclo[2.2.1]heptane. Compound 5.17 bearing adamantine showed 
moderate CB2 binding affinity (compound 5.17, CB2 Ki = 1860 nM, CB1 Ki = 8000 nM). 
However, compound 5.20 bearing the bicyclo[2.2.1]heptane group showed weaker binding affinity 
(CB2 Ki = 9400 nM).  
By keeping two phenyl rings, we tested the effects introducing aliphatic chain instead of 
the phenyl group. Long aliphatic chain (C7H15) lost the CB2 binding affinity (compound 5.8, CB2 
Ki 15000 nM). However, shorter aliphatic chain (C4H9, compound 5.16) showed improved CB2 
binding affinity (CB2 Ki = 1500 nM) compared to compound 5.8. Finally, reducing the fragment 
size connected to the amide group showed moderate CB2 as well as CB1 binding affinity 
(compound 5.14, CB2 Ki = 2900 nM, CB1 Ki = 5600 nM).  
Collectively, these data demonstrated that this intermediate, methyl (R)-2-((4-
methoxyphenyl)sulfonamido)-2-phenylacetate, may not be a suitable scaffold for developing CB2 
selective ligands and different intermediate scaffold should be explored. 
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Table 5.2. Intermediate I radioligand competition binding affinity and physicochemical 
properties 
 
Entry R MW cLogP Ki (CB2), µM Ki (CB1), µM 
5.7 -OH 321.35 2.45 NB NT 
5.8 
 
418.55 5.12 15 NT 
5.9 
 
410.49 3.83 15 NT 
5.10 
 
416.53 4.59 5.2 NT 
5.11 
 
444.93 4.54 9.5 NT 
5.12 
 
479.38 5.13 3.49 10.6 
5.13 
 
481.61 5.05 0.586 > 2000 
5.14 
 
376.47 3.40 2.90 5.6 
5.15 
 
396.46 3.64 13.7 NT 
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5.16 
 
390.50 4.06 1.5 NT 
5.17 
 
454.58 4.60 1.86 8 
5.18 
 
416.51 3.47 14.5 NT 
5.19 
 
400.45 3.00 NB NT 
5.20 
 
414.52 4.25 9.4 NT 
5.21 
 
405.47 2.69 NB NT 
5.22 
 
440.51 3.37 6.92 NT 
5.23 
 
439.53 3.81 4.26 NT 
5.24 
 
416.54 4.53 7.02 NT 
SR144528    0.002 - 
SR141716    - 0.0018 
Binding affinities for CB1 and CB2 receptor were evaluated using [3H]CP-55,940 radioligand competition 
binding assay utilizing SR141716 for CB1 and SR144528 for CB2 as reference compounds. NB: no 
binding, Ki > 20000 nM. NT: not tested. 
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Next, we replaced the p-methoxyphenyl with a naphthalene fragment as this intermediate 
showed relatively better CB2 binding affinity compared to other intermediates (compound 5.5, 
CB2 Ki = 1080 nM, Table 5.1) and synthesized 8 derivatives (Table 5.3). Comparing compound 
5.27 bearing 1,2-dichlorobenzene group with compound 5.12, both compounds showed 
comparable CB2 binding affinity with a slight improvement in compound 5.27 (CB2 Ki = 2840 
nM) but weaker when compared to compound 5.5. Introducing an un-substituted phenyl ring 
showed weak CB2 binding affinity (compound 5.29, CB2 Ki = 4960 nM) but better than compound 
5.15 (CB2 Ki = 13700 nM). In addition, increasing the distance between the phenyl ring and the 
amide group showed no effect on the CB2 affinity (compound 5.25, CB2 Ki = 4720 nM) but better 
than compound 5.9 (CB2 Ki = 15000 nM). Introducing adamantine group improved the CB2 
binding affinity (CB2 Ki = 618 nM, CB1 Ki = 4640 nM, SI = 7.5). In addition, compound 5.28 
bearing bicyclo[2.2.1]heptane group exhibited low CB2 binding affinity (CB2 Ki = 976 nM). 
Introducing 5-methy-1,2,3-trimethoxybenzene and methylcyclohexane showed weak-to-no 
binding (compounds 5.26, and 5.30 with CB2 Ki of 7140 nM and 4880 nM, respectively). 
Introducing adamantine group showed weak CB2 binding (compound 5.31, CB2 Ki = 6180 nM). 
As a result, we conclude that the scaffold 2-(sulfonylamino)-2-phenylacetamide is not optimal for 
the design and synthesis of selective CB2 ligands. 
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Table 5.3. Intermediate II radioligand competition binding affinity and physicochemical 
properties 
 
Entry R MW cLogP Ki (CB2), µM Ki (CB1), µM 
5.25 
 
430.52 4.72 4.97 2.6 
5.26 
 
436.57 5.49 7.14 NT 
5.27 
 
499.41 6.03 2.84 NT 
5.28 
 
434.55 5.15 0.976 1.2 
5.29 
 
416.50 4.54 4.96 NT 
5.30 
 
520.60 4.02 4.88 NT 
5.31 
 
474.62 5.50 6.18 4.64 
5.32 -OH 341.4 3.34 NB NT 
160 
SR144528    0.002 - 
SR141716    - 0.0018 
Binding affinities for CB1 and CB2 receptor were evaluated using [3H]CP-55,940 radioligand competition 
binding assay utilizing SR141716 for CB1 and SR144528 for CB2 as reference compounds. NB: no 
binding, Ki > 20000 nM. NT: not tested. 
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5.2.3 Multiple Myeloma Anti-Proliferation Studies 
Despite the weak to moderate binding affinity and selectivity toward the CB2, we carried out anti-
proliferation screening studies utilizing two MM cell-lines RPMI8226 and MM1.S. As detailed in 
the experimental section, Chapter 3.0 cell-lines were seeded at a density of 3 × 103 cells/well in a 
96-well plate and treated with 5.0 µM of the tested derivatives for 3 days. MTT assay was carried 
out as previously described to measure the inhibition rates of the different derivatives in 
comparison to the control wells. As illustrated in Figure 5.2, two 2-(sulfonylamino)-2-
phenylacetamide derivatives, compounds 5.12 and 5.31, exhibited inhibition rates of 58% and 92% 
in the RPMI8226 cell-lines, respectively, as well as 42% and 68% in the MM1.S cell-line 
respectively. However, these two compounds exhibited distinct CB2 binding profile, thus 
suggesting that these two compounds may have different targets. 
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Figure 5.2. Cell viability screening of the 2-(sulfonylamino)-2-phenylacetamide derivatives on MM cell-lines 
MM cell-lines, (A) RPMI8226, and (B) MM1.S were utilized to study the anti-proliferation effects of the synthesized derivatives. Cells 
were plated at density of 3 × 103/well in 96-well plates. Cells were incubated with 5 µM concentration of the tested derivatives for 3 
days. The cell viability was determined by the MTT assay. Data are represented as the mean ± SD of three experiments carried out in 
triplicates. Statistical differences are as follows: *P<0.05, and ****P<0.0001 compared with control incubations which were defined as 
100%.
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5.2.4 Target Exploration for Compounds 5.12 and 5.31 
The two compounds 5.12 and 5.31 exhibited potent anti-MM on two MM cell-lines with moderate 
CB2 receptor binding affinity. As a result, we attempted to explore the possible target of these two 
compounds by utilizing the High-Throughput Docking (HTD, https://www.cbligand.org/MM) tool 
developed in our lab [133]. The HTD tool is a webpage interface that allows the user to enter the 
chemical structure(s) and perform docking screenings on different known MM protein targets to 
identify possible targets for a chemical structure. A tabulated results including protein 
abbreviations (as identified in the Protein Data Bank, i.e., PDB name), full protein name, and the 
docking score as well as hyperlinks to the published co-crystal structures or published NMR 
protein structures.  
 We carried out HT-Docking on MM targets utilizing the two compounds. As shown in 
Figure 5.3, the two compounds exhibited high docking scores on three important MM protein 
targets, MAPK 14, CDK-2, and JAK-2. The docking scores were the highest with the two 
compounds targeting MAPK-14 (docking scores for 5.12 and 5.31 were 8.60 and 8.47, 
respectively). 
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Figure 5.3. Illustration of the HT-Docking of compounds 5.12 and 5.31 
High-throughput docking was carried out using our web-based HTD tool. MAPK: Mitogen-
activated protein kinase-14, CDK2: cyclin-dependent kinase-2, JAK2: Tyrosine-protein kinase-2, 
PPAR-γ: Peroxisome proliferator-activated receptor gamma. HSP-90: Heat-shock protein-90, 
EGFR: Epidermal growth factor receptor, HGFR: Hepatocyte growth factor receptor, AKT: 
protein kinase B. 
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As the highest docking score was achieved with MAPK-14, we performed specific 
molecular docking studies utilizing MAPK-14 co-crystal structure (PDB: 3NEW) to analyze the 
detailed molecular interactions between compounds 5.12 and 5.31 with important amino acids in 
the binding pocket of MAPK-14. Comess and coworkers reported the X-ray crystal structure of 
MAPK in complex with their in-house ligand. They reported the following important amino acids 
in the binding pocket of MAPK-14: Pro191, Trp197, Leu246, Ile250, Ser252, and Leu291 
(Figure 5.4).  
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Figure 5.4. Co-crystal structure of MAPK-14 complex with MAPK-14 inhibitor 
Reported important amino acids are Pro191, Trp197, Leu246, Ile250, Ser252, and Leu291. Protein 
structure was retrieved from the Protein Data Bank using PDB ID: 3NEW. Protein preparation and 
binding pocket illustration was carried out by the SYBYL X1.3 software and refined using PyMol. 
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Docking studies was carried out by the Surflex-Dock (SYBYL X1.3) software on the 
MAPK-14 co-crystal structure (PDB: 3NEW). Docking results of compounds 5.12 and 5.31 
demonstrated an excellent fit of these two compounds in the binding pocket as well as interactions 
with surrounding amino acids. Furthermore, these two compounds superimposed perfectly over 
the reported MAPK-14 lignad reported in the co-crystal structure (Figure 5.5). This suggests that 
these two compounds are promising MAPK-14 modulators that may play essentials roles in the 
MAPK signaling cascades. 
 
 
Figure 5.5. Binding pocket analysis 
Compound 5.12 and 5.31 interaction with MAPK-14 defined binding pocket in complex with the 
reported inhibitor. Compound 5.12 is color coded in cyan, compound 5.31 is color coded in yellow 
and the reported inhibitor is color coded in red. Important amino acids are color coded in magenta.  
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5.3 CONCLUSION 
Scaffold hopping was performed on the di-amide scaffold to overcome the limitations associated 
with it. As described earlier, the di-amide backbone rendered the synthesized ligands instability in 
acidic medium, which resulted in poor PK profile. A new scaffold, the 2-(sulfonylamino)-2-
phenylacetamide, was introduced bearing an amide and a sulfonamide groups. SAR studies were 
carried out to explore the different fragments connected with the scaffold with the aim of achieving 
high affinity and selectivity for the CB2 receptor. A library of 32 derivatives were synthesized and 
analyzed for SAR based on CB2 binding profile. Nearly, all the derivatives exhibited moderate-
to-weak CB2 receptor binding profile except for compound 5.13 with CB2 Ki = 586 nM.  
The anti-proliferation on MM cell-lines were carried out in order to study the inhibition 
profile of the 2-(sulfonylamino)-2-phenylacetamide derivatives. MTT assay was carried out to 
perform high-throughput anti-proliferation studies utilizing compound concentrations at 5 µM on 
two MM cell-lines (RPMI8226 and MM1.S). Among the synthesized analogs, two compounds, 
5.12 and 5.31, exhibited strong inhibition rates on the MM cell-lines. However, as shown in their 
CB2 binding profile, these two compounds showed different binding profiles suggesting that the 
MM inhibition may arise from the two compounds targeting other MM proteins. 
In order to explore different protein target that the two compounds are targeting, we carried 
out high-throughput docking studies utilizing our generated HTD-Anti-MM web-based tool. 
Interestingly, the results of the HTD of the two compounds were almost identical. Both compounds 
exhibited high docking scores on MAPK-14, JAK-2, and CDK-2, in which all are known MM 
proteins. As a result, we carried out extensive docking studies utilizing MAPK-14 co-crystal 
structure to identify the binding pocket and the possible binding pose of our two analogs. 
Interestingly, the two compounds exhibited similar binding pose as the reported MAPK-14 ligand 
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as well as several interactions of the analogs with important amino acids within the binding pocket. 
These data suggests that these two analogs target the MAPK-14 protein with high affinity and 
these two compounds may be further studies for in-vitro experiments to verify their ability as 
MAPK-14 modulators and ultimately anti-MM agents. 
Collectively, to serve the purpose of designing and developing highly potent and selective 
CB2 ligands, this scaffold was terminated as a CB2 scaffold. As a result, we had to look further 
for the development of CB2 ligands with optimized therapeutic activities, drug-like properties, as 
well as improved PK profile. However, with the interesting HTD data, the two compounds 5.13 
and 5.31 represent a novel chemical structure with potential anti-MM properties. 
 
 
 
 
 
 
 
 
 
  
171 
5.4 EXPERIMENTAL 
5.4.1 Chemistry 
General Synthesis of Sulfonamide Building Blocks [217]: 
 Methyl (R)-2-((4-methoxyphenyl)sulfonamido)-2-phenylacetate (5.1). 
 Methyl (R)-2-amino-2-phenylacetate (165 mg, 1.0 mmol) in 
dichloromethane (DCM, 10 mL) was chilled in ice bath with the 
exclusion of moisture, and then triethylamine (TEA, 121 mg, 1.2 
mmol) was added to it. The resulting solution was treated drop wise under stirring with 4-
methoxybenzenesulfonyl chloride (206 mg, 1.0 mmol), then left overnight at room temperature. 
The reaction solution was poured into water and extracted with EA. The combined organic layers 
were washed with water and brine and then dried over Na2SO4. The mixture was filtered and the 
solvent was evaporated in vacuum. The residue was purified by flash chromatography (ethyl 
acetate/ petroleum ether, 1:2) on silica gel to obtain methyl (R)-2-((4-
methoxyphenyl)sulfonamido)-2-phenylacetate. White solid (250 mg, yield: 74%). 1H NMR (400 
MHz, DMSO-d6) δ8.74 (d, J = 9.6 Hz, 1H), 7.68–7.64 (m, 2H), 7.29–7.27 (m, 5H), 7.03–7.00 (m, 
2H), 4.98 (d, J = 9.20 Hz, 1H), 3.81 (s, 3H), 3.46 (s, 3H). LC-MS (ESI): m/z 335.9 (M + H)+. 
Methyl (R)-2-((4-isopropoxyphenyl)sulfonamido)-2-phenylacetate (5.2).  
Off-white solid (60 mg, yield: 17%). 1H NMR (400 MHz, DMSO-
d6) δ8.71 (s, 1H), 7.63–7.60 (m, 2H), 7.35 (s, 5H), 6.99–6.95 (m, 
2H), 4.98 (d, J = 13.20 Hz, 1H), 4.73–4.67 (m, 1H), 3.61 (s, 3H), 
1.31 (d, J = 6.0 Hz, 6H). LC-MS (ESI): m/z 364.1 (M + H)+. 
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Methyl (R)-2-phenyl-2-(phenylsulfonamido)acetate (5.3).  
White solid (30 mg, yield: 10%). 1H NMR (400 MHz, DMSO-d6) δ8.92 
(s, 1H), 7.74–7.72 (m, 2H), 7.58–7.48 (m, 3H), 7.28 (s, 5H), 5.04 (s, 1H), 
3.45 (s, 3H). LC-MS (ESI): m/z 306.1 (M + H)+. 
Methyl (R)-2-([1,1'-biphenyl]-4-sulfonamido)-2-phenylacetate (5.4).  
Yellow solid (150 mg, yield: 40%). 1H NMR (400 MHz, DMSO-
d6) δ8.97 (s, 1H), 7.88 (s, 4H), 7.81–7.61 (m, 2H), 7.53–7.37 (m, 
3H), 7.36–7.20 (m, 5H), 5.08 (d, J = 9.20 Hz, 1H), 3.47 (s, 3H). 
LC-MS (ESI): m/z 382.0 (M + H)+. 
Methyl (R)-2-(naphthalene-2-sulfonamido)-2-phenylacetate (5.5).  
White solid (37 mg, yield: 11%). 1H NMR (400 MHz, DMSO-d6) 
δ8.36 (s, 1H), 8.10 (d, J = 7.60 Hz, 1H), 8.02 (t, J = 10.0 Hz, 2H), 
7.76–7.75 (m, 1H), 7.72–7.64 (m, 2H), 7.29–7.19 (m, 5H), 5.23 (s, 
1H), 3.25–3.17 (m, 3H). LC-MS (ESI): m/z 356.1 (M + H)+. 
Methyl (R)-2-(pentylsulfonamido)-2-phenylacetate (5.6). 
Yellow oil (10 mg, yield: 5%). 1H NMR (400 MHz, DMSO-d6) 
δ7.56-7.27(m, 6H), 4.74 (s, 1H), 3.66 (s, 3H), 3.48 (s, 3H), 3.38 (t. J 
= 7.0 Hz, 2H), 1.65-1.60 (m, 4H). LC-MS (ESI): m/z 300.1 (M + H)+. 
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Ester hydrolysis: 
 (R)-2-((4-methoxyphenyl)sulfonamido)-2-phenylacetic acid (5.7) [218].  
Methyl (R)-2-((4-methoxyphenyl)sulfonamido)-2-phenylacetate 
(5.1) (335 mg, 1 mmol) was dissolved in THF (10 mL), and a solution 
of LiOH·H2O (3 mmol) in an equal volume of water was added. When 
hydrolysis was completed (24 h), the reaction solution was poured 
into water and extracted with EA. The combined organic layers were washed with water and brine 
and then dried over Na2SO4. The mixture was filtered and the solvent was evaporated in vacuum 
without further purification needed to obtain (R)-2-((4-methoxyphenyl)sulfonamido)-2-
phenylacetic acid (5.7). Yellow solid (300 mg, yield: 94%). 1H NMR (400 MHz, DMSO-d6) 
δ12.92 (s, 1H), 8.52 (d, J = 8.8 Hz, 1H), 7.68–7.64 (m, 2H), 7.28–7.24 (m, 5H), 7.00–6.88 (m, 
2H), 4.83 (d, J = 9.2 Hz, 1H), 3.80 (s, 3H). LC-MS (ESI): m/z 322.1 (M + H)+. 
(R)-2-(naphthalene-2-sulfonamido)-2-phenylacetic acid (5.32).  
White solid (65 mg, yield: 19%). 1H NMR (400 MHz, DMSO-d6) 
δ12.90 (s, 1H), 8.35 (s, 1H), 8.09–7.99 (m, 3H), 7.79–7.63 (m, 4H), 
7.29–7.14 (m, 5H), 4.92 (s, 1H). LC-MS (ESI): m/z 342.1 (M + H)+. 
General methods for amide preparations: 
Method 1 [219]:   
(R)-N-heptyl-2-((4-methoxyphenyl)sulfonamido)-2-phenylacetamide (5.8). 
 The ester Methyl (R)-2-((4-
methoxyphenyl)sulfonamido)-2-phenylacetate (5.1) 
(335 mg, 1 mmol) was dissolved in methanol (10 mL) 
and then heptyl amine (138 mg, 0.2 mL, 4 mmol) was added drop wise.  The solution was heated 
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to reflux for 24 h, and then cooled to room temperature. The resulting mixture was concentrated 
in vacuum which was purified by flash chromatography (ethyl acetate/petroleum ether, 1:2) to give 
the desired product (R)-N-heptyl-2-((4-methoxyphenyl)sulfonamido)-2-phenylacetamide. Yellow 
solid (15 mg, yield: 4%). 1H NMR (400 MHz, DMSO-d6) δ8.90 (s, 1H), 7.96 (t, J = 1.6 Hz, 2H), 
7.74–7.57 (m, 5H), 7.45 (d, J = 7.6 Hz, 2H), 3.96 (s, 1H), 3.91 (s, 2H), 3.29–3.23 (m, 3H), 1.30–
1.56 (m, 10H), 0.88–0.81 (m, 3H). LC-MS (ESI): m/z 419.0 (M + H)+. 
(R)-N-benzyl-2-((4-methoxyphenyl)sulfonamido)-2-phenylacetamide (5.9).  
White solid (170 mg, yield: 41%). 1H NMR (400 MHz, 
DMSO-d6) δ8.64 (t, J = 6.0 Hz, 1H), 8.42 (s, 1H), 7.66 (d, J 
= 8.8 Hz, 2H), 7.34–7.31 (m, 2H), 7.26–7.21 (m, 5H), 7.03–
6.98 (m, 2H), 6.96 (d, J = 10.8 Hz, 2H), 4.98 (s, 1H), 4.19–4.04 (m, 2H), 3.80 (s, 3H). LC-MS 
(ESI): m/z 411.2 (M + H)+. 
(R)-N-(4-chlorobenzyl)-2-((4-methoxyphenyl)sulfonamido)-2-phenylacetamide (5.11). 
Yellow solid (30 mg, yield: 7%). 1H NMR (400 MHz, 
DMSO-d6) δ8.80 (t, J = 7.0 Hz, 1H), 7.70-7.66 (m, 3H), 
7.38-7.25 (m, 9H), 7.09-7.0 (m, 2H), 4.82 (s, 1H), 4.04-
4.00 (m, 2H), 3.79 (s, 3H). LC-MS (ESI): m/z 446.0 (M + H)+. 
(R)-N-benzyl-2-(naphthalene-2-sulfonamido)-2-phenylacetamide (5.25).  
Yellow solid (90 mg, yield: 21%). 1H NMR (400 MHz, 
DMSO-d6) δ8.62–8.8.55 (m, 2H), 8.01-7.99 (m, 5H), 7.80–
7.78 (m, 3H), 7.71-7.68 (m, 4H), 7.48-7.46 (m, 3H), 6.85-
5.09 (m, 2H), 4.79 (s, 1H), 4.76 (s, 2H). LC-MS (ESI): m/z 430.8 (M + H)+. 
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Method 2:  
(R)-N-(cyclohexylmethyl)-2-((4-methoxyphenyl)sulfonamido)-2-phenylacetamide (5.10). 
 Methyl (R)-2-((4-methoxyphenyl)sulfonamido)-2-
phenylacetate (5.1) (335 mg, 1 mmol) was dissolved in 
toluene. Cyclohexylmethanamine (226 mg, 2 mmol) was 
added to the mixture. The mixture was allowed to reflux for 1 h at 125 °C. The reaction was cooled 
at room temperature and stirred for 24 h. The residue was purified by preparative TLC (ethyl 
acetate/petroleum ether, 1:2) to give the desired product. White solid (100 mg, yield: 24%). 1H 
NMR (400 MHz, DMSO-d6) δ8.26 (t, J = 6.0 Hz, 2H), 7.59-7.51 (m, 5H), 7.39 (t, J = 8.0 Hz, 3H), 
4.55 (s, 1H), 3.59 (s, 2H), 1.92-1.89 (m, 11H). LC-MS (ESI): m/z 417.5 (M + H)+. 
(R)-N-(3,4-dichlorobenzyl)-2-((4-methoxyphenyl)sulfonamido)-2-phenylacetamide (5.12).  
Yellow solid (120 mg, yield: 25%). 1H NMR (400 MHz, 
DMSO-d6) δ8.75 (t, J = 8.0 Hz, 1H), 7.64-7.57 (m, 1H), 
7.49 (d, J = 8.4 Hz, 2H), 7.30-7.24 (m, 7H), 7.03-6.95 (m, 
3H), 4.96 (s, 1H), 4.14 (t, J = 5.2 Hz, 2H), 3.79 (s, 3H). LC-MS (ESI): m/z 480.5 (M + H)+. 
Enantiomeric excess (ee) = 98% (R). 
(R)-N-(4-(diethylamino)benzyl)-2-((4-methoxyphenyl)sulfonamido)-2-phenylacetamide 
(5.13). Brown red solid (80 mg, 17%).1H NMR (400 
MHz, DMSO-d6) δ8.42 (t, J = 8.2 Hz, 1H), 7.66 (d, J = 
2.0 Hz, 2H), 7.33–7.31 (m, 1H), 7.42 (s, 1H), 7.26–7.21 
(m, 2H), 6.98 (d, J = 9.2 Hz, 2H), 6.82 (d, J = 9.6 Hz, 2H), 6.54 (d, J = 8.4 Hz, 2H), 4.97 (s, 1H), 
3.81 (s, 2H), 2.45–2.43 (m, 3H), 1.06 (t, J = 6.80 Hz, 6H), 0.94 (t, J = 7.2 Hz, 4H).  LC-MS (ESI): 
m/z 482.0 (M + H)+. 
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(R)-N-isobutyl-2-((4-methoxyphenyl)sulfonamido)-2-phenylacetamide (5.14).  
Yellow solid (10 mg, yield: 3%). 1H NMR (400 MHz, DMSO-
d6) δ7.82 (d, J = 8.20 Hz, 1H), 7.67-7.38 (m, 7H), 6.85 (d, J = 
8.0 Hz, 2H), 6.49 (s, 1H), 3.87 (s, 1H), 2.62 (s, 1H), 1.59 (t, J = 
7.60 Hz, 2H), 1.34–1.30 (m, 1H), 1.24 (d, J = 7.2 Hz, 3H), 0.92 (t, J = 7.2 Hz, 6H). LC-MS (ESI): 
m/z 377.2 (M + H)+. 
(R)-2-((4-methoxyphenyl)sulfonamido)-N-pentyl-2-phenylacetamide (5.16).  
Yellow oil (30 mg, yield: 8%). 1H NMR (400 MHz, 
DMSO-d6) δ8.91 (s, 1H), 7.96 (t, J = 8.2 Hz, 1H), 7.86-
7.52 (m, 9H), 3.81 (s, 1H), 3.47 (s, 3H), 1.53 (s, 3H), 1.32-
1.24 (m, 5H), 0.91 (t, J = 7.2 Hz, 3H). LC-MS (ESI): m/z 391.8 (M + H)+. 
(R)-N-(4-(dimethylamino)phenyl)-2-((4-methoxyphenyl)sulfonamido)-2-phenylacetamide 
(5.23). Dark brown oil (102 mg, yield: 24%).1H NMR (400 
MHz, DMSO-d6) δ8.12 (d, J = 7.2 Hz, 2H), 7.79–7.77 (m, 
3H), 7.57–7.51 (m, 4H), 6.94 (d, J = 9.2 Hz, 3H), 6.75-
6.73 (m, 3H), 3.96 (s, 1H), 3.78 (s, 3H), 1.24 (t, J = 8.2 Hz, 
6H). LC-MS (ESI): m/z 440.6 (M + H)+. 
(R)-N-(cyclohexylmethyl)-2-(naphthalene-2-sulfonamido)-2-phenylacetamide (5.26).  
Yellow solid (60 mg, yield: 14%).1H NMR (400 MHz, 
DMSO-d6) δ8.10 (s, 1H), 7.69-7.56 (m, 3H), 7.45-7.39 (m, 
5H), 7.16 (d, J = 7.2 Hz, 2H), 4.55 (s, 1H), 3.69 (s, 3H), 3.33 
(d, J = 8.2 Hz, 2H), 1.61-1.55 (m, 11H). LC-MS (ESI): m/z 417.2 (M + H)+. 
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(R)-N-(3,4-dichlorobenzyl)-2-(naphthalene-2-sulfonamido)-2-phenylacetamide (5.27). 
Yellow solid (30 mg, yield: 20%). 1H NMR (400 MHz, 
DMSO-d6) δ8.78–8.72 (m, 2H), 8.34 (s, 1H), 8.05–7.97 
(m, 3H), 7.79 (t, J = 8.4 Hz, 1H), 7.70–7.65 (m, 2H), 
7.32–7.27 (m, 4H), 7.22–7.16 (m, 4H), 6.85 (t, J = 6.4 Hz, 1H), 5.07 (d, J = 8.4 Hz, 1H), 1.25 (s, 
2H). LC-MS (ESI): m/z 500.1 (M + H)+. 
Method 3: 
General procedure for acid acylation and coupling [220]: 
(R)-2-((4-methoxyphenyl)sulfonamido)-N,2-diphenylacetamide (5.15). 
The ester hydrolyzed product (5.7) (321 mg, 1 mmol) was 
treated with thionyl chloride (238 mg, 2 mmol) in ethyl acetate. 
The mixture was refluxed for 2 h at 80 °C to give the 
corresponding acid chloride. The acid chloride intermediate (339 mg, 1 mmol) was dissolved in 
ethyl acetate. Aniline (97 mg, 1.05 mmol) was added to the mixture. Triethylamine (121 mg, 1.2 
mmol) was added. The mixture was allowed to stir at room temperature for 12 h. The reaction 
solution was poured into water and extracted with EA. The combined organic layers were washed 
with water and brine and then dried over Na2SO4. The mixture was filtered and the solvent was 
evaporated in vacuum. The residue was purified by flash chromatography (ethyl acetate/petroleum 
ether, 1:2) on silica get to obtain the final product. Dark brown oil (144 mg, yield: 36%). 1H NMR 
(400 MHz, DMSO-d6) δ7.76 (d, J = 9.2 Hz, 1H), 7.68 (d, J = 9.2 Hz, 2H), 7.57 (d, J = 7.6 Hz, 1H), 
7.41–7.36 (m, 4H), 7.28–7.26 (m, 6H), 6.90 (d, J = 8.8 Hz, 2H), 5.14 (s, 1H), 3.68 (s, 3H). LC-
MS (ESI): m/z 397.1 (M + H)+. 
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(R)-N-cycloheptyl-2-((4-methoxyphenyl)sulfonamido)-2-phenylacetamide (5.24).  
Yellow solid (65 mg, 16%). 1H NMR (400 MHz, DMSO-d6) 
δ8.36 (d, J = 7.0 Hz, 1H), 8.01 (d, J = 6.8 Hz, 1H), 7.66 (d, J 
= 8.8 Hz, 2H), 7.40-7.20 (m, 5H), 7.00-6.94 (m, 2H), 4.91 (d, 
J = 9.6 Hz, 1H), 3.80 (s, 3H), 3.18 (d, J = 4.8 Hz, 1H), 1.48-1.18 (m, 12H). ). LC-MS (ESI): m/z 
416.9 (M + H)+. 
(R)-2-(naphthalene-2-sulfonamido)-N,2-diphenylacetamide (5.29).  
Brown oil (30 mg, 7%). 1H NMR (400 MHz, DMSO-d6) δ8.70–
8.67 (m, 2H), 8.42 (s, 1H), 8.21-8.19 (m, 4H), 7.98 (t, J = 7.2 
Hz, 1H), 7.77-7.68 (m, 4H), 7.62 (t, J = 8.2 Hz, 2H), 7.36-7.33 
(m, 5H), 5.06 (s, 1H). LC-MS (ESI): m/z 417.2 (M + H)+. 
Method 4 [221]:  
General procedure for coupling between amine and carbonyl: 
(R)-N-((3S,5S,7S)-adamantan-1-yl)-2-((4-methoxyphenyl)sulfonamido)-2-phenylacetamide 
(5.17). The ester hydrolyzed product (5.7) (321 mg, 1 mmol) 
was dissolved in THF. 1-Hydroxybenzotriazole (HOBt) (162 
mg, 1.2 mmol), 1-[3-(dimethylamino)propyl]-3-
ethylcarbodiimide hydrochloride (EDCI‚ HCl) (310 mg, 2.0 
mmol), and triethylamine (111 mg, 0.15 mL,1.1 mmol) were added. The mixture was stirred at 
room temperature for 2 h. Then adamantan-1-amine (181 mg, 1.2 mmol) was added. The mixture 
was stirred at room temperature for 24 h. The reaction solution was poured into water and extracted 
with EA. The combined organic layers were washed with water and brine and then dried over 
Na2SO4. The mixture was filtered and the solvent was evaporated in vacuum. The residue was 
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purified by flash chromatography (ethyl acetate/petroleum ether, 1:2) on silica get to obtain the 
final product. Yellow solid (50 mg, 11%). 1H NMR (400 MHz, DMSO-d6) δ8.16 (d, J = 9.20 Hz, 
1H), 7.68 (d, J = 8.8 Hz, 2H), 7.54 (s, 1H), 7.33–7.21 (m, 5H), 7.02 (d, J = 9.2 Hz, 2H), 4.93 (d, J 
= 8.8 Hz, 1H), 3.81 (s, 3H), 1.92 (s, 3H), 1.65–1.60 (m, 6H), 1.58 – 1.50 (m, 6H). LC-MS (ESI): 
m/z 545.8 (M + H)+. 
(R)-2-((4-methoxyphenyl)sulfonamido)-2-phenyl-N-(thiophen-2-ylmethyl)acetamide (5.18).  
Yellow solid (110 mg, yield: 27%). 1H NMR (400 MHz, 
DMSO-d6) δ8.75 (t, J = 5.6 Hz, 1H), 8.41 (d, J = 9.60 Hz, 
1H), 7.63 (d, J = 8.8 Hz, 2H), 7.37–7.21 (m, 6H), 6.97–6.89 
(m, 2H), 6.94–6.79 (m, 1H), 6.80–6.79 (m, 1H), 4.96 (d, J = 9.6 Hz, 1H), 4.28–4.26 (m, 2H), 3.80 
(s, 3H). LC-MS (ESI): m/z 416.9 (M + H)+. 
(R)-N-(furan-2-ylmethyl)-2-((4-methoxyphenyl)sulfonamido)-2-phenylacetamide (5.19). 
Yellow solid (151 mg, yield: 38%). 1H NMR (400 MHz, 
DMSO-d6) δ8.64 (t, J = 5.2 Hz, 1H), 8.40 (d, J = 9.6 Hz, 1H), 
7.64–7.55 (m, 2H), 7.55 (d, J = 1.2 Hz, 1H), 7.31–7.21 (m, 
5H), 6.95 (d, J = 8.8 Hz, 2H), 6.36–6.34 (m, 1H), 6.03–6.02 (m, 1H), 4.98 (d, J = 9.2 Hz, 1H), 
4.11–4.08 (m, 2H), 3.80 (s, 3H). LC-MS (ESI): m/z 401.1 (M + H)+. 
(2R)-N-(bicyclo[2.2.1]heptan-2-yl)-2-((4-methoxyphenyl)sulfonamido)-2-phenylacetamide 
(5.20). Yellow solid (86 mg, yield: 21%). 1H NMR (400 MHz, 
DMSO-d6) δ8.32–8.27 (m, 1H), 7.92 (t, J = 11.6 Hz, 1H), 7.69–
7.65 (m, 2H), 7.34–7.22 (m, 5H), 7.02–7.00 (m, 2H), 4.93-4.89 
(m, 1H), 3.81 (s, 3H), 1.25–1.16 (m, 6H), 0.88–0.85 (m, 5H). LC-MS (ESI): m/z 414.9 (M + H)+. 
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(R)-2-((4-methoxyphenyl)sulfonamido)-N-morpholino-2-phenylacetamide (5.21).  
Yellow solid (65 mg, yield: 16%). 1H NMR (400 MHz, DMSO-
d6) δ8.20 (d, J = 9.2 Hz, 1H), 7.67–7.65 (m, 2H), 7.28–7.25 (m, 
5H), 7.01–6.99 (m, 2H), 5.34 (d, J = 9.20 Hz, 1H), 3.81 (s, 3H), 
1.25 (s, 2H), 1.10 (t, J = 7.2 Hz, 2H), 1.00 (t, J = 6.8 Hz, 2H), 0.86–0.84 (m, 2H). LC-MS (ESI): 
m/z 406.3 (M + H)+. 
(R)-N-(4-hydroxyphenethyl)-2-((4-methoxyphenyl)sulfonamido)-2-phenylacetamide (5.22).  
Yellow solid (20 mg, yield: 5%). 1H NMR (400 MHz, 
DMSO-d6) δ9.16 (s, 1H), 8.31 (d, J = 8.8 Hz, 8.17 (t, 
J = 5.6 Hz, 1H), 7.66–7.64 (m, 2H), 7.25–7.21 (m, 
5H), 6.99–6.84 (m, 2H), 6.62–6.60 (m, 2H), 6.58 (s, 2H), 4.89 (d, J = 8.4 Hz, 1H), 3.78 (s, 3H), 
2.99 (t, J = 4.0 Hz, 2H), 2.39 (t, J = 6.8 Hz, 2H). LC-MS (ESI): m/z 441.2 (M + H)+. 
(2R)-N-(bicyclo[3.1.1]heptan-6-yl)-2-(naphthalene-2-sulfonamido)-2-phenylacetamide 
(5.28). Yellow solid (75 mg, yield: 18%). 1H NMR (400 MHz, 
DMSO-d6) δ8.33 (d, J = 10.8 Hz, 1H), 8.05–8.00 (m, 3H), 7.96-
7.86 (m, 2H), 7.82-7.77 (m, 1H), 7.69–7.63 (m, 2H), 7.36–7.33 
(m, 2H), 7.26–7.17 (m, 3H), 4.34 (s, 1H), 2.90 (s, 1H), 2.74 (s, 1H), 1.25 (s, 3H), 1.08–1.05 (m, 
3H), 0.88–0.84 (m, 3H). LC-MS (ESI): m/z 435.1 (M + H)+. 
(R)-2-(naphthalene-2-sulfonamido)-2-phenyl-N-(3,4,5-trimethoxybenzyl)acetamide (5.30).  
Yellow solid (60 mg, yield: 12%). 1H NMR (400 MHz, 
DMSO-d6) δ8.73–8.67 (m, 2H), 8.32 (s, 1H), 8.05–7.96 
(m, 3H), 7.77 (t, J = 8.8 Hz, 1H), 7.70–7.62 (m, 3H), 
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7.34 (d, J = 7.2 Hz, 2H), 7.18–7.11 (m, 4H), 6.29 (s, 2H), 5.09 (d, J = 8.0 Hz, 1H), 3.89–3.83 (m, 
2H), 3.56 (s, 9H). LC-MS (ESI): m/z 521.2 (M + H)+. 
(2R)-N-((1R,3R,5S)-adamantan-1-yl)-2-(naphthalene-2-sulfonamido)-2-phenylacetamide 
(5.31). Yellow solid (52 mg, 11%). 1H NMR (400 MHz, 
DMSO-d6) δ8.01 (s, 1H), 7.98–7.94 (m, 2H), 7.86–7.85 (m, 
5H), 7.55–7.51 (m, 2H), 7.49–7.46 (m, 4H), 4.86 (s, 1H), 
2.38–1.89 (m, 12H). LC-MS (ESI): m/z 474.9 (M + H)+. 
Enantiomeric excess (ee) > 98% (R). 
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6.0  DESIGN, SYNTHESIS, AND BIOLOGICAL EVALUATION OF SUBSTITUTED 
4-(AMINOMETHYL)-N,N-DIETHYLANILINE DERIVATIVS AS SELECTIVE CB2 
LIGANDS 
6.1 INTRODUCTION 
The previous two series demonstrated novel CB2 chemical scaffolds with advantages and 
disadvantages for each. In order to overcome the limitations we faced in the previous two series, 
we aimed at designing and synthesizing selective and potent CB2 ligands by exploring different 
chemical scaffold. This was accomplished by performing structure-based drug design where we 
utilized molecular docking studies employing our CB2 homology model. Due to the lack of high-
resolution 3D X-ray crystallographic co-crystal structure of the CB2 protein, our homology model 
developed in our lab served as a good starting point for our screening studies. We utilized the 
structure-based virtual screening protocol to screen known chemical databases based on docking 
and conformational analysis. The National Cancer Institute (NCI) 2010 chemical database was 
used to perform flexible molecular docking by the Surflex-Dock program in SYBYL X1.3 [207, 
222]. Approximately 100 molecules with docking score greater than 7.0 were structurally 
inspected for binding mode conformation, chemical diversity and drug-like properties. Among the 
100 molecules, 10 compounds were biologically evaluated for cannabinoid receptor binding 
activity using radio-ligand competitive binding assay (see appendix B, Table 7.1) [209]. 
As shown in Figure 6.1, the CB2 binding pocket is formed by helices III, V, VI, and VII. 
The important amino acids in this pocket are: Phe872.57, Phe912.61, Phe942.64, Asp101 (ECL1), 
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Phe1063.25, Lys1093.28, Ile1103.29, Val1133.32, Phe1173.36, Glu181 (ECL2), Leu182 (ECL2), Phe183 
(ECL2), Trp1945.43, Phe1975.46, Trp2586.48, Val2616.51, Met2656.55, Phe2817.35, and Ser2857.39.  
 
 
Figure 6.1. The CB2 homology model and the potential binding pocket. 
The potential binding pocket is formed by helices III, V, VI, and VII. Important amino acids in the 
pocket are: Phe872.57, Phe912.61, Phe942.64, Asp101 (ECL1), Phe1063.25, Lys1093.28, Ile1103.29, 
Val1133.32, Phe1173.36, Glu181 (ECL2), Leu182 (ECL2), Phe183 (ECL2), Trp1945.43, Phe1975.46, 
Trp2586.48, Val2616.51, Met2656.55, Phe2817.35, and Ser2857.39. 
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Compound 6.1 (Figure 6.2) was chosen as a lead compound due to: a) docking score of 
7.68, b) weak cannabinoid receptor affinity (CB2 Ki = 9 μM and CB1 Ki = 11 μM) which can be 
further optimized to generate selective CB2 ligands, further, c) this compound showed an 
interesting backbone as it has 3 phenyl rings connected to a chiral center in addition to the para 
nitro group that can be further modified. In addition, docking analysis showed multiple interactions 
with the amino acids in the binding pocket of the CB2 model. Hydrophobic interactions of ring A 
with Phe281 and Trp194 were observed. In addition, the sulphonyl group connected to ring A 
showed a hydrogen bonding interaction with Trp194. Rings B and C exhibited hydrophobic 
interactions with Phe91, Ph87, and Phe197, respectively. Another important interaction was 
observed between the p-NO2 and Trp258. However, the sulphonyl group of ring B showed weak 
interactions with Ser285 and Lys109, suggesting that the hydrogen bond acceptor group at this 
position is not essential (Figure 6.3). 
The modification strategy was to replace the central carbon with nitrogen, retain one of the sulfonyl 
groups and test different lengths, sizes and charges connected to the sulfonyl group, replacing the 
other sulfonyl group with different fragments varying at sizes, lengths and properties. In addition, 
the para-nitro group was replaced with para-diethylamine since this moiety had shown previously 
in Chapter 4, the di-amide scaffold, to improve the CB2 affinity; Figure 6.2 shows the new scaffold 
and modification points. 
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Figure 6.2. Chemical structure of the lead compound (6.1) and the lead optimization 
strategy. 
Molecular docking screening studies were performed using Surflex-Dock software in SYBYL 
X1.3. NCI-2010 database was utilized for the screening studies with the following criteria: docking 
score > 7.0, and molecular weight between 200 – 500 Da. The lead optimization strategy was to 
connect different amine fragments at the R1 position, connect different sulfonyl and aryl fragments 
at the R2 position, to replace the carbon center nitrogen, and to replace the para-nitro group with 
diethylamine. 
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Figure 6.3 Molecular docking interactions of compound 6.1 with different amino acids in 
the CB2 binding pocket. 
Molecular docking analysis was carried out using SYBYL X1.3 ® (Tripos Inc.) and refined using 
PyMol (Schrodinger). Red lines: hydrogen bonding, dashed lines: hydrophobic or pi-pi 
interactions. Compound 6.1 (NCI-294739) showed pi-pi stacking interaction between ring A and 
Phe281. Hydrogen bonding between the sulfonyl moiety of ring A and Trp194. Pi-pi stacking 
interaction was also observed between ring C and Phe197 as well as Trp258.  The nitro group on 
ring C showed a weak interaction with the Trp258. Pi-pi between ring B and Phe91 as well as 
Phe87. Weak interaction between the sulfonyl moiety of ring B and Lys109 as well as Ser285. 
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6.2 RESULTS AND DISCUSSION 
6.2.1 Chemistry Synthesis 
The synthetic routes to obtain the target substituted 4-(aminomethyl)-N,N-diethylaniline 
derivatives are depicted in Scheme 3. The commercially available 4-(diethylamino)benzaldehyde 
was reacted with 3,4,5-trimethoxybenzylamine to give 6.2. Compound 6.2 was treated with NaBH4 
to give the secondary amine 6.3. A coupling reaction was carried out between the intermediate 6.3 
and sulfonyl chloride or acyl chloride yielded the corresponding compounds 6.4 - 6.18 (Table 6.1). 
Similarly, reaction of 4-(diethylamino)benzaldehyde with 3-(aminomethyl)pyridine, 
piperonylamine, and pentanamine, then treated with NaBH4 gave the intermediates 6.20, 6.28 and 
6.36, respectively. Finally, coupling reaction of 6.20, 6.28 and 6.36 with sulfonyl chloride and acyl 
chloride yielded the corresponding compounds 6.21 - 6.26 (Table 6.2), 6.29 - 6.34 (Table 6.3) and 
6.37 - 6.42 (Table 6.4), respectively. All final products were purified by flash column 
chromatography and verified by NMR (400 Hz or 600 Hz) and LC/MS. 
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Scheme 3. Synthesis routes for 4-(aminomethyl)-N,N-diethylaniline derivatives. 
Synthesis schemes of (A) N,N-diethyl-4-(((3,4,5-trimethoxybenzyl)amino)methyl)aniline 
derivatives; (B) N,N-diethyl-4-(((pyridin-3-ylmethyl)amino)methyl)aniline derivatives; (C) 4-
(((benzo[d][1,3]dioxol-5-ylmethyl)amino)methyl)-N,N-diethylaniline derivatives, and (D) N,N-
diethyl-4-((pentylamino)methyl)aniline.  Reagents and conditions: (i) methanol, refluxed, 10 h; 
(ii) NaBH4, methanol, rt, 12 h; (iii) sulfonyl chloride or acyl chloride, anhydrous dichloromethane, 
triethylamine, rt, 12 h. 
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6.2.2 Structure Activity Relationship Analysis 
The structure activity relationship studies was carried out based on the CB2 binding affinity and 
selectivity. The binding affinities toward CB1 and CB2 were determined by performing [
3H]CP- 
55,940 radioligand competition binding assays using membrane  protein preparations of CHO cells 
stably expressing human CB2 receptor. The CB1 binding affinity was conducted on derivatives 
exhibiting a CB2 Ki < 1000 nM by utilizing membrane protein preparations of CHO cells stably 
transfected with human CB1 receptor. SR144528 (CB2 inverse agonist) and SR141716 (CB1 
inverse agonist) were used as CB2 and CB1 positive controls in bioassays experiments, 
respectively. The detailed radio-ligand competition binding assay was detailed in Chapter 3. 
Among the 41 analogues, ten compounds showed high CB2 affinity and selectivity with nanomolar 
Ki values (eight compounds exhibiting < 500 nM binding affinity). Table 6.1 - Table 6.4 
summarize the chemical structure, physicochemical properties, binding affinities and selectivity 
indices.   
For the SAR studies, several functional groups were introduced to the lead compound 6.1 
aiming at obtaining high potency and selectivity toward the CB2 receptor. The strategies were to 
replace the p-nitrophenyl group with p-(diethylamino)benzyl group as previous studies (Chapter 
4) have shown that this fragment played important roles to the selectivity towards the CB2 
receptor. In addition, one of the sulfonyl groups was replaced with 3,4,5-trimethoxybenzylamine, 
3-(aminomethyl)pyridine, piperonylamine, and pentanamine as these fragments varied in size, 
charge and properties. Further, the second sulfonyl group was either retained or replaced with a 
carbonyl group. Our studies have shown that the removal of one of the hydrophobic groups 
dramatically decreased the CB2 binding affinity (compounds 6.3, 6.20, 3.28, and 6.36, CB2 Ki = 
190 
42,350 nM, > 20,000 nM, > 20,000 nM and 40,170 nM, respectively) indicating the importance of 
having hydrophobic groups at the R1 and R2 positions to retain the binding activities. 
The fragment (3,4,5-trimethoxyphenyl)methanamine was introduced at the R1 position and 
synthesized 16 compounds (6.3 – 6.18, Table 6.1). These compounds differ at the R2 position by 
replacing the phenylmethanesulfonyl fragment with different sulfonyl or carbonyl fragments 
varying in size and properties. Compared with compound 6.1, reducing the distance between the 
benzene ring and the sulfonyl group by removing the methyl group and replacing the other 
phenylmethanesulfonyl with (3,4,5-trimethoxyphenyl)methanamine fragment dramatically 
increased the CB2 binding affinity with no affinity towards the CB1 receptor (compound 6.7, CB2 
Ki = 453 nM, CB1 Ki > 20,000 nM, selectivity index = 44). This indicates that the distance between 
the benzene ring and the sulfonyl group should be narrow and the other phenylmethanesulfonyl 
fragment is not necessary for selectivity and can be replaced with other fragments. To test the 
substitutions on the benzene ring of the benzene sulfonyl group at the R2 position, we introduced 
different substituents at different positions on the ring. The introduction of p-methyl group retained 
the CB2 binding affinity but induced the CB1 binding affinity (compound 6.6, CB2 Ki = 387 nM, 
CB1 Ki = 774 nM, selectivity index = 2). The introduction of m-methyl group improved the CB2 
binding affinity yet retaining good CB1 binding affinity (compound 6.5, CB2 Ki = 291 nM, CB1 
Ki = 732 nM, selectivity index = 2.5). In addition, o-methyl substitution on the benzene ring 
increased the CB2 binding affinity as well as the CB1 binding affinity (compound 6.14, CB2 Ki = 
157 nM, CB1 Ki = 180 nM, selectivity index = 2). These results indicate that para substituents are 
more favorable than meta- and ortho- substitutions in increasing CB2 binding affinity, selectivity, 
and reducing CB1 affinity. Next, we explored different functional groups at the para position. The 
introduction of a methoxy group at the para position retained good CB2 binding affinity with no 
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CB1 affinity (compound 6.4, CB2 Ki = 410 nM). However, introducing the p-isopropyl group 
improved the CB2 binding affinity but the CB1 binding affinity is much higher (compound 6.8, 
CB2 Ki = 230 nM, CB1 Ki = 122 nM). Introducing trifluoromethoxy at the para position reduced 
the CB2 binding affinity and selectivity (compound 6.13, CB2 Ki = 990 nM, CB1 Ki = 1240 nM, 
selectivity index = 2). Introduction of a p-formyl group improved CB2 binding affinity and 
selectivity (compound 6.18, CB2 Ki = 242 nM, CB1 Ki = 2290, selectivity index = 9). Next, we 
explored different group sizes at the R2 position. The introduction of naphthalene-2-sulfonyl at the 
R2 position increased the CB1 binding affinity (compound 6.9, CB2 Ki = 239 nM, CB1 Ki = 71 
nM). Further, the introduction of [1,1'-biphenyl]-4-sulfonyl at the R2 position abolished the CB1 
binding affinity and improved the CB2 binding affinity (compound 6.10, CB2 Ki = 322 nM).  
Then we studied the effect of introducing heterocycle groups at the R2 position. The 
introduction of a small heterocyclic group at the R2 position (thiophene-2-sulfonyl) showed an 
increase in the CB2 binding affinity without CB1 binding affinity (compound 6.16, CB2 Ki = 639 
nM, CB1 Ki > 20000 nM). However, the introduction of a heterocyclic group with the replacement 
of the sulfonyl group with carbonyl group dramatically increased the CB2 binding affinity 
(compound 6.11, CB2 Ki = 99 nM, CB1 Ki = 3282 nM, selectivity index = 33). In addition, we 
explored large heterocyclic groups at the R2 position by introducing quinoxaline-2-carbonyl. The 
CB2 binding affinity and selectivity was greatly improved (compound 6.12, CB2 Ki = 249 nM, 
CB1 Ki = 13020 nM, selectivity index = 52). These results indicated that introducing heterocyclic 
rings at the R2 position will potentiate the affinity and selectivity towards the CB2 receptor. 
Finally, in order to improve the conjugation system between the two functional groups (sulfonyl 
and the benzyl ring) of the fragment at the R2 position, we introduced a double bond between the 
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two functional groups. This modification improved dramatically the CB2 binding affinity and 
selectivity (compound 6.15, CB2 Ki = 138 nM, CB1 Ki > 20000 nM). 
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Table 6.1. Chemical structures, physicochemical properties, radioligand competition 
binding affinity and selectivity index for intermediate 1 derivatives (Compounds 6.3 – 6.18) 
 
 
Entry R MW cLogP Ki (CB2), nM  Ki (CB1), nM SI 
6.3 H 358.48 3.19 42350 NT  - 
6.4 
 
528.66 5.47 410 NB 50 
6.5 
 
512.66 5.80 291 732 3 
6.6 
 
512.66 5.80 387 774 2 
6.7 
 
498.64 5.30 453 NB 44 
6.8 
 
540.72 6.72 230 122 - 
6.9 
 
548.70 6.47 239 71 - 
6.10 
 
574.74 7.18 322 NB  62 
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6.11 
 
468.61 4.86 99 3282 33 
6.12 
 
514.63 4.62 249 13020 52 
6.13 
 
582.64 6.57 990 1240 2 
6.14 
 
512.66 5.80 157 180 2 
6.15 
 
524.68 5.94 138 NB 145 
6.16 
 
504.66 5.02 639 NB 32 
6.17 
 
558.69 5.17 657 NT - 
6.18 
 
526.65 4.87 242 2290 9 
SR144528    1.55 NT - 
SR141716    NT 1.2 - 
Binding affinities for CB1 and CB2 receptor were evaluated using [3H]CP-55,940 radioligand competition 
binding assay. NB: no binding, Ki > 20000 nM. NT: not tested.  SI: selectivity index for CB2, calculated as 
Ki(CB1)/Ki(CB2) ratio. CB2 reference compound SR144528. CB1 reference compound SR141716. 
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To extend the SAR studies, we retained the 4-(diethylamino)benzyl group and replaced 
one of the phenylmethanesulfonyl with a heterocyclic group, 3-(aminomethyl)pyridine, and 
replaced the other phenylmethanesulfonyl with different sulfonyl and carbonyl groups to evaluate 
the effect on reducing the size of the fragment at the R1 on the binding affinity and selectivity 
(compounds 6.20 – 6.26, Table 6.2). Unfortunately, all of these compounds showed decreased 
CB2 binding activity (CB2 Ki > 1000 nM). However, introducing a bulky non-heterocyclic group 
at the R2 position improved the CB2 binding affinity (compounds 6.24 and 6.25, CB2 Ki < 1000 
nM). In addition, introducing a double bond between the sulfonyl and the benzyl group slightly 
improved the CB2 binding affinity and selectivity (compound 6.23, CB2 Ki = 899 nM, CB1 Ki = 
5460 nM, selectivity index = 6). 
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Table 6.2. Chemical structures, physicochemical properties, radioligand competition binding 
affinity and selectivity index for intermediate 2 derivatives (Compounds 6.20 – 6.26) 
 
 
Entry R MW cLogP Ki (CB2), nM  Ki (CB1), nM SI 
6.20 H 269.39 2.39 NB NT  - 
6.21 
 
379.52 4.07 1020 NT  - 
6.22 
 
425.54 3.83 1205 NT  - 
6.23 
 
435.59 5.14 899 5460  6 
6.24 
 
459.61 5.67 866  12040  14 
6.25 
 
485.65 6.39 946 NB  21 
SR144528    1.55 NT - 
SR141716    NT 1.2 - 
Binding affinities for CB1 and CB2 receptor were evaluated using [3H]CP-55,940 radioligand competition 
binding assay. NB: no binding, Ki > 20000 nM. NT: not tested.  SI: selectivity index for CB2, calculated as 
Ki(CB1)/Ki(CB2) ratio. CB2 reference compound SR144528. CB1 reference compound SR141716. 
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We then replaced one of the phenylmethanesulfonyl with the fragment piperonylamine and 
the other phenylmethanesulfonyl with different sulfonyl and carbonyl groups (compounds 6.28 – 
6.34, Table 6.3). Replacing the phenylmethanesulfonyl at the R2 position with a bulky heterocyclic 
group showed good CB2 binding affinity with weak CB1 binding affinity (compound 6.31, CB2 
Ki = 775 nM, CB1 Ki = 1267 nM, selectivity index = 2). On the other hand, smaller heterocyclic 
group abolished the CB2 selectivity (compound 6.32, CB2 Ki = 574 nM, CB1 Ki = 727 nM, 
selectivity index = 2) indicating that the presence of two bulky heterocyclic groups at positions R1 
and R2 improved the CB2 affinity and selectivity. This result is further confirmed by replacing 
phenylmethanesulfonyl at the R2 position with 4-formylbenzenesulfonyl which showed a 
reduction in CB2 affinity and selectivity (compound 6.30, CB2 Ki = 1872 nM, CB1 Ki = 2745 nM, 
selectivity index = 1). Similarly, the introduction of a double bond between the sulfonyl and the 
benzyl group showed good CB2 binding affinity as well as selectivity (compound 6.29, CB2 Ki = 
381 nM, CB1 Ki = 1159 nM, selectivity index = 3). Also, introducing bulky groups at the R2 
position such as naphthalene-2-sulfonyl and [1,1'-biphenyl]-4-sulfonyl reduced the CB2 binding 
affinity (compounds 6.33, 6.34, CB2 Ki = 882 nM, and 1995 nM, respectively). 
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Table 6.3. Chemical structures, physicochemical properties, radioligand competition binding 
affinity and selectivity index for intermediate 3 derivatives (Compounds 6.28 – 6.34) 
 
Entry R MW cLogP Ki (CB2), nM  Ki (CB1), nM SI 
6.28 H 312.41 3.86 NB NT NT 
6.29 
 
478.61 6.60 381 1159 3 
6.30 
 
480.58 5.53 1872 2745 1 
6.31 
 
454.57 5.74 775 1267 2 
6.32 
 
422.54 5.53 574 727 2  
6.33 
 
502.63 7.14 882 NT - 
6.34 
 
528.67 7.85 1995 NT - 
SR144528    1.55 NT - 
SR141716    NT 1.2 - 
Binding affinities for CB1 and CB2 receptor were evaluated using [3H]CP-55,940 radioligand competition 
binding assay. NB: no binding, Ki > 20000 nM. NT: not tested.  SI: selectivity index for CB2, calculated as 
Ki(CB1)/Ki(CB2) ratio. CB2 reference compound SR144528. CB1 reference compound SR141716. 
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Finally, we replaced one of the phenylmethanesulfonyl with pentanamine to examine the 
effect of replacing aromatic groups with aliphatic groups (compounds 6.36 – 6.42, Table 6.4). 
These compounds showed comparable results as previous series. Introducing a double bond 
between the sulfonyl and the benzyl group exhibited an increase in the CB2 affinity and selectivity 
(compound 6.37, CB2 Ki = 1872 nM, CB1 Ki = 2745 nM, selectivity index = 10). In addition, 
small heterocyclic group showed good CB2 affinity and selectivity (compound 6.40, CB2 Ki = 362 
nM, CB1 Ki = 2437 nM, selectivity index = 7). However, bulky heterocyclic group showed an 
abolished CB2 selectivity (compound 6.39, CB2 Ki = 1852 nM, CB1 Ki = 1863 nM). Also, 
introducing bulky groups at the R2 position such as naphthalene-2-sulfonyl and [1,1'-biphenyl]-4-
sulfonyl reduced the CB2 binding affinity (compounds 6.41, and 6.42, CB2 Ki = 1139 nM and 
3147 nM, respectively). These results showed that it is not necessary to retain aromatic properties 
at all positions and the introduction of an aliphatic group will retain moderate CB2 binding affinity 
and selectivity but to a lesser extent than aromatic groups. 
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Table 6.4. Chemical structure, physicochemical properties, radioligand competition binding 
affinity and selectivity index for intermediate 4 derivatives (Compounds 6.36 – 6.42) 
 
Entry R MW cLogP Ki (CB2), nM  Ki (CB1), nM SI 
6.36 H 248.41 4.85 40170 NT NT 
6.37 
 
414.61 6.61 515 5242 10 
6.38 
 
416.58 6.02 657 1786 3 
6.39 
 
404.56 5.67 1852 1863 1 
6.40 
 
358.54 5.91 362 2437 7 
6.41 
 
438.63 7.62 1139 NT - 
6.42 
 
464.67 8.33 3147 NT - 
SR144528    1.55 NT - 
SR141716    NT 1.2 - 
Binding affinities for CB1 and CB2 receptor were evaluated using [3H]CP-55,940 radioligand competition 
binding assay. NB: no binding, Ki > 20000 nM. NT: not tested.  SI: selectivity index for CB2, calculated as 
Ki(CB1)/Ki(CB2) ratio. CB2 reference compound SR144528. CB1 reference compound SR141716. 
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6.2.3 In-Vitro Functional Assay  
The CB2 functional activities of the substituted 4-(aminomethyl)-N,N-diethylaniline derivatives 
were investigated by utilizing the cell-based LANCE cAMP assay. This assay distinguishes 
between agonists, inverse agonists and antagonists in GPCRs. The detailed experimental procedure 
was carried out as highlighted in Chapter 3. The cell-based LANCE cAMP assays were performed 
on 384-well plates using CHO cells stably expressing the CB2 receptors in the presence of 
phosphodiesterase inhibitor RO20-1724 and adenylate cyclase activator forskolin. 
Three highly potent and selective compounds were selected; 6.11, 6.15, 6.18 as well as CB2 
reference compounds SR144528 and CP55,940. As shown in Figure 6.4, reduction of the LANCE 
signal occurred with increasing concentrations of compounds 6.15, 6.18, and SR-144,528. These 
ligands act as inverse agonists, indicated by increasing forskolin-induced cAMP production. On 
the other hand, compound 6.11 and the known CB2 agonist, CP55,940, inhibited cAMP 
production, which indicates that compound 6.11 is a CB2 selective agonist.  
 
 
 
 
 
 
 
 
 
 
202 
 
 
 
-1 2 -1 0 -8 -6 -4 -2
5 0
1 0 0
6 .1 1
6 .1 5
C P 5 5 4 9 0
S R 1 4 4 5 2 8
6 .1 8
L o g  [c o m p o u n d s ] M
L
A
N
C
E
 S
ig
n
a
l 
(6
6
5
n
m
, 
%
 o
f 
c
o
n
tr
o
l)
 
Figure 6.4. Functional activity of the 4-(aminomethyl)-N,N-diethylaniline derivatives. 
Comparisons of LANCE signal of different CB2 receptor ligands in stably transfected CHO cells 
expressing human CB2 receptors in a concentration-dependent manner. Compounds CP55,940 as 
well as 6.11 behaved as agonists while compounds 6.15, 6.18 as well as SR-144,528 behaved as 
inverse agonists. Data represented as the mean ± SEM of one representative experiment of two or 
more carried out in triplicates. 
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6.2.4 Osteoclast Formation Assay 
The osteoclast formation assay was carried out using mouse whole bone marrow cells obtained 
from 4- to 6-week old C57BL/6 mouse as described in Chapter 3. The three top compounds 6.11, 
6.15, and 6.18 were chosen for the RANKL-induced osteoclast differentiation studies. In addition, 
we wanted to compare the different functionality the compounds (agonist 6.11 and inverse agonist 
6.15 and 6.18) on the osteoclast formation effects. As shown in Figure 6.5, compounds 6.15 and 
6.18 induced a concentration-dependent inhibition of osteoclastogenesis, with > 95% inhibition 
rate at concentrations 5 µM and 10 µM. Good inhibitions was maintained even at lower doses (2.5 
µM) for compounds 6.15 and 6.18. These results indicated that the inhibition activities are 
consistent with the CB2 affinities. On the other hand, the agonist (compound 6.11) showed an 
induction of osteoclast formation at higher doses (10 µM). These results showed that designing 
CB2 selective inverse agonist is more promising in the inhibition of OCL formation and the 
ultimate treatment of osteoporosis. 
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Figure 6.5. Anti-osteoclastogenesis activity of the potent 4-(Aminomethyl)-N,N-
diethylaniline derivatives. 
(A) Compounds 6.15 and 6.18 inhibited the RANKL-induced osteoclast differentiation in a dose-
dependent manner. Compound 6.11 had low effect in inducing the osteoclast formation at higher 
doses. BM cells were seeded at a density of 2 × 105 cells/well in 96-well plates and treated with or 
without RANKL (100 ng/mL) and M-CSF (30 ng/mL). CB2 compounds were added at the 
indicated concentrations for 10 days and stained for TRAP expression. Data is the mean ± SD of 
three experiments carried out in triplicates. (B) Microscopic photographs of cells for compound 
6.15 (magnification 100×). Statistical analysis: ***P<0.001, ****P<0.0001 compared to the 
control (RANKL+). 
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6.2.5 Multiple Myeloma Anti-proliferation Studies 
To test the anti-proliferation effects of our synthesized CB2 ligands against multiple myeloma, 
MTT colorimetric assay was conducted. MTT assay was carried out using two multiple myeloma 
cell-lines; MM1.S and RPMI8226. The detailed experimental details were highlighted in 
Chapter 3.0 .The first run of the MTT assay was to screen the derivatives exhibiting high affinity 
and selectivity on the MM cell-lines using 10 µM constant concentrations for the compounds and 
utilizing nocodazole as a positive control and the negative control wells having < 0.1% 
concentration of DMSO. Eleven compounds with CB2 Ki < 500 nM were evaluated for their 
inhibition ability of MM cell-lines. As illustrated in Figure 6.6, compounds 6.11 and 6.15 exhibited 
an inhibitory effect of MM cell-lines (inhibition rate < 45%). Both were utilized to measure the 
IC50 effects using concentrations 100 µM to 6.25 µM. Compound 6.11 demonstrated an IC50 value 
of 5.1 µM and 6.0 µM for MM1.S and RPMI8226 cell-lines, respectively. In comparison, 
compound 6.15 exhibited an IC50 of 8.3 µM and 7.6 µM for MM1.S and RPMI8226, respectively. 
These results indicates that designing a CB2 agonist is promising in treating MM while inverse 
agonist may need higher concentrations. 
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Figure 6.6. Anti-proliferation effects of the 4-(aminomethyl)-N,N-diethylaniline derivatives on MM cell-lines. 
Two multiple myeloma cell-lines (MM1.S and RPMI8226) were utilized to study the anti-proliferation effects of the synthesized 
derivatives. Cells were plated at density of 3 × 103/well in 96-well plates. Cells were incubated with 10 µM concentration of the tested 
derivatives for 3 days. The cell viability was determined with the MTT assay. Compounds 6.11 and 6.15 exhibited cell viability of < 
75% (inhibition rate > 45%). Data is the mean ± SD of three experiments carried out in triplicates. *P < 0.05 compared to the control.
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Figure 6.7. IC50 determination curve for the 4-(aminomethyl)-N,N-diethylaniline 
derivatives 
50% inhibitory concentration of compounds 6.11, and 6.15 were measured by utilizing the MTT 
colorimetric assay. Multiple myeloma cell-lines (MM1.S and RPMI8226) were utilized to study 
the anti-proliferation effects of the synthesized derivatives. Cells were plated at density of 3 × 
103/well in 96-well plates. The cell viability was determined with the MTT assay. (A) IC50 of 6.11 
= 5.1 µM and 6.0 µM for RPMI8226 and MM1.S cell-lines, respectively. (B) IC50 of 6.15 = 8.3 
µM and 7.6 µM for RPMI8226 and MM1.S cell-lines, respectively. Data is the mean ± SD of three 
experiments carried out in triplicates 
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6.2.6 Cytotoxicity Studies of Compounds 6.15 and 6.18 
Our newly discovered compounds 6.15 and 6.18 showed promising inhibition effects on 
osteoclastogenesis (osteoclast formation). To examine whether the impaired osteoclastogenesis 
effects of compounds 6.15 and 6.18 is due to decrease in the viability of the precursor cells not 
due to toxic effects, we investigated the cytotoxicity profile of these two compounds on osteoclast 
precursors RAW 264.7 and mouse bone marrow macrophages (BMM) by the MTT colorimetric 
cell viability assay. The assay was carried out as outlines in Chapter 3. First, RAW 264.7 cells and 
mouse BMM were plated on 96-well plates and incubated with compounds 6.15 and 6.18 for 3 
days. The percentage of cell survival was determined with the MTT assay. 
The results showed that cell viability was not significantly affected by the two compounds 
in comparison to the vehicle control group at 2.5 µM and 5 µM. Minor effects on cell viability 
were observed at higher concentrations 10 µM and 20 µM (Figure 6.8 and Figure 6.9). These 
results suggest that our newly discovered compounds have favorable therapeutic index and the 
effects on osteoclast differentiation were not derived from cytotoxicity effects. 
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Figure 6.8. Cytotoxic effects of compounds 6.15 and 6.18 on RAW264.7 Cell-line. 
Murine myeloid cell line (RAW264.7) cells were plated at density of 3 × 103/well on 96-well 
plates. Cells were incubated with the indicated doses of compounds (A) 6.15 and (B) 6.18 for 3 
days. The cell viability was determined with the MTT assay. The data are the mean ± SD of two 
experiments carried out in triplicates. All test samples showed statistical non-significant (P>0.05) 
compared to control. 
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Figure 6.9. Cytotoxic effects of compounds 6.15 and 6.18 on BMM 
Mouse BMM were plated at density of 3 × 103/well on 96-well plates. Cells were incubated with 
the indicated doses of compounds (A) 6.15 and (B) 6.18 for 3 days. The cell viability was 
determined with the MTT assay. The data are the mean ± SD of two experiments carried out in 
triplicates. All test samples showed statistical non-significant (P>0.05) compared to control. 
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6.2.7 Pharmacokinetic/Pharmacodynamic Studies of 6.11 and 6.15 
The two highly potent and selective compounds 6.11 and 6.15 were evaluated for their 
pharmacokinetic properties. As demonstrated in Table 6.5, after oral administration, 6.11 exhibited 
an elimination half-life (t1/2) of 1.646 hours and the maximum serum concentration was 87.03 µg/L 
in 0.19 hour and a clearance of 114.9 L/h/kg (Table 6.5). However, after iv administration, the 
elimination half-life was improved dramatically (14.79 h), maximum serum concentration was 
422.10 µg/L in 0.08 h with a clearance of 4.56 L/h/kg (Table 6.5). 
 
 
Table 6.5. Pharmacokinetic properties of 6.11 
Parameter Unit 
Route of Administration 
p.o. i.v. 
AUC µg/L*h 160.3 336.30 
t1/2 h 1.65 14.79 
Tmax h 0.19 0.08 
Vd L/kg 269.3 96.59 
CL L/h/kg 114.9 4.53 
Cmax µg/L 87.03 422.10 
Data is the mean of three rats. 
Abbreviations: Cmax, peak plasma concentration of a drug after administration; Tmax, time to reach 
Cmax; t1/2, elimination half-life; AUC, area under the concentration−time curve; CL, clearance; V, 
volume of distribution; p.o., per oral; i.v., intravenous. 
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Compound 6.15 exhibited an elimination half-life of 0.45 h after an oral administration. 
However, improved PK profiles was also observed after i.v. administration. The elimination half-
life was 10.49 h, maximum serum concentration was 340.32 µg/L in 0.25 h, and the clearance was 
3.56 L/h/kg after i.v. administration. (Table 6.6). 
 
 
Table 6.6. Pharmacokinetic properties of 6.15 
Parameter Unit 
Route of Administration 
p.o. i.v. 
AUC µg/L*h 11.50 298.52 
t1/2 h 0.45 10.49 
Tmax h 0.50 0.25 
Vd L/kg 1.56 21.56 
CL L/h/kg 1649.10 3.56 
Cmax µg/L 13.95 340.32 
Data is the mean of three rats. 
Abbreviations: Cmax, peak plasma concentration of a drug after administration; Tmax, time to reach 
Cmax; t1/2, elimination half-life; AUC, area under the concentration−time curve; CL, clearance; V, 
volume of distribution; p.o., per oral; i.v., intravenous. 
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6.2.8 3D Quantitative Structure Activity Relationship (QSAR) 
3D QSAR modeling studies were carried out on our synthesized derivatives in order to correlate 
the theoretical SAR model data and the experimental SAR data for further SAR studies. 3D QSAR 
CoMFA studies were carried out based on our published protocol [223, 224]. Compound 6.11 was 
chosen as a template compound in our CoMFA studies. Molecular dynamic simulations and 
molecular mechanics (MD/MM) were carried to search for the preferred conformation of 
compound 6.11. The resulted conformations were compared with the docking pose conformation 
that resulted from molecular docking simulations using our in-house CB2 receptor homology 
model [225]. The closest conformation to the docking pose was chosen a template conformation. 
Compounds from training set (Table 6.7) and test set (Table 6.8) were subjected to molecular 
alignment to the preferred conformer of compound 6.11. Figure 6.10 shows the final alignment of 
the training set and the test set. 
 
 
 
 
214 
 
Figure 6.10. Database alignment to reference compound 6.11 
Database alignment was achieved using the multi-fit module in SYBYL X 1.3 and manual 
alignment. (A) Training set database alignments to active molecule 6.11. (B) Test set database 
alignments to the active molecule 6.11 
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Partial least-square (PLS) analysis was performed using leave-one-out cross-validation 
(LOOCV). Leave-one-out cross-validation analysis is a method where each training sample is left 
out repeatedly and systemically in each training round to determine the optimal number of 
components. The predictive ability of each CoMFA model was determined by the cross-validated 
r2: The r2 is defined as rcv
2 = (SD – PRESS)/SD, where SD is the sum of the squared deviations 
between the biological activity of the molecules. PRESS is the sum of all the squared deviations 
between the actual and predicted activity values.  
The PLS analysis demonstrated that the optimal number of components was 6 and rcv
2 was 
0.503. The correlation coefficient (r2) for the non-cross validated PLS analysis was 0.989 with a 
standard error of estimate (SEE) of 0.012. The field contribution of steric and electrostatic were 
0.398 and 0.602, respectively. These results indicate that the trained CoMFA model correlates the 
structural information of the synthesized analogs to their CB2 receptor affinities. Further, the 
model was used to predict the binding affinities of test set compounds differing from those used 
before in the training set in order to evaluate our generated CoMFA model generalization ability. 
The correlation coefficient (r2) for the test set was 0.956. Such results indicate that the CoMFA 
model had good generalization performance on the test set molecules. Figure 6.11 show the 
regression lines of the experimental and predicted activity of the training and test sets, respectively. 
The two regression lines display good linearity fit between the experimental pKi and the predicted 
pKi values indicating that the developed CoMFA model is able to predict CB2 receptor binding 
affinity (Figure 6.11). 
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Table 6.7. Experimental (expt.) and predicted (pred.) pKi values of 4-(aminomethyl)-N,N-
diethylaniline derivatives in the training set 
Compd. CB2 Ki (nM) pKi (expt.) pKi (pred.) Residual 
6.5 291 6.536107 6.537 -0.00089 
6.8 230 6.638272 6.642 -0.00373 
6.17 657 6.182435 6.18 0.002435 
6.41 1139 5.943476 5.953 -0.00952 
6.42 3147 5.502103 5.491 0.011103 
6.11 99 6.970616 6.959 0.011616 
6.24 866 6.062482 5.883 0.179482 
6.13 990 6.004365 6.012 -0.00764 
6.21 1020 5.9914 5.98 0.0114 
6.18 242 6.616185 6.63 -0.01382 
6.17 657 6.182435 6.167 0.015435 
6.14 157 6.8041 6.795 0.0091 
6.29 381 6.419075 6.074 0.345075 
6.30 1872 5.727694 5.733 -0.00531 
6.33 882 6.054531 6.045 0.009531 
6.39 1852 5.732359 5.72 0.012359 
6.31 775 6.110698 6.115 -0.0043 
6.32 574 6.241088 6.254 -0.01291 
pKi calculated as –log Ki 
Residual is the difference between pKi (experimental) and pKi (predicted). 
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Table 6.8. Experimental (expt.) and predicted (pred.) pKi values of 4-(aminomethyl)-N,N-
diethylaniline derivatives in the test set 
Compd. CB2 Ki (nM) pKi (expt.) pKi (pred.) Residual 
6.4 410 6.387216 6.226 0.161216 
6.40 362 6.441291 6.469 -0.02771 
6.37 515 6.288193 6.21 0.078193 
6.12 249 6.603801 6.689 -0.0852 
6.23 899 6.04624 6.185 -0.13876 
6.25 946 6.024109 6.195 -0.17089 
6.15 138 6.860121 6.899 -0.03888 
6.22 1205 5.919013 5.896 0.023013 
6.16 639 6.194499 6.095 0.099499 
6.6 387 6.412289 6.466 -0.05371 
6.7 453 6.343902 6.469 -0.1251 
6.11 99 6.970616 6.956 0.014616 
pKi calculated as –log Ki 
Residual is the difference between pKi (experimental) and pKi (predicted). 
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Figure 6.11. Plots of CoMFA-calculated and experimental binding affinity. 
(A) CoMFA calculated and experimental binding affinity correlation for the training set. (B) 
CoMFA calculated and experimental binding affinity correlation for the test set. 
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CoMFA contour maps were then generated to predict the favorable and unfavorable 
regions of the new derivatives for CB2 binding affinity. The CoMFA contour maps display the 
color-coded steric and electrostatic regions around the molecules relating the ligands to their 
biological activities. Steric regions are displayed in green and yellow color-coding for sterically 
favored interactions and sterically unfavored interactions for the binding affinity, respectively. On 
the other hand, the electrostatic interactions are depicted in blue and red color-coding. The 
electropositive favored regions are displayed in blue contours while electronegative favored 
regions are displayed in red contours. As shown in Figure 6.12, a sterically favored region is 
present near the R1 position indicating that the introduction of bulky groups in this position will 
enhance the CB2 binding affinity. Also, at position R2, there is a large sterically unfavored region 
indicating that bulky groups at this position will negatively affect the binding affinity. In addition, 
electronegative interactions are preferred near the R1 position as highlighted by the blue region. 
Further, electropositive interactions are preferred near the R2 position as highlighted by the red 
region. 
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Figure 6.12. CoMFA contour maps of compound 6.11 showing steric and electrostatic 
interactions 
Contour maps were generated using the QSAR module in SYBYL X1.3. Compound 6.11 was used 
as the reference molecule for QSAR model generation. (A) Sterically (bulk) favored areas are 
color-coded in green and sterically unfavored areas are in yellow. (B) The blue and red contours 
reflect whether electropositive or electronegative substituents, respectively, are favored at a 
particular position. 
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6.3 CONCLUSION 
In this series, we have carried-out high throughput molecular docking screening of the NCI-2010 
chemical database utilizing our 3D CB2 homology model in order to identify a novel chemical 
scaffold. As a result, the lead compound, (((4-
nitrophenyl)methylenedisulfonyl)bis(methylene))dibenzene (compound 6.1) was discovered. 
Compound 6.1 was subjected to  medicinal chemistry structural modifications based on molecular 
docking studies aiming at increasing the CB2 affinity and potency synthesizing 42 analogs and 
evaluating their binding affinity and selectivity for the CB2/CB1 receptors in further SAR studies. 
Among the 42 analogs, nine compounds exhibited high binding affinity to the CB2 receptor (CB2 
Ki < 500 nM) as well as optimal CB2 selectivity (CB1/CB2 of 7 to 145 fold). Top three compounds 
were measured in functional assays to evaluate their cellular properties. Compounds 6.15 and 6.18 
behaved as inverse agonists, while compound 6.11 behaved as an agonist. Compound 6.11, N-(4-
(diethylamino)benzyl)-N-(3,4,5-trimethoxybenzyl)thiophene-2-carboxamide, represents a novel 
CB2 agonist. Consistent with previous results, the compounds behaving as inverse agonists (6.15 
and 6.18) showed potent inhibitory activity on RANKL-induced osteoclast formation. While the 
agonist, 6.11, stimulated the RANKL-induced osteoclast formation at high doses. The cytotoxicity 
studies of compounds 6.15 and 6.18 on RAW 264.7 and bone marrow macrophages (BMM) 
demonstrated low cytotoxicity effects as utilized by the MTT assay proving that the anti-OCL 
effects were not due to cytotoxicity. These results indicate that CB2 inverse agonists are potential 
agents for osteoporosis treatment. 
The anti-proliferative effects on multiple myeloma of the top three compounds were 
evaluated by performing the MTT cell-viability assay utilizing two anti-MM cell-lines (RPMI 
8226 and MM1.S). Compound 6.11 showed an inhibitory effect with IC50 of 5.1 µM and 6.0 on 
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RPMI 8226 and MM1.S, respectively. While compound 6.15 showed moderate inhibitory effects 
on these cell-lines (IC50 > 7 µM) suggesting that CB2 agonists holds promising effects as anti-MM 
agents. In addition, as the CB2 inverse agonist 6.15 showed high OCL inhibitory effects and good 
MM inhibition effects, this may be potential dual ligand treating MM while preventing bone 
lesions associated with MM disease. 
In addition, we carried out pharmacokinetic studies in order to analyze the PK properties 
of our new scaffold. Compounds 6.11 and 6.15 were utilized in the in-vivo PK studies. The new 
scaffold showed improved PK profile as demonstrated with improved elimination half-life and 
clearance for both compounds especially after intravenous administration. These results indicate 
that our new scaffold is more stable than the di-amide scaffold. 
Furthermore, 3D QSAR studies also confirmed our finding correlating experimental 
biological evaluations with mathematical calculations. The QSAR studies generated a CoMFA 
model that can be utilized for further design of CB2 ligands possessing high potency and 
selectivity. 
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6.4 EXPERIMENTAL 
6.4.1 Chemistry 
6.4.1.1 General Synthesis Procedure of Secondary Amine Building Blocks 
(E)-N,N-diethyl-4-(((3,4,5-trimethoxybenzyl)imino)methyl)aniline (6.2). 
(3,4,5-trimethoxyphenyl)methanamine (1972 mg, 10 mmol) was 
added slowly to a solution of 4-(diethylamino)benzaldehyde  
(1770 mg, 10 mmol) and methanol (20 mL). The reaction mixture 
was stirred and refluxed for 12 h. The reaction mixture was cooled 
to room temperature, and the solvent was removed by evaporation in vacuum to give the crude 
compound 6.2, which was used in the next step without further purification. 
 N,N-diethyl-4-(((3,4,5-trimethoxybenzyl)amino)methyl)aniline (6.3).  
The crude compound (E)-N,N-diethyl-4-(((3,4,5-
trimethoxybenzyl)imino)methyl)aniline (6.2) was 
dissolved in methanol (20 mL), and NaBH4 (570 mg, 15 
mmol) was added. Stirring of the mixture was continued for 12 h at room temperature. The reaction 
solution was poured into water and extracted with EA. The combined organic layers were washed 
with water and brine and then dried over Na2SO4. The residue was purified by flash 
chromatography (ethyl acetate/petroleum ether, 1:2) on silica get to obtain the final product (6.3). 
Yellow oil (3350 mg, yield: 93%). 1H NMR (400 MHz, DMSO-d6) δ 7.12 (d, J = 8.4 Hz, 2H), 
6.65 (s, 2H), 6.62 (d, J = 8.8 Hz, 2H), 3.76 (s, 6H), 3.64 (s, 3H), 3.60 (s, 2H), 3.54 (s, 2H), 1.07 (t, 
J = 7.2 Hz, 6H). LC-MS (ESI): m/z 359.0 (M + H)+. 
 
224 
(E)-N,N-diethyl-4-(((pyridin-3-ylmethyl)imino)methyl)aniline (6.19).  
Compound 6.19 was prepared from pyridin-3-ylmethanamine (1081 
mg, 10 mmol) and 4-(diethylamino)benzaldehyde  (1770 mg, 10 
mmol). The crude compound 6.19 was used in the next step without further purification. 
N,N-diethyl-4-(((pyridin-3-ylmethyl)amino)methyl)aniline (6.20).  
Compound 6.20 was prepared from the crude compound (E)-N,N-
diethyl-4-(((pyridin-3-ylmethyl)imino)methyl)aniline (6.19) and 
NaBH4 (570 mg, 15 mmol). The residue was purified by flash 
chromatography (methanol/DCM, 1:9) on silica get to obtain the final product (6.20). Yellow oil 
(1140 mg, yield: 84%). 1H NMR (400 MHz, DMSO-d6) δ 8.52 (s, 1H), 8.51–8.43 (m, 1H), 7.76-
7.32 (m, 1H), 7.36–7.32 (m, 1H), 7.11 (d, J = 8.4 Hz, 2H), 6.61 (d, J = 8.8 Hz, 2H), 3.68 (s, 2H), 
3.54 (s, 2H), 3.31–3.28 (m, 4H), 2.85 (s, 1H), 1.07 (t, J = 6.8 Hz, 6H). LC-MS (ESI): m/z 270.2 
(M + H)+. 
(Z)-4-(((benzo[d][1,3]dioxol-5-ylmethyl)imino)methyl)-N,N-diethylaniline (6.27). 
Compound 6.27 was prepared from benzo[d][1,3]dioxol-5-
ylmethanamine (1511 mg, 10 mmol) and  4-(diethylamino)benzaldehyde  
(1770 mg, 10 mmol). The crude compound 6.27 was used in the next 
step without further purification. 
4-(((benzo[d][1,3]dioxol-5-ylmethyl)amino)methyl)-N,N-diethylaniline (6.28). Compound 
6.28 was prepared from the crude compound (Z)-4-
(((benzo[d][1,3]dioxol-5-ylmethyl)imino)methyl)-N,N-diethylaniline 
(6.27) and NaBH4 (570 mg, 15 mmol). The residue was purified by flash 
chromatography (ethyl acetate/petroleum ether, 1:2) on silica get to 
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obtain the final product (6.28). Yellow oil (2900 mg, yield: 92%). 1H NMR (400 MHz, DMSO-
d6) δ7.09 (d, J = 8.4 Hz, 2H), 6.92 (s, 1H), 6.92–6.78 (m, 1H), 6.76 (d, J = 8.8 Hz, 2H), 5.98 (s, 
2H), 3.57 (s, 2H), 3.50 (s, 2H), 3.31–3.27 (m, 4H), 1.07 (t, J = 7.2 Hz, 6H). LC-MS (ESI): m/z 
313.3 (M + H)+. 
(Z)-N,N-diethyl-4-((pentylimino)methyl)aniline (6.35). 
Compound 6.25 was prepared from pentan-1-amine (871 mg, 10 
mmol) and 4-(diethylamino)benzaldehyde  (1770 mg, 10 mmol). 
The crude compound 6.35 was used in the next step without further purification. 
N,N-diethyl-4-((pentylamino)methyl)aniline (6.36). 
 Compound 6.36 was prepared from the crude compound (Z)-N,N-
diethyl-4-((pentylimino)methyl)aniline (6.35) and (570 mg, 15 
mmol). The residue was purified by flash chromatography (ethyl 
acetate/petroleum ether, 2:1) on silica get to obtain the final product (6.36). Yellow oil, (2450 mg, 
yield: 99%).1H NMR (600 MHz, DMSO-d6) δ7.08 (d, J = 13.2 Hz, 2H), 6.59 (d, J = 13.2 Hz, 2H), 
3.52 (s, 2H), 3.31–3.27 (m, 4H), 2.47–2.43 (m, 2H), 1.42–1.39 (m, 2H0, 1.28–1.24 (m, 4H), 1.07 
(t, J = 10.2 Hz, 6H), 0.85 (t, J = 7.80 Hz, 3H). LC-MS (ESI): m/z 249.4 (M + H)+. 
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6.4.1.2 General Procedure for the Coupling Reaction Between Secondary Amine and Acyl 
Chloride or Sulfonic Chloride 
N-(4-(diethylamino)benzyl)-4-methoxy-N-(3,4,5-trimethoxybenzyl)benzenesulfonamide 
(6.4). The intermediate N,N-diethyl-4-(((3,4,5-
trimethoxybenzyl)amino)methyl)aniline (compound 6.3) (358 
mg, 1.0 mmol) in dichloromethane (DCM, 10 mL) was chilled 
in ice bath with the exclusion of moisture, and then 
triethylamine (TEA, 121 mg, 1.2 mmol) was added to it. The resulting solution was treated 
dropwise under stirring with 4-methoxybenzenesulfonyl chloride (206 mg, 1.0 mmol), also 
dissolved in DCM, over 30 min at 0 ºC and then left overnight at room temperature. The reaction 
solution was poured into water and extracted with EA. The combined organic layers were washed 
with water and brine and then dried over Na2SO4. The mixture was filtered and the solvent was 
evaporated in vacuum. The residue was purified by flash chromatography (ethyl acetate/petroleum 
ether, 1:2) on silica gel to obtain N-(4-(diethylamino)benzyl)-4-methoxy-N-(3,4,5-
trimethoxybenzyl)benzenesulfonamide (6.4). Yellow solid (432 mg, yield: 82%). 1H NMR (400 
MHz, DMSO-d6) δ 7.82 (d, J = 9.2 Hz, 2H), 7.14 (d, J = 8.8 Hz, 2H), 6.94 (d, J = 8.8 Hz, 2H), 
6.54 (d, J = 8.8 Hz, 2H), 6.23 (s, 2H), 4.14 (d, J = 8.0 Hz, 4H), 3.86 (s, 3H), 3.59 (s, 3H), 3.58 (s, 
6H), 3.31–3.28 (m, 5H), 1.05 (t, J = 6.8 Hz, 6H). LC-MS (ESI): m/z 529.1 (M + H)+. 
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N-(4-(diethylamino)benzyl)-3-methyl-N-(3,4,5-trimethoxybenzyl)benzenesulfonamide (6.5). 
Compound 6.5 was prepared from the intermediate N,N-diethyl-4-
(((3,4,5-trimethoxybenzyl)amino)methyl)aniline (compound 6.3)  
(358 mg, 1.0 mmol) and 3-methylbenzenesulfonyl chloride (190 
mg, 1.0 mmol). The residue was purified by flash chromatography 
(ethyl acetate/petroleum ether, 1:2) on silica gel to obtain N-(4-(diethylamino)benzyl)-3-methyl-
N-(3,4,5-trimethoxybenzyl)benzenesulfonamide (6.5). Yellow solid (331 mg, yield: 64%). 1H 
NMR (400 MHz, DMSO-d6) δ 7.68–7.64 (m, 2H), 7.50 (d, J = 5.6 Hz, 1H), 7.49 (s, 1H), 6.95 (d, 
J = 8.80 Hz, 2H), 6.55 (d, J = 8.8 Hz, 2H), 6.25 (s, 2H), 4.18 (d, J = 8.0 Hz, 4H), 3.59 (s, 9H), 
3.31–3.27 (m, 4H), 2.39 (s, 3H), 1.06 (t, J = 7.2 Hz, 6H). LC-MS (ESI): m/z 513.3 (M + H)+. 
N-(4-(diethylamino)benzyl)-4-methyl-N-(3,4,5-trimethoxybenzyl)benzenesulfonamide (6.6). 
Compound 6.6 was prepared from the intermediate N,N-diethyl-4-
(((3,4,5-trimethoxybenzyl)amino)methyl)aniline (compound 6.3)  
(358 mg, 1.0 mmol) and 4-methylbenzenesulfonyl chloride (190 
mg, 1.0 mmol). The residue was purified by flash chromatography 
(ethyl acetate/petroleum ether, 1:2) on silica gel to obtain N-(4-(diethylamino)benzyl)-4-methyl-
N-(3,4,5-trimethoxybenzyl)benzenesulfonamide (6.6). Yellow solid (322 mg, yield: 62%). 1H 
NMR (400 MHz, DMSO-d6) δ 7.77 (d, J = 8.4 Hz, 2H), 7.43 (d, J = 8.0 Hz, 2H), 6.95 (d, J = 8.8 
Hz, 2H), 6.54 (d, J = 8.8 Hz, 2H), 6.21 (s, 2H), 4.15 (d, J = 8.4 Hz, 4H), 3.59 (s, 3H), 3.58 (s, 6H),  
3.30–3.26 (m, 4H), 2.42 (s, 3H), 1.06 (t, J = 7.20 Hz, 6H). LC-MS (ESI): m/z 513.3 (M + H)+. 
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N-(4-(diethylamino)benzyl)-N-(3,4,5-trimethoxybenzyl)benzenesulfonamide (6.7).  
Compound 6.7 was prepared from the intermediate N,N-diethyl-
4-(((3,4,5-trimethoxybenzyl)amino)methyl)aniline (compound 
6.3) (358 mg, 1.0 mmol) and benzenesulfonyl chloride (176 mg, 
1.0 mmol). The residue was purified by flash chromatography 
(ethyl acetate/petroleum ether, 1:2) on silica gel to obtain N-(4-(diethylamino)benzyl)-N-(3,4,5-
trimethoxybenzyl)benzenesulfonamide (6.7). Brown solid (359 mg, yield: 72%). 1H NMR (400 
MHz, DMSO-d6) δ 7.90 (d, J = 7.2 Hz, 2H), 7.71–7.63 (m, 3H), 6.93 (d, J = 8.8 Hz, 2H), 6.54 (d, 
J = 8.8 Hz, 2H), 6.23 (s, 2H), 4.18 (d, J = 6.8 Hz, 4H), 3.59 (s, 3H), 3.58 (s, 6H), 3.30–3.26 (m, 
4H), 1.07 (t, J = 7.2 Hz, 6H). LC-MS (ESI): m/z 499.1 (M + H)+. 
N-(4-(diethylamino)benzyl)-4-isopropyl-N-(3,4,5-trimethoxybenzyl)benzenesulfonamide 
(6.8).  
Compound 6.8 was prepared from the intermediate N,N-diethyl-
4-(((3,4,5-trimethoxybenzyl)amino)methyl)aniline (compound 
6.3) (358 mg, 1.0 mmol) and 4-isopropylbenzenesulfonyl 
chloride (218 mg 1.0 mmol). The residue was purified by flash 
chromatography (ethyl acetate/petroleum ether, 1:2) on silica gel to obtain N-(4-
(diethylamino)benzyl)-4-isopropyl-N-(3,4,5-trimethoxybenzyl)benzenesulfonamide (6.8). Brown 
solid (229 mg, yield: 42%). 1H NMR (400 MHz, DMSO-d6) δ 7.80 (d, J = 8.40 Hz, 2H), 7.49 (d, 
J = 8.40 Hz, 2H), 6.93 (d, J = 8.40 Hz, 2H), 6.54 (d, J = 8.80 Hz, 2H), 6.23 (s, 2H), 4.18 (d, J = 
7.20 Hz, 4H), 3.59 (s, 3H), 3.58 (s, 6H), 3.31–3.26 (m, 4H), 3.04–2.98 (m, 1H), 1.25 (d, J = 6.80 
Hz, 6H), 1.06 (t, J = 6.80 Hz, 6H). LC-MS (ESI): m/z 541.20 (M + H)+.  
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N-(4-(diethylamino)benzyl)-N-(3,4,5-trimethoxybenzyl)naphthalene-2-sulfonamide (6.9). 
Compound 6.9 was prepared from  the intermediate N,N-
diethyl-4-(((3,4,5-trimethoxybenzyl)amino)methyl)aniline 
(compound 6.3) (358 mg, 1.0 mmol) and  4-
isopropylbenzenesulfonyl chloride (218 mg 1.0 mmol). The 
residue was purified by flash chromatography (ethyl acetate/petroleum ether, 1:2) on silica gel to 
obtain N-(4-(diethylamino)benzyl)-N-(3,4,5-trimethoxybenzyl)naphthalene-2-sulfonamide (6.9). 
Yellow solid (454 mg, yield: 82%). 1H NMR (400 MHz, DMSO-d6) δ 8.52 (s, 1H), 8.16 (t, J = 8.4 
Hz, 2H), 8.07, (d, J = 8.0 Hz, 1H), 7.91 (d, J = 1.6 Hz, 1H), 7.89–7.67 (m, 2H), 6.98 (d, J = 8.8 
Hz, 2H), 6.53 (d, J = 8.8, 2H), 6.22 (s, 2H), 4.26 (s, 2H), 4.25 (s, 2H), 3.54 (s, 3H), 3.49 (s, 6H), 
3.33–3.27 (m, 4H), 1.05 (t, J = 4.4 Hz, 6H). LC-MS (ESI): m/z 549.1(M + H)+. 
N-(4-(diethylamino)benzyl)-N-(3,4,5-trimethoxybenzyl)-[1,1'-biphenyl]-4-sulfonamide 
(6.10). 
Compound 6.10 was prepared from the intermediate N,N-
diethyl-4-(((3,4,5-trimethoxybenzyl)amino)methyl)aniline 
(compound 6.3) (358 mg, 1.0 mmol) and 4-
isopropylbenzenesulfonyl chloride (218 mg 1.0 mmol). The 
residue was purified by flash chromatography (ethyl acetate/petroleum ether, 1:2) on silica gel to 
obtain N-(4-(diethylamino)benzyl)-N-(3,4,5-trimethoxybenzyl)-[1,1'-biphenyl]-4-sulfonamide 
(6.10). Yellow solid (365 mg, yield: 63%). 1H NMR (400 MHz, DMSO-d6) δ 7.97–7.89 (m, 4H), 
7.75 (d, J = 7.2 Hz, 2H), 7.56–7.47 (m, 3H), 6.98 (d, J = 8.8 Hz, 2H), 6.55 (d, J = 8.8 Hz, 2H), 
6.25 (s, 2H), 4.23 (d, J = 7.6 Hz, 4H), 3.57 (s, 9H), 3.27–3.26 (m, 4H), 1.05 (t, J = 6.8 Hz, 6H). 
LC-MS (ESI): m/z 575.1 (M + H)+. 
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N-(4-(diethylamino)benzyl)-N-(3,4,5-trimethoxybenzyl)thiophene-2-carboxamide (6.11). 
Compound 6.11 was prepared from  the intermediate N,N-diethyl-
4-(((3,4,5-trimethoxybenzyl)amino)methyl)aniline (compound 
6.3) (358 mg, 1.0 mmol) and thiophene-2-carbonyl chloride (146 
mg 1.0 mmol).  The residue was purified by flash chromatography 
(ethyl acetate/petroleum ether, 1:2) on silica gel to obtain N-(4-(diethylamino)benzyl)-N-(3,4,5-
trimethoxybenzyl)thiophene-2-carboxamide (6.11). Yellow oil (363 mg, yield: 77%). 1H NMR 
(400 MHz, CDCl3) δ 7.76 (s, 1H), 7.49 (t, J = 6.8 Hz, 2H), 7.35 (s, 1H), 7.15 (s, 1H), 7.015 (s. 
1H), 6.70 (s, 1H), 6.49 (s, 2H), 4.67 (t, J = 9.6 Hz, 4H), 3.86 (s, 9H), 3.38 (d, J = 6.8 Hz, 3H), 3.15 
(t, J = 5.2 Hz, 1H), 1.07 (d, J = 5.6 Hz, 6H). LC-MS (ESI): m/z 469.4 (M + H)+. 
N-(4-(diethylamino)benzyl)-N-(3,4,5-trimethoxybenzyl)quinoxaline-2-carboxamide (6.12). 
Compound 6.12 was prepared from  the intermediate N,N-diethyl-
4-(((3,4,5-trimethoxybenzyl)amino)methyl)aniline (compound 
6.3) (358 mg, 1.0 mmol) and quinoxaline-2-carbonyl chloride (192 
mg 1.0 mmol). The residue was purified by flash chromatography 
(ethyl acetate/petroleum ether, 1:2) on silica gel to obtain N-(4-
(diethylamino)benzyl)-N-(3,4,5-trimethoxybenzyl)quinoxaline-2-carboxamide (6.12). Yellowish 
oil (400 mg, yield: 77%). 1H NMR (400 MHz, DMSO-d6) δ 8.92 (s, 1H), 8.16–8.09 (m, 2H), 7.98–
7.93 (m, 2H), 7.27 (d, J = 8.8 Hz, 1H), 7.10 (d, J = 8.8 Hz, 1H), 6.70–6.58 (m, 3H), 6.25 (s, 1H), 
4.62–4.49 (m, 4H), 1.052 (t, J = 3.6 Hz, 6H). LC-MS (ESI): m/z 515.2 (M + H)+. 
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N-(4-(diethylamino)benzyl)-4-(trifluoromethoxy)-N-(3,4,5-
trimethoxybenzyl)benzenesulfonamide (6.13). 
Compound 6.13 was prepared from the intermediate N,N-
diethyl-4-(((3,4,5-trimethoxybenzyl)amino)methyl)aniline 
(compound 6.3) (358 mg, 1.0 mmol) and 4-
(trifluoromethoxy)benzenesulfonyl chloride (260 mg, 1.0 
mmol. The residue was purified by flash chromatography (ethyl acetate/petroleum ether, 1:2) on 
silica gel to obtain N-(4-(diethylamino)benzyl)-4-(trifluoromethoxy)-N-(3,4,5-
trimethoxybenzyl)benzenesulfonamide (6.13). Yellow solid (455 mg, yield: 78 %). 1H NMR (400 
MHz, DMSO-d6) δ 8.0 (d, J = 8.80 Hz, 2H), 7.59 (d, J = 8.0 Hz, 2H), 6.94 (d, J = 8.8 Hz, 2H), 
6.54 (d, J = 8.8 Hz, 2H), 6.27 (s, 2H), 4.23 (d, J = 7.6 Hz, 4H), 3.60 (s, 6H), 3.59 (s, 3H), 3.30–
3.25 (m, 4H), 1.06 (t, J = 7.2 Hz, 6H). LC-MS (ESI): m/z 583.1 (M + H)+. 
N-(4-(diethylamino)benzyl)-2-methyl-N-(3,4,5-trimethoxybenzyl)benzenesulfonamide 
(3.14). Compound 6.14 was prepared from the intermediate N,N-
diethyl-4-(((3,4,5-trimethoxybenzyl)amino)methyl)aniline 
(compound 6.3) (358 mg, 1.0 mmol) and 2-methylbenzenesulfonyl 
chloride (190 mg, 1.0 mmol). The residue was purified by flash 
chromatography (ethyl acetate/petroleum ether, 1:2) on silica gel to obtain N-(4-
(diethylamino)benzyl)-2-methyl-N-(3,4,5-trimethoxybenzyl)benzenesulfonamide (6.14). Yellow 
solid (216 mg, yield: 42%). 1H NMR (400 MHz, DMSO-d6) δ 7.90 (d, J = 6.8 Hz, 1H), 7.59 (t, J 
= 6.4 Hz, 1H), 7.49–7.40 (m, 2H), 6.94 (d, J = 8.8 Hz, 2H), 6.54 (d, J = 8.8 Hz, 2H), 6.27 (s, 2H), 
4.22 (s, 2H), 4.19 (s, 2H), 3.62 (s, 6H), 3.61 (3H), 3.30–3.28 (m, 4H), 2.56 (s, 3H), 1.07 (t, J = 6.8 
Hz, 6H). LC-MS (ESI): m/z 513.1 (M + H)+. 
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 (E)-N-(4-(diethylamino)benzyl)-2-phenyl-N-(3,4,5-trimethoxybenzyl)ethene-1-sulfonamide 
(6.15). Compound 6.15 was prepared from the intermediate 
N,N-diethyl-4-(((3,4,5-trimethoxybenzyl)amino)methyl)aniline 
(compound 6.3) (358 mg, 1.0 mmol) and (E)-2-phenylethene-1-
sulfonyl chloride (202 mg, 1.0 mmol).  The residue was purified 
by flash chromatography (ethyl acetate/petroleum ether, 1:2) on silica gel to obtain (E)-N-(4-
(diethylamino)benzyl)-2-phenyl-N-(3,4,5-trimethoxybenzyl)ethene-1-
sulfonamidebenzenesulfonamide (6.15). White solid (278 mg, yield: 53%). 1H NMR (400 MHz, 
DMSO-d6) δ7.65 (t, J = 2.4 Hz, 2H), 7.44–7.42 (m, 3H), 7.38 (s, 1H), 7.26 (s, 1H), 7.09 (d, J = 
8.80 Hz, 2H), 6.59 (d, J = 8.40 Hz, 2H), 6.47 (s, 2H), 4.22 (s, 2H), 4.19 (s, 2H), 3.65 (s, 6H), 3.59 
(s, 3H), 3.30–3.25 (m, 4H), 1.06 (t, J = 7.20 Hz, 6H). 1H NMR (400 MHz, CDCl3) δ7.44 – 7.37 
(m, 6H), 6.64 (d, J = 8.80 Hz, 2H), 6.56–6.502 (m, 3H), 4.28 (s, 4H), 3.85 (s, 3H), 3.82 (s, 6H), 
1.18 (t, J = 6.80 Hz, 6H). LC-MS (ESI): m/z 525.2 (M + H)+. 
N-(4-(diethylamino)benzyl)-N-(3,4,5-trimethoxybenzyl)thiophene-2-sulfonamide (6.16). 
Compound 6.16 was prepared from the intermediate N,N-diethyl-
4-(((3,4,5-trimethoxybenzyl)amino)methyl)aniline (compound 
6.3) (358 mg, 1.0 mmol) and thiophene-2-sulfonyl chloride (182 
mg, 1.0 mmol). The residue was purified by flash chromatography 
(ethyl acetate/petroleum ether, 1:2) on silica gel to obtain N-(4-(diethylamino)benzyl)-N-(3,4,5-
trimethoxybenzyl)thiophene-2-sulfonamide (6.16). Yellow solid (270 mg, yield: 54%). 1H NMR 
(400 MHz, DMSO-d6) δ 8.03–8.02 (m, 1H), 7.76–7.75 (m, 1H), 7.28–7.25 (m, 1H), 6.96 (d, J = 
8.40 Hz, 2H), 6.55 (d, J = 8.80 Hz, 2H), 6.28 (s, 2H), 4.20 (s, 2H), 4.17 (s, 2H), 3.61 (s, 6H), 3.60 
(s, 3H), 3.30–3.26 (m, 4H), 1.06 (t, J = 11.20 Hz, 6H). LC-MS (ESI): m/z 505.5 (M + H)+. 
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N-(4-(diethylamino)benzyl)-3,4-dimethoxy-N-(3,4,5-trimethoxybenzyl)benzenesulfonamide 
(6.17). Compound 6.17 was prepared from the intermediate 
N,N-diethyl-4-(((3,4,5-trimethoxybenzyl)amino)methyl)aniline 
(compound 6.3) (358 mg, 1.0 mmol) 3,4-
dimethoxybenzenesulfonyl chloride (236 mg, 1.0 mmol. The 
residue was purified by flash chromatography (ethyl acetate/petroleum ether, 1:2) on silica gel to 
obtain N-(4-(diethylamino)benzyl)-3,4-dimethoxy-N-(3,4,5-
trimethoxybenzyl)benzenesulfonamide (6.17). Brown oil (436 mg, yield: 78%). 1H NMR (400 
MHz, DMSO-d6) δ 7.49 (d, J = 2.4 Hz, 1H), 7.47 (s, 1H), 7.46–7.223 (m, 1H), 7.15 (d, J = 8.80 
Hz, 2H), 6.55 (d, J = 8.80 Hz, 2H), 6.25 (s, 2H), 4.18 (s, 2H), 4.17 (s, 2H), 3.86 (s, 3H), 3.79 (s, 
3H), 3.79 (s, 6H), 3.59 (s, 3h), 3.31–3.28 (m, 4H), 1.06 (t, J = 7.20 Hz, 6H). LC-MS (ESI): m/z 
559.4 (M + H)+. 
N-(4-(diethylamino)benzyl)-4-formyl-N-(3,4,5-trimethoxybenzyl)benzenesulfonamide 
(6.18).  Compound 6.18 was prepared from the intermediate 
N,N-diethyl-4-(((3,4,5-
trimethoxybenzyl)amino)methyl)aniline (compound 6.3) (358 
mg, 1.0 mmol) and 4-formylbenzenesulfonyl chloride (204 mg, 
1.0 mmol). The residue was purified by flash chromatography (ethyl acetate/petroleum ether, 1:2) 
on silica gel to obtain N-(4-(diethylamino)benzyl)-4-formyl-N-(3,4,5-
trimethoxybenzyl)benzenesulfonamide (6.18). Yellow solid (374 mg, yield: 71%). 1H NMR (400 
MHz, DMSO-d6) δ10.13 (s, 1H), 8.11–8.06 (m, 4H), 6.95 (d, J = 8.80 Hz, 2H), 6.53 (d, J = 8.40 
Hz, 2H), 6.26 (s, 2H), 4.24 (d, J = 7.20 Hz, 4H), 3.59 (s, 9H), 3.30 – 3.26 (m, 4H), 1.05 (t, J = 6.80 
Hz, 6H). 1H NMR (600 MHz, CDCl3) δ7.99 (d, J = 1.80 Hz, 4H), 6.86 (d, J = 9.0 Hz, 2H), 6.49 
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(d, J = 8.40 Hz, 2H), 6.30 (s, 2H), 4.30 (s, 2H), 4.27 (s, 2H), 3.81 (s, 3H), 3.72 (s, 6H), 1.13 (t, J 
= 7.20 Hz, 6H). LC-MS (ESI): m/z 527.4 (M + H)+.  
N-(4-(diethylamino)benzyl)-N-(pyridin-3-ylmethyl)thiophene-2-carboxamide (6.21). 
Compound 6.21 was prepared from the intermediate N,N-diethyl-4-
(((pyridin-3-ylmethyl)amino)methyl)aniline (compound 6.20) (269 mg, 
1.0 mmol) and thiophene-2-carbonyl chloride (156 mg, 1.0 mmol). The 
residue was purified by flash chromatography (ethyl acetate/petroleum 
ether, 1:2) on silica gel to obtain N-(4-(diethylamino)benzyl)-N-(pyridin-3-ylmethyl)thiophene-2-
carboxamide (6.21). Dark brown oil (342 mg, yield: 90%). 1H NMR (400 MHz, DMSO-d6) δ8.50–
8.47 (m, 2H), 7.78 (d, J = 4.40 Hz, 1H), 7.77–7.66 (m, 1H), 7.39–7.36 (m, 2H), 7.11–7.04 (m, 
3H), 6.65 (d, J = 8.40 Hz, 2H), 4.62 (d, J = 12.40 Hz, 4H), 3.31–3.28 (m, 4H), 1.08 (t, J = 6.80 
Hz, 6H). LC-MS (ESI): m/z 380.0 (M + H)+. 
N-(4-(diethylamino)benzyl)-N-(pyridin-3-ylmethyl)quinoxaline-2-carboxamide (6.22). 
Compound 6.22 was prepared from the intermediate N,N-diethyl-
4-(((pyridin-3-ylmethyl)amino)methyl)aniline (compound 6.20) 
(269 mg, 1.0 mmol) and quinoxaline-2-carbonyl chloride (192 mg, 
1.0 mmol. The residue was purified by flash chromatography 
(ethyl acetate/petroleum ether, 1:2) on silica gel to obtain N-(4-
(diethylamino)benzyl)-N-(pyridin-3-ylmethyl)quinoxaline-2-carboxamide (6.22). Yellow solid 
(305 mg, yield: 72%). 1H NMR (400 MHz, DMSO-d6) δ9.17 (s, 1H), 8.57 (d, J = 1.60 Hz, 1H), 
8.52–8.51 (m, 1H), 8.48–8.43 (m, 1H), 8.18–8.14 (m, 1H), 7.99–7.91 (m, 2H), 7.80–7.76 (m, 1H), 
4.68 (s, 2H), 4.57 (s, 1H), 4.53 (s, 1H), 3.37–3.28 (m, 4H), 1.06 (t, J = 7.20 Hz, 6H). LC-MS (ESI): 
m/z 426.1 (M + H)+. 
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(E)-N-(4-(diethylamino)benzyl)-2-phenyl-N-(pyridin-3-ylmethyl)ethene-1-sulfonamide 
(6.23).  Compound 6.23 was prepared from the intermediate N,N-
diethyl-4-(((pyridin-3-ylmethyl)amino)methyl)aniline (compound 
3.20) (269 mg, 1.0 mmol) and (E)-2-phenylethene-1-sulfonyl 
chloride (202 mg, 1.0 mmol). The residue was purified by flash 
chromatography (ethyl acetate/petroleum ether, 1:2) on silica gel to obtain (E)-N-(4-
(diethylamino)benzyl)-2-phenyl-N-(pyridin-3-ylmethyl)ethene-1-sulfonamide (6.23). Brown 
solid (270 mg, yield: 62%). 1H NMR (400 MHz, DMSO-d6) δ8.43–8.41 (m, 2H), 7.66–7.61 (m, 
3H), 7.454–7.43 (m, 3H), 7.42 (s, 1H), 7.31–7.27 (m, 1H), 7.28 (s, 1H), 7.07 (d, J = 8.80 Hz, 2H), 
4.31 (s, 2H), 4.20 (s, 2H), 3.31–3.26 (m, 4H), 1.05 (t, J = 6.80 Hz, 6H). LC-MS (ESI): m/z 436.2 
(M + H)+.  
N-(4-(diethylamino)benzyl)-N-(pyridin-3-ylmethyl)naphthalene-2-sulfonamide (6.24). 
Compound 6.24 was prepared from the intermediate N,N-diethyl-4-
(((pyridin-3-ylmethyl)amino)methyl)aniline (compound 6.20) (269 
mg, 1.0 mmol) and naphthalene-2-sulfonyl chloride (226 mg, 1.0 
mmol). The residue was purified by flash chromatography (ethyl 
acetate/petroleum ether, 1:2) on silica gel to obtain N-(4-(diethylamino)benzyl)-N-(pyridin-3-
ylmethyl)naphthalene-2-sulfonamide (6.24). Brown solid (285 mg, yield: 62%). 1H NMR (400 
MHz, DMSO-d6) δ8.51 (s, 1H), 8.36 (d, J = 1.60 Hz, 1H), 8.28 (s, 1H), 8.18–8.14 (m, 2H), 8.09 
(d, J = 7.60 Hz, 1H), 7.88 (dd, J1 = 2.0 Hz, J2 = 8.80 Hz, 2H), 7.76–7.70 (m, 3H), 7.22–7.18 (m, 
1H), 6.91 (d, J = 8.80 Hz, 2H), 6.45 (d, J = 8.80 Hz, 2H), 4.35 (s, 2H), 4.24 (s, 2H), 3.27–3.24 (m, 
4H), 1.02 (t, J = 7.20 Hz, 6H). LC-MS (ESI): m/z 460.3 (M + H)+. 
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N-(4-(diethylamino)benzyl)-N-(pyridin-3-ylmethyl)-[1,1'-biphenyl]-4-sulfonamide (6.25). 
Compound 6.25 was prepared from the intermediate N,N-diethyl-
4-(((pyridin-3-ylmethyl)amino)methyl)aniline (compound 6.20) 
(269 mg, 1.0 mmol) and [1,1'-biphenyl]-4-sulfonyl chloride (252 
mg, 1.0 mmol. The residue was purified by flash chromatography 
(ethyl acetate/petroleum ether, 1:2) on silica gel to obtain N-(4-
(diethylamino)benzyl)-N-(pyridin-3-ylmethyl)-[1,1'-biphenyl]-4-sulfonamide (6.25). Yellow 
solid (273 mg, yield: 56%). 1H NMR (400 MHz, DMSO-d6) δ8.38–8.37 (m, 1H), 8.28 (d, J = 1.60 
Hz, 1H), 7.96–7.90 (m, 4H), 7.79–7.77 (m, 2H), 7.57–7.53 (m, 2H), 7.49–7.45 (m, 2H), 7.23–7.19 
(m, 1H), 6.91 (d, J = 8.80 Hz, 2H), 6.48 (d, J = 8.80 Hz, 2H), 4.32 (s, 2H), 4.22 (s, 2H), 3.29–3.25 
(m, 4H), 1.03 (t, J = 6.80 Hz, 6H). LC-MS (ESI): m/z 486.2 (M + H)+. 
(E)-N-(benzo[d][1,3]dioxol-5-ylmethyl)-N-(4-(diethylamino)benzyl)-2-phenylethene-1-
sulfonamide (6.29). Compound 6.29 was prepared from the 
intermediate 4-(((benzo[d][1,3]dioxol-5-
ylmethyl)amino)methyl)-N,N-diethylaniline (compound 6.28) 
(312 mg, 1.0 mmol) and (E)-2-phenylethene-1-sulfonyl chloride (202 mg, 1.0 mmol. The residue 
was purified by flash chromatography (ethyl acetate/petroleum ether, 1:2) on silica gel to obtain 
(E)-N-(benzo[d][1,3]dioxol-5-ylmethyl)-N-(4-(diethylamino)benzyl)-2-phenylethene-1-
sulfonamide (6.29). White solid (100 mg, yield: 20%). 1H NMR (400 MHz, DMSO-d6) δ7.61–
7.59 (m, 2H), 7.43 (s, 2H), 7.42 (s, 1H), 7.31 (s, 1H), 7.11 (s, 1H), 7.07 (t, J = 4.80 Hz, 2H), 6.84 
(d, J = 7.60 Hz, 1H), 6.81 (s, 1H), 6.76 (d, J = 7.60 Hz, 1H), 6.58 (d, J = 8.80 Hz, 2H), 5.96 (s, 
2H), 4.15 (d, J = 6.40 Hz, 4H), 3.31–3.27 (m, 4H), 1.05 (t, J = 7.20 Hz, 6H). LC-MS (ESI): 479.4  
(M + H)+. 
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N-(benzo[d][1,3]dioxol-5-ylmethyl)-N-(4-(diethylamino)benzyl)-4-
formylbenzenesulfonamide (6.30).  
Compound 6.30 was prepared from the intermediate 4-
(((benzo[d][1,3]dioxol-5-ylmethyl)amino)methyl)-N,N-diethylaniline 
(compound 6.28) (312 mg, 1.0 mmol) and 4-formylbenzenesulfonyl 
chloride (204 mg, 1.0 mmol). The residue was purified by flash 
chromatography (ethyl acetate/petroleum ether, 1:2) on silica gel to 
obtain N-(benzo[d][1,3]dioxol-5-ylmethyl)-N-(4-
(diethylamino)benzyl)-4-formylbenzenesulfonamide (6.30). Yellow solid (410 mg, yield: 
85%).1H NMR (400 MHz, DMSO-d6) δ10.13 (s, 1H), 8.07 (d, J = 8.40 Hz, 2H), 8.01 (d, J = 8.40 
Hz, 2H), 6.86 (d, J = 8.80 Hz, 2H), 6.78 (d, J = 8.0 Hz, 1H), 6.62–6.57 (m, 1H), 6.57 (s, 1H), 6.49 
(d, J = 8.80 Hz, 2H), 5.95 (s, 2H), 4.23 (s, 2H), 4.19 (s, 2H), 3.30–3.25 (m, 4H), 1.04 (t, J = 7.20 
Hz, 6H), LC-MS (ESI): m/z 480.2  (M + H)+. 
4-(((benzo[d][1,3]dioxol-5-ylmethyl)(quinoxalin-2-ylmethyl)amino)methyl)-N,N-
diethylaniline (6.31).  
Compound 6.31 was prepared from the intermediate 4-
(((benzo[d][1,3]dioxol-5-ylmethyl)amino)methyl)-N,N-
diethylaniline (compound 6.28) (312 mg, 1.0 mmol and 
quinoxaline-2-carbonyl chloride (192 mg, 1.0 mmol). The residue 
was purified by flash chromatography (ethyl acetate/petroleum 
ether, 1:2) on silica gel to obtain 4-(((benzo[d][1,3]dioxol-5-ylmethyl)(quinoxalin-2-
ylmethyl)amino)methyl)-N,N-diethylaniline (6.31). Brown oil (418 mg, yield: 89%).1H NMR (600 
MHz, DMSO-d6) δ9.13 (s, 1H), 8.16–8.13 (m, 2H), 7.96–7.93 (m, 2H), 6.40–6.91 (m, 2H), 6.87–
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6.83 (m, 1H), 6.67 (d, J = 8.40 Hz, 2H), 6.57 (d, J = 8.40 Hz, 2H), 5.99 (s, 2H), 4.50 (s, 2H), 4.40 
(s, 2H), 3.30–3.27 (m, 4H), 1.05 (t, J = 7.20 Hz, 6H). LC-MS (ESI): m/z 469.1 (M + H)+. 
N-(benzo[d][1,3]dioxol-5-ylmethyl)-N-(4-(diethylamino)benzyl)thiophene-2-carboxamide 
(6.32).  
Compound 6.32 was prepared from the intermediate 4-
(((benzo[d][1,3]dioxol-5-ylmethyl)amino)methyl)-N,N-diethylaniline 
(compound 6.28) (312 mg, 1.0 mmol) and thiophene-2-carbonyl chloride 
(146 mg, 1.0 mmol). The residue was purified by flash chromatography 
(ethyl acetate/petroleum ether, 1:2) on silica gel to obtain N-(benzo[d][1,3]dioxol-5-ylmethyl)-N-
(4-(diethylamino)benzyl)thiophene-2-carboxamide (6.32). Dark brown oil (290 mg, yield: 
69%).1H NMR (400 MHz, DMSO-d6) δ7.78–7.76 (m, 1H), 7.33 (s, 1H), 7.09–7.07 (m, 1H), 7.04 
(d, J = 8.0 Hz, 2H), 6.90 (d, J = 8.0 Hz, 1H), 6.82 (s, 1H), 6.73 (d, J = 7.20 Hz, 1H), 6.65 (d, J = 
8.80 Hz, 2H), 6.02 (s, 2H), 4.52 (s, 4H), 3.36–3.02 (m, 4H), 1.08 (t, J = 7.20 Hz, 6H). LC-MS 
(ESI): m/z 423.2 (M + H)+. 
N-(benzo[d][1,3]dioxol-5-ylmethyl)-N-(4-(diethylamino)benzyl)naphthalene-2-sulfonamide 
(6.33).  
Compound 6.33 was prepared from the intermediate 4-
(((benzo[d][1,3]dioxol-5-ylmethyl)amino)methyl)-N,N-
diethylaniline (compound 6.28) (312 mg, 1.0 mmol) and 
naphthalene-2-sulfonyl chloride (226 mg, 1.0 mmol). The residue was purified by flash 
chromatography (ethyl acetate/petroleum ether, 1:2) on silica gel to obtain N-
(benzo[d][1,3]dioxol-5-ylmethyl)-N-(4-(diethylamino)benzyl)naphthalene-2-sulfonamide (6.33). 
Yellow oil (76 mg, yield: 15%).1H NMR (400 MHz, DMSO-d6) δ8.42 (d, J = 1.6 Hz, 1H), 8.14–
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8.11 (m, 12H), 8.07 (d, J = 8.0 Hz, 1H), 7.84–7.82 (m, 1H), 7.73–7.68 (m, 2H), 6.88 (d, J = 8.8 
Hz, 2H), 6.75 (d, J = 8.0 Hz, 1H), 6.64–6.61 (m, 1H), 6.57 (d, J = 1.6 Hz, 1H), 6.47 (d, J = 8.8 Hz, 
2H), 5.91 (s, 2H), 4.22 (d, J = 6.8 Hz, 4H), 3.29–3.23 (m, 4H), 1.02 (t, J = 6.8 Hz, 6H). LC-MS 
(ESI): m/z 503.6 (M + H)+. 
N-(benzo[d][1,3]dioxol-5-ylmethyl)-N-(4-(diethylamino)benzyl)-[1,1'-biphenyl]-4-
sulfonamide (6.34). 
Compound 6.34  was prepared from the intermediate 4-
(((benzo[d][1,3]dioxol-5-ylmethyl)amino)methyl)-N,N-
diethylaniline (compound 6.28) (312 mg, 1.0 mmol) and 
[1,1'-biphenyl]-4-sulfonyl chloride (252 mg, 1.0 mmol). 
The residue was purified by flash chromatography (ethyl acetate/petroleum ether, 1:2) on silica 
gel to obtain N-(benzo[d][1,3]dioxol-5-ylmethyl)-N-(4-(diethylamino)benzyl)-[1,1'-biphenyl]-4-
sulfonamide (6.34). Yellow oil (363 mg, yield: 69%).1H NMR (400 MHz, DMSO-d6) δ7.88 (d, J 
= 2.0 Hz, 4H), 7.77–7.75 (m, 2H), 7.56–7.52 (m, 2H), 7.49–7.45 (m, 1H), 6.88 (d, J = 8.4 Hz, 2H), 
6.77 (d, J = 8.0 Hz, 1H), 6.62–6.60 (m, 1H), 6.57 (d, J = 1.6 Hz, 1H), 6.50 (d, J = 8.8 Hz, 2H), 
4.19 (d, J = 9.6 Hz, 4H), 3.28–3.24 (m, 4H), 1.03 (t, J = 7.2 Hz, 6H). LC-MS (ESI): m/z 529.1 (M 
+ H)+. 
(E)-N-(4-(diethylamino)benzyl)-N-pentyl-2-phenylethene-1-sulfonamide (6.37). 
Compound 6.37 was prepared from the intermediate N,N-diethyl-
4-((pentylamino)methyl)aniline (compound 6.36) (248 mg, 1.0 
mmol) and (E)-2-phenylethene-1-sulfonyl chloride (202 mg, 1.0 
mmol). The residue was purified by flash chromatography (ethyl 
acetate/petroleum ether, 1:2) on silica gel to obtain (E)-N-(4-(diethylamino)benzyl)-N-pentyl-2-
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phenylethene-1-sulfonamide (6.37). Dark brown oil (285 mg, yield: 69%).1H NMR (600 MHz, 
DMSO-d6) δ7.67 (t, J = 3.60 Hz, 2H), 7.43 (s, 3H), 7.34 (d, J = 15.60 Hz, 1H), 7.18–7.13 (m, 2H), 
6.62 (d, J = 8.40 Hz, 2H), 4.18 (a, 2H), 3.29–3.05 (m, 4H), 3.03–3.02 (m, 2H), 1.41 (t, J = 7.20 
Hz, 2H), 1.89–1.16 (m, 4H), 1.05 (t, J = 6.60 Hz, 6H), 0.76 (t, J = 7.20 Hz, 3H). LC-MS (ESI): 
m/z 415.2 (M + H)+.  
N-(4-(diethylamino)benzyl)-4-formyl-N-pentylbenzenesulfonamide (6.38). 
Compound 6.38 was prepared from the intermediate N,N-diethyl-
4-((pentylamino)methyl)aniline (compound 6.36) (248 mg, 1.0 
mmol) and 4-formylbenzenesulfonyl chloride (204 mg, 1.0 
mmol). The residue was purified by flash chromatography (ethyl 
acetate/petroleum ether, 1:2) on silica gel to obtain N-(4-(diethylamino)benzyl)-4-formyl-N-
pentylbenzenesulfonamide (6.38). Yellow solid (259 mg, yield: 62%).1H NMR (600 MHz, 
DMSO-d6) δ8.10 (d, J = 8.40 Hz, 2H), 8.03 (d, J = 7.80 Hz, 2H), 7.04 (d, J = 8.40 Hz, 2H), 6.58 
(d, J = 9.0 Hz, 2H), 4.19 (s, 2H), 3.32–3.28 (m, 4H), 3.04 (t, J = 7.80 Hz, 2H), 1.26 (t, J = 7.20 
Hz, 2H), 1.08 (t, J = 6.40 Hz, 4H), 1.02 (t, J = 7.20 Hz, 6H), 0.707 (t, J = 7.80 Hz, 3H). LC-MS 
(ESI): m/z 417.7 (M + H)+. 
N-(4-(diethylamino)benzyl)-N-pentylquinoxaline-2-carboxamide (6.39). 
Compound 6.39 was prepared from the intermediate N,N-diethyl-
4-((pentylamino)methyl)aniline (compound 6.35) (248 mg, 1.0 
mmol) and quinoxaline-2-carbonyl chloride (192 mg, 1.0 mmol). 
The residue was purified by flash chromatography (ethyl 
acetate/petroleum ether, 1:2) on silica gel to obtain N-(4-(diethylamino)benzyl)-N-
pentylquinoxaline-2-carboxamide (6.39). Yellow solid (364 mg, yield: 90%).1H NMR (600 MHz, 
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DMSO-d6) δ9.06 (s, 1H), 7.22 (d, J = 9.0 Hz, 2H), 7.09 (d, J = 9.0 Hz, 2H), 6.67 (d, J = 8.40 Hz, 
2H), 6.58 (d, J = 8.40 Hz, 2H), 4.49 (s, 2H), 3.29 – 3.27 (m, 4H), 1.62–1.58 (m, 2H), 1.32–1.24 
(m, 4H), 1.08 (t, J = 7.20 Hz, 6H), 0.87 (t, J = 6.60 Hz, 3H). LC-MS (ESI): m/z 405.5 (M + H)+. 
N-(4-(diethylamino)benzyl)-N-pentylthiophene-2-carboxamide (6.40). 
Compound 6.40 was prepared from the intermediate N,N-diethyl-4-
((pentylamino)methyl)aniline (compound 6.35) (248 mg, 1.0 mmol) and 
thiophene-2-carbonyl chloride (146 mg, 1.0 mmol). The residue was 
purified by flash chromatography (ethyl acetate/petroleum ether, 1:2) on 
silica gel to obtain N-(4-(diethylamino)benzyl)-N-pentylthiophene-2-carboxamide (6.40). Dark 
brown solid (230 mg, yield: 69%).1H NMR (600 MHz, DMSO-d6) δ7.74 (d, J = 4.80 Hz, 1H), 7.35 
(s, 1H), 7.08 (d, J = 6.0 Hz, 3H), 6.65 (s, 2H), 4.58 (s, 2H), 3.34–3.31 (m, 4H), 1.98 (t, J = 6.40 
Hz, 2H), 1.56 (s, 2H), 1.17 (t, J = 7.20 Hz, 4H), 1.07 (t, J = 4.80 Hz, 6H), 0.83 (d, J = 5.40 Hz, 
3H). LC-MS (ESI): m/z 359.6 (M + H)+. 
N-(4-(diethylamino)benzyl)-N-pentylnaphthalene-1-sulfonamide (6.41). 
Compound 6.41 was prepared from the intermediate N,N-diethyl-4-
((pentylamino)methyl)aniline (compound 6.35) (248 mg, 1.0 mmol) 
and naphthalene-2-sulfonyl chloride (226 mg, 1.0 mmol). The 
residue was purified by flash chromatography (ethyl 
acetate/petroleum ether, 1:2) on silica gel to obtain N-(4-
(diethylamino)benzyl)-N-pentylnaphthalene-1-sulfonamide (6.41). Yellow solid (308 mg, yield: 
70%).1H NMR (600 MHz, DMSO-d6) δ8.47 (s, 1H), 8.19–8.17 (m, 1H), 8.14–8.12 (m, 1H), 8.07–
8.05 (m, 1H), 7.84–7.82 (m, 1H), 7.73–7.69 (m, 2H), 7.07–7.05 (m, 2H), 6.58–6.56 (m, 2H), 4.22 
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(d, J = 3.0 Hz, 2H), 3.30–3.27 (m, 4H), 3.06–3.03 (m, 2H), 1.33–1.23 (m, 2H), 1.05–1.04 (m, 4H), 
1.02 (t, J = 5.40 Hz, 6H), 0.65 (t, J = 3.60 Hz, 3H). LC-MS (ESI): m/z 439.4 (M + H)+. 
N-(4-(diethylamino)benzyl)-N-pentyl-[1,1'-biphenyl]-4-sulfonamide (6.42).  
Compound 6.42 was prepared from the intermediate N,N-
diethyl-4-((pentylamino)methyl)aniline (compound 6.35) (248 
mg, 1.0 mmol) and [1,1'-biphenyl]-4-sulfonyl chloride (252 mg, 
1.0 mmol). The residue was purified by flash chromatography 
(ethyl acetate/petroleum ether, 1:2) on silica gel to obtain N-(4-
(diethylamino)benzyl)-N-pentyl-[1,1'-biphenyl]-4-sulfonamide (6.42). Yellow solid (272 mg, 
yield: 59%).1H NMR (400 MHz, DMSO-d6) δ7.90 (s, 4H), 7.77–7.75 (m, 2H), 7.56–7.52 (m, 2H), 
7.48–7.44 (m, 1H), 7.08 (d, J = 8.8 Hz, 2H), 6.61 (d, J = 8.8 Hz, 2H), 4.20 (s, 2H), 3.32–3.28 (m, 
4H), 3.04 (t, J = 7.6, 2H), 1.30–1.27 (m, 2H), 1.6 (t, J = 7.2, 6H), 0.71 (t, J = 7.20 Hz, 3H). LC-
MS (ESI): m/z 464.1 (M + H)+. 
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6.4.2 3D QSAR/CoMFA Studies 
Out of the 41 compounds from Table 6.1 - Table 6.4, 32 compounds were used in the 3D QSAR 
CoMFA studies. Compounds that showed no binding were ignored in the study. The compounds 
were randomly divided into training (20 compounds) and test (12 compounds) sets. SYBYL X1.3 
was used for the CoMFA studies. The best compound, 6.11, was selected to perform the molecular 
dynamic simulations. As previously described, dynamic simulations were simulated at 300 K with 
a time of steps of 1 fs for a total duration of 300 ps, and sampling of the conformations were 
collected at every 1 ps resulting in 300 conformers of the compound 6.11. The conformers are then 
minimized and converged into five families. The five families were compared to the docking pose 
to generate the most preferable conformation. The docking was performed using the Surflex-Dock 
module from the Tripos modeling software. Finally, the conformer with maximum agreement from 
these experiments was further used for CoMFA studies. The structures were built and energy 
minimized using Tripos force field with 0.05 kcal/ (mol Å). Charges were calculated using the 
Gasteiger-Huckel method. Powell method was used for energy minimization with 2000 iterations. 
Alignments of the structures to the preferred conformer of compound 6.11 were performed using 
the MultiFit program in Sybyl X 1.3. The CoMFA study was then carried out using the 
SYBYL/CoMFA module. Leave one-out cross-validation (LOOCV) partial least-squares (PLS) 
analysis was performed with a minimum σ (column filter) value of 5.0 kcal·mol−1 to improve the 
signal-to-noise ratio by omitting those lattice points with an energy variation below this threshold. 
The final model (non-cross-validated analysis) was developed from the LOOCV model with the 
highest cross-validated r2, using the optimal number of components determined by the LOOCV 
model. 
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7.0  SUMMARY AND CONCLUSION 
 
The cannabinoid system emerged as a major therapeutic target in recent years. Several research 
groups have represented the potential of cannabinoid ligands for treating several disease, such as 
pain, multiple sclerosis, bone diseases as well as cancer attenuation. With the recent withdrawal 
of the CB1 inverse agonist, Rimonabant, research groups are focusing on targeting the CB2 
receptor to avoid serious psychoactive side effects. However, designing novel CB2 ligands 
remains challenging due to the lack of high-resolution X-ray crystal structure. Several chemical 
design approaches were employed in the designing of some of the known CB2 ligands, such as 
molecular docking, pharmacophore modeling, high-throughput screening methods as well as 
mutational studies.  
The main objective of this dissertation is to discover novel CB2 ligands with therapeutic 
potentials on MM and on bone diseases. This was accomplished by: 1) employing chemistry design 
and discovery tools, such as pharmacophore, molecular docking and interaction studies as well as 
high-throughput screening, in order to identify novel chemical structures (scaffolds) with optimal 
CB2 potency, 2) to carry out medicinal chemistry design and chemistry synthesis in order to 
perform SAR studies utilizing the newly discovered scaffolds aiming at identifying chemical 
derivatives with high CB2 receptor affinity and selectivity, 3) addressing the functionality of the 
newly discovered compounds, and 4)  to validate the therapeutic efficacy of the these derivatives. 
In our first series of compounds, we developed a pharmacophore model based on known 
CB2 inverse agonists along with our novel compound XIE-35. The pharmacophore model was 
utilized in the high-throughput screening module UNITY which aided in the discovery of the di-
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amide scaffold (lead compound 4.1). The di-amide scaffold represented a novel CB2 chemotype 
and was subjected to chemical modifications in order to generate derivatives with high CB2 
receptor affinity and selectivity. The highly potent and selective derivatives were then further 
validated for their in-vitro functionality as well as their therapeutic potentials. As a result, several 
derivatives with high potency and selectivity were identified ((compounds 4.9, 4.12, and 4.17; 
CB2 Ki < 100 nM, CB1 Ki > 20000). The new di-amide derivatives were identified as novel CB2 
inverse agonists by cAMP assay. Furthermore, OCL formation assay showed that these new CB2 
inverse agonists were potent OCL inhibitors. However, anti-proliferations studies demonstrated 
low inhibition rates of these CB2 inverse agonists on MM cell-lines. Nevertheless, PK studies 
illustrated stability limitations of the di-amide scaffold which resulted in poor PK profile.    
In the second series, we performed scaffold-hopping and replaced the di-amide scaffold 
with an amide-sulfonamide scaffold (the substituted 2-(sulfonylamino)-2-phenylacetamide 
scaffold). Chemistry modifications and SAR studies were carried out and generated several 
derivatives. However, nearly all the derivatives exhibited weak-to-no binding to the CB2 receptor 
(CB2 Ki > 1860 nM, except compound 5.13 CB2 Ki = 586 nM). Anti-proliferation studies, on the 
other hand, demonstrated two compounds (compounds 5.12 and 5.31) with high inhibition rates. 
As a result, we employed our developed HTD tool to identify the potential targets of the two 
ligands. Both compounds showed high docking score and excellent fit to the MAPK-14 protein 
with strong interactions to important amino acids identified in the binding pocket. This new 
discovery will be further investigated in order to study the in-vitro biochemical mechanisms.  
As the previous two series demonstrated some limitations, we performed high-throughput 
screening utilizing NCI-2010 database in order to identify new CB2 scaffolds. A new lead 
compound (lead compound 6.1) was identified and its scaffold was subjected to medicinal 
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chemistry modifications and SAR studies. As a result, several compounds with the 4-
(aminomethyl)-N,N-diethylaniline scaffold demonstrated high CB2 affinity (CB2 Ki < 500 nM). 
Further studies of these new derivatives demonstrated the discovery of a novel CB2 agonist 
(compound 6.11) and novel CB2 inverse agonists (compounds 6.15 and 6.18) with unique scaffold. 
OCL formation assay demonstrated high inhibition rates of the inverse agonists; however, the 
agonist stimulated the OCL formation at high doses. In addition, anti-proliferation studies 
demonstrated that the new CB2 agonist has anti-MM properties and the CB2 inverse agonists 
demonstrated moderate anti-MM properties. Furthermore, PK studies showed that the 4-
(aminomethyl)-N,N-diethylaniline scaffold is much more stable than the di-amide scaffold.  
In conclusion, developing CB2 inverse agonists is a promising approach for developing 
novel osteoporosis agents as CB2 inverse agonists are potent inhibitors of OCL formation. Also, 
to develop anti-MM agents, CB2 agonists showed the most promising approach as anti-cancer 
agents, although, the CB2 inverse agonists demonstrated moderate MM growth inhibition. As the 
major complications of MM disease is bone lesions and osteoporosis, another advantage of 
developing inverse agonists is that these ligands will act as dual inhibitors of OCL and MM growth, 
eradicating the disease and preventing serious side effects. 
In this dissertation, we opened up new avenues in the structure-based and ligand-based 
drug design. We were able to identify novel scaffolds as well as novel functional groups. The first 
identification of the diethylamine group in Chapter 4.0 aided in further design of novel CB2 
ligands. This group can be introduced in different scaffold that may potentiate the CB2 receptor 
affinity. In addition, we concluded that designing CB2 inverse agonists are more promising as anti-
OCL agents and for the ultimate treatment of osteoporosis. However, CB2 agonists is more 
promising as anti-MM agents Furthermore. The newly discovered CB2 inverse agonists and 
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agonist can serve as chemical probes in different biochemical and computational experiments. 
Molecular signaling mechanism studies are needed in order to study the signaling cascades of both 
diseases. Nevertheless, chemistry modifications should focus on optimizing the PK profiles and 
obtain further insights into the metabolism of these ligands. Importantly, in-vivo studies utilizing 
MM diseases animal models as well as osteoporotic animal models are needed in order to develop 
these newly discovered ligands to reach the clinic.  
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APPENDIX A 
 
Figure 7.1. HPLC-LC/MS chromatogram for compound 4.9 
Upper panel: UV absorption spectrum using UV detection at 254 and 214 nm, lower panel MS. 
Column: Hamilton reverse phase column (HxSil, C18, 3µm, 2.1 mm × 50 mm (H2)). Flow rate: 
0.2 mL/min. Mobile phase: eluent A consists of 5% CH3CN in H2O; eluent B consists of 90% 
CH3CN in H2O. N,N'-((4-isopropylphenyl)methylene)bis(2-phenylacetamide), calculated 
molecular weight: 400.52 Da. LC-MS (ESI): m/z 401.2 (M + H)+. 
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Figure 7.2. HPLC-LC/MS chromatogram for compound 4.12 
Upper panel: UV absorption spectrum using UV detection at 254 and 214 nm, lower panel MS. 
Column: Hamilton reverse phase column (HxSil, C18, 3µm, 2.1 mm × 50 mm (H2)). Flow rate: 
0.2 mL/min. Mobile phase: eluent A consists of 5% CH3CN in H2O; eluent B consists of 90% 
CH3CN in H2O. N,N'-((4-isopropoxyphenyl)methylene)bis(2-phenylacetamide), calculated 
molecular weight: 416.52 Da. LC-MS (ESI): m/z 417.2 (M + H)+. 
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Figure 7.3. HPLC-LC/MS chromatogram for compound 4.17 
Upper panel: UV absorption spectrum using UV detection at 254 and 214 nm, lower panel MS. 
Column: Hamilton reverse phase column (HxSil, C18, 3µm, 2.1 mm × 50 mm (H2)). Flow rate: 
0.2 mL/min. Mobile phase: eluent A consists of 5% CH3CN in H2O; eluent B consists of 90% 
CH3CN in H2O. N,N'-((4-(diethylamino)phenyl)methylene)bis(2-phenylacetamide), calculated 
molecular weight: 430.56 Da. LC-MS: m/z 431.3 (M + H)+. 
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Figure 7.4. HPLC-LC/MS chromatogram for compound 6.11 
Upper panel: UV absorption spectrum using UV detection at 254 and 214 nm, lower panel MS. 
Column: Hamilton reverse phase column (HxSil, C18, 3µm, 2.1 mm × 50 mm (H2)). Flow rate: 
0.2 mL/min. Mobile phase: eluent A consists of 5% CH3CN in H2O; eluent B consists of 90% 
CH3CN in H2O. N-(4-(diethylamino)benzyl)-N-(3,4,5-trimethoxybenzyl)thiophene-2-
carboxamide, calculated molecular weight: 468.61 Da. LC-MS: m/z 469.4 (M + H)+. 
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Figure 7.5. HPLC-LC/MS chromatogram for compound 6.15 
Upper panel: UV absorption spectrum using UV detection at 254 and 214 nm, lower panel MS. 
Column: Hamilton reverse phase column (HxSil, C18, 3µm, 2.1 mm × 50 mm (H2)). Flow rate: 
0.2 mL/min. Mobile phase: eluent A consists of 5% CH3CN in H2O; eluent B consists of 90% 
CH3CN in H2O. (E)-N-(4-(diethylamino)benzyl)-2-phenyl-N-(3,4,5-trimethoxybenzyl)ethene-1-
sulfonamide, calculated molecular weight: 424.68 Da. LC-MS: m/z 425.2 (M + H)+. 
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Figure 7.6. HPLC-LC/MS chromatogram for compound 6.18 
Upper panel: UV absorption spectrum using UV detection at 254 and 214 nm, lower panel MS. 
Column: Hamilton reverse phase column (HxSil, C18, 3µm, 2.1 mm × 50 mm (H2)). Flow rate: 
0.2 mL/min. Mobile phase: eluent A consists of 5% CH3CN in H2O; eluent B consists of 90% 
CH3CN in H2O. N-(4-(diethylamino)benzyl)-4-formyl-N-(3,4,5-
trimethoxybenzyl)benzenesulfonamide, calculated molecular weight: 426.65 Da. LC-MS: m/z 
427.4 (M + H)+. 
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Figure 7.7. 1H NMR Spectrum for 4.9 using DMSO-d6 solvent 
BRUKER 400 MHz NMR machine using deuterated dimethyl sulfoxide ((CD3)2S=O)) solvent with TMS internal standard 
255 
 
Figure 7.8. 1H NMR Spectrum for 4.12 using DMSO-d6 solvent 
BRUKER 400 MHz NMR machine using deuterated dimethyl sulfoxide ((CD3)2S=O)) solvent with TMS internal standard 
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Figure 7.9. 1H NMR Spectrum for 4.17 using DMSO-d6 solvent 
BRUKER 400 MHz NMR machine using deuterated dimethyl sulfoxide ((CD3)2S=O)) solvent with TMS internal standard 
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Figure 7.10. 1H NMR Spectrum for 4.18 using CD3OD solvent 
BRUKER 400 MHz NMR machine using deuterated methanol (CD3OD) solvent with TMS internal standard 
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Figure 7.11. 1H NMR Spectrum for 4.21 using DMSO-d6 solvent 
BRUKER 400 MHz NMR machine using deuterated dimethyl sulfoxide ((CD3)2S=O)) solvent with TMS internal standard 
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Figure 7.12. 1H NMR Spectrum for 4.47 using CD3OD solvent 
BRUKER 400 MHz NMR machine using deuterated methanol (CD3OD) solvent with TMS internal standard 
260 
 
Figure 7.13. 1H NMR Spectrum for 6.11 using DMSO-d6 solvent 
BRUKER 400 MHz NMR machine using deuterated dimethyl sulfoxide ((CD3)2S=O)) solvent with TMS internal standard. 
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Figure 7.14. 1H NMR Spectrum for 6.11 using CDCl3 solvent 
BRUKER 600 MHz NMR machine using deuterated chloroform (CDCl3) solvent with TMS internal standard. 
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Figure 7.15. 1H NMR Spectrum for 6.15 using CDCl3 solvent 
BRUKER 400 MHz NMR machine using deuterated chloroform (CDCl3) solvent with TMS internal standard. 
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Figure 7.16. 1H NMR Spectrum for 6.15 using DMSO-d6 solvent 
BRUKER 600 MHz NMR machine using deuterated dimethyl sulfoxide ((CD3)2S=O)) solvent with TMS internal standard. 
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Figure 7.17. 1H NMR Spectrum for 6.18 using CDCl3 solvent 
BRUKER 400 MHz NMR machine using deuterated chloroform (CDCl3) solvent with TMS internal standard 
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APPENDIX B 
266 
 
 
Figure 7.18. High-throughput molecular screening of NCI database. 
267 
The hit compound (6.1) was subjected to radio-ligand competition binding assay to confirm its CB affinity. a NCI compound screening 
was performed using Surflex-Dock program in SYBYL-X1.3. b Binding affinities for CB1 and CB2 receptors were evaluated using 
[3H]CP-55,940 radioligand competition binding assay.  
The National Cancer Institute (NCI) 2010 database contains more than 265,000 compounds that were subjected to refinements based on 
the Lipinski rule of five; molecular weight < 500, calculated logarithmic partition coefficient (cLog P) value of < 5, number of hydrogen 
bond donors (the sum of OHs and NHs) ≤ 5, and the number of hydrogen bond acceptors (the sum of Ns and Os) ≤ 10 [226]. The resulted 
new refined database (i.e. NCI2010_refined) was subjected the computational molecular docking studies using the Surflex-Dock module 
in the SYBYL X 1.3 software (Tripos Inc.). We utilized our published 3D CB2 homology receptor [207, 208, 222]. The docking 
interactions were analyzed based on the FlexX-Pharm Docking/CScore method to rank the hits with a better value of interactions. The 
docking criteria cutoff was 7.0 which was utilized as to filter the docking results. Ten compounds (listed in Table 7.1) showed a docking 
score of > 7.0 that were subjected to radio-ligand displacement assay. Compound 6.1 (NCI-294739) exhibited a docking score of 7.68, 
molecular weight of 445.50 (< 500), cLogP of 2.40 (< 5), number of hydrogen bond donors of 0 (< 5), number of hydrogen bond 
acceptors 7 (< 10), and with a CB2 Ki = 9236 nM, CB1 Ki = 11023 nM. This compound was chosen as a lead compound for further 
modifications. 
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Table 7.1. NCI database screening results 
No. Chemical Structure NCI namea 
CB2 Docking 
Scoreb 
MWc cLog Pd HBDe HBAf 
CB2 Ki 
(nM)g 
CB1 Ki 
(nM)h 
1 
 
NCI-85077 7.74 343.43 4.66 0 3 8530 NT 
2 
 
NCI-294739 7.68 445.50 2.40 0 7 9236 11023 
3 
 
NCI-46432 9.13 422.48 7.14 0 4 NB NT 
4 
 
NCI-313383 7.74 451.01 6.79 0 3 7018 NT 
269 
5 
 
NCI-173740 10.31 464.60 5.01 0 6 NB NT 
6 
 
NCI-39810 8.23 340.51 5.23 1 3 NB NT 
7 
 
NCI-25896 7.27 353.47 1.75 2 5 NB NT 
8 
 
NCI-118451 8.92 477.47 3.97 2 10 16850 NT 
9 
 
NCI-681179 6.11 437.92 2.53 3 8 NB NT 
10 
 
NCI-21559 8.26 388.42 0.21 6 8 NB NT 
 
a National Cancer Institute chemical structure name, b CB2 molecular docking score  by the Surflex-Dock module in SYBYL X1.3 
(Tripos Inc.), c Molecular weight (Da), d calculated logarithmic partition coefficient using ChemDraw (Perkin Elmer), e hydrogen bond 
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donor, f hydrogen bond acceptor, g CB2 binding affinity utilizing [3H]CP-55,940 radioligand competition binding assay, h CB1 binding 
affinity utilizing [3H]CP-55,940 radioligand competition binding assay (NB = no binding Ki >20000 nM, NT = not determined
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Figure 7.19 Binding profile of 4.9 
Competition displacement of the [3H]-CP55,940 was obtained by using an increased amount of 
the cold ligand 4.9 utilizing (A) human CB2 membrane (Ki = 85 nM), and (B) human CB1 
membrane (Ki > 20000 nM). Assay was performed in triplicate (n = 3). Data represented as mean 
± SEM. 
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Figure 7.20. Binding profile of 4.12 
Competition displacement of the [3H]-CP55,940 was obtained by using an increased amount of 
the cold ligand 4.12 utilizing (A) human CB2 membrane (Ki = 313 nM), and (B) human CB1 
membrane (Ki > 20000 nM). Assay was performed in triplicate (n = 3). Data represented as mean 
± SEM. 
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Figure 7.21. Binding profile of 4.17 
Competition displacement of the [3H]-CP55,940 was obtained by using an increased amount of 
the cold ligand 4.17 utilizing (A) human CB2 membrane (Ki = 64 nM), and (B) human CB1 
membrane (Ki > 20000 nM). Assay was performed in triplicate (n = 3). Data represented as mean 
± SEM. 
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Figure 7.22. Binding profile of 4.18 
Competition displacement of the [3H]-CP55,940 was obtained by using an increased amount of 
the cold ligand 4.18 utilizing (A) human CB2 membrane (Ki = 72 nM), and (B) human CB1 
membrane (Ki > 20000 nM). Assay was performed in triplicate (n = 3). Data represented as mean 
± SEM. 
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Figure 7.23. Binding profile of 4.21 
Competition displacement of the [3H]-CP55,940 was obtained by using an increased amount of 
the cold ligand 4.21 utilizing (A) human CB2 membrane (Ki = 71 nM), and (B) human CB1 
membrane (Ki > 20000 nM). Assay was performed in triplicate (n = 3). Data represented as mean 
± SEM. 
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Figure 7.24. Binding profile of 4.47 
Competition displacement of the [3H]-CP55,940 was obtained by using an increased amount of 
the cold ligand 4.47 utilizing (A) human CB2 membrane (Ki = 25 nM), and (B) human CB1 
membrane (Ki > 20000 nM). Assay was performed in triplicate (n = 3). Data represented as mean 
± SEM. 
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Figure 7.25 Binding profile of 6.11 
Competition displacement of the [3H]-CP55,940 was obtained by using an increased amount of 
the cold ligand 6.11 utilizing (A) human CB2 membrane (Ki = 99 nM), and (B) human CB1 
membrane (Ki = 2382 nM). Assay was performed in triplicate (n = 3). Data represented as mean ± 
SEM. 
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Figure 7.26. Binding profile of 6.15. 
Competition displacement of the [3H]-CP55,940 was obtained by using an increased amount of 
the cold ligand 6.15 utilizing (A) human CB2 membrane (Ki = 138 nM), and (B) human CB1 
membrane (Ki = 20000 nM). Assay was performed in triplicate (n = 3). Data represented as mean 
± SEM. 
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Figure 7.27. Binding profile of 6.18. 
Competition displacement of the [3H]-CP55,940 was obtained by using an increased amount of 
the cold ligand 6.18 utilizing (A) human CB2 membrane (Ki = 242 nM), and (B) human CB1 
membrane (Ki = 2290 nM). Assay was performed in triplicate (n = 3). Data represented as mean ± 
SEM. 
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APPENDIX C 
Pharmacokinetic/Pharmacodynamic Studies 
A. Pharmacokinetic Studies of 4.17 
 
 
Table 7.2. Oral plasma concentration for 4.17 
T(h) Conc. (ng/mL) SD 
0 0 0 
0.08 5.851 2.205 
0.17 7.240 4.106 
0.25 6.279 2.936 
0.5 3.232 1.292 
0.75 3.828 1.411 
1 3.895 0.8213 
2 2.760 0.5935 
4 1.294 0.2148 
6 1.695 0.3184 
8 0.8374 0.3342 
12 0.6186 0.1067 
24 0.4740 0.0148 
Concentration mean of three rats (n = 3) measured in ng/mL 
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Figure 7.28. Plasma concentration after oral administration of 4.17 
Plots of the plasma concentration after oral administration of 4.17. Data are mean ± SD of three 
rats. 
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Table 7.3. Oral pharmacokinetic parameters of 4.17 
Parameter Unit No.1 No.2 No.3 Mean 
AUC(0-t) µg/L*h 14.20 28.08 28.10 23.46 
AUC(0-∞) µg/L*h 16.47 28.10 28.19 24.25 
λ 1/h 0.23 0.32 0.24 0.26 
Clast µg/L 0.52 0.01 0.023 0.18 
t1/2 h 3.04 2.20 2.84 2.69 
Tmax h 0.17 0.17 1.00 0.44 
Vd L/kg 5326 2260 2908 3498 
CL L/h/kg 1214 712 709 879 
Cmax µg/L 8 11 4 8 
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B. Pharmacokinetic Studies of 6.11 
 
 
Table 7.4. Oral plasma concentration for 6.11 
Time (h) Conc. (ng/mL) SD 
0 0 0 
0.08 76.09 11.91 
0.17 81.82 12.47 
0.25 85.54 14.31 
0.5 71.34 17.21 
0.75 43.20 6.52 
1 39.28 1.12 
2 32.78 4.58 
4 14.79 6.72 
6 5.709 0.68 
8 - - 
10 - - 
24 - - 
Concentration mean of three rats (n = 3) measured in ng/mL. 
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Figure 7.29. Plasma concentration after oral administration of 6.11 
Plots of the plasma concentration after oral administration of 6.11. Data are mean ± SD of three 
rats. 
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Table 7.5. Oral pharmacokinetic properties of 6.11 
Parameter Unit No.1 No.2 No.3 Mean 
AUC(0-t) µg/L*h 181.5 136.1 163.2 160.3 
AUC(0-∞) µg/L*h 198.6 153.0 176.3 176.0 
λ 1/h 0.37 0.51 0.41 0.43 
Clast µg/L 6.34 8.61 5.32 6.75 
t1/2 h 1.87 1.37 1.70 1.65 
Tmax h 0.25 0.25 0.08 0.19 
Vd L/kg 271.6 257.6 278.7 269.3 
CL L/h/kg 100.7 130.7 113.5 114.9 
Cmax µg/L 96.73 90.47 73.88 87.03 
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Table 7.6. Intravenous plasma concentration of 6.11 
Time (h) Conc. (ng/mL) SD 
0 0 0 
0.08 422.1 86.33 
0.17 246.9 43.16 
0.25 141.2 32.25 
0.5 56.80 11.25 
0.75 32.09 5.41 
1 22.32 2.10 
2 16.37 1.41 
4 13.35 0.57 
6 11.51 0.77 
8 10.70 1.07 
10 7.52 1.28 
24 4.99 0.26 
Concentration mean of three rats (n = 3) measured in ng/mL. 
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Figure 7.30. Plasma concentration after intravenous administration of 6.11 
Plots of the plasma concentration after intravenous administration of 6.11. Data are mean ± SD of 
three rats. 
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Table 7.7. Intravenous pharmacokinetic properties of 6.11 
Parameter Unit No.1 No.2 No.3 Mean 
AUC(0-t) µg/L*h 363.4 331.6 313.9 336.3 
AUC(0-∞) µg/L*h 475.5 431.2 421.9 442.9 
λ 1/h 0.05 0.05 0.05 0.05 
Clast µg/L 5.16 4.67 5.15 4.99 
t1/2 h 15.05 14.79 14.54 14.79 
Tmax h 0.08 0.08 0.08 0.08 
Vd L/kg 91.33 98.98 99.46 96.59 
CL L/h/kg 4.21 4.64 4.74 4.53 
Cmax µg/L 499.5 437.8 329.0 422.1 
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C. Pharmacokinetic Studies of 6.15 
 
 
 
Table 7.8. Oral plasma concentration for 6.15 
T (h) Average conc. (ng/mL) SD 
0 0 0 
0.08 4.52 1.86 
0.17 9.01 3.54 
0.25 12.38 2.02 
0.5 13.05 5.59 
0.75 7.86 3.52 
1 4.47 2.44 
2 4.52 3.05 
4 - - 
6 - - 
8 - - 
12 - - 
24 - - 
Concentration mean of three rats (n = 3) measured in ng/mL 
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Figure 7.31. Plasma concentration after oral administration of 6.15 
Plots of the plasma concentration after oral administration of 6.15. Data are mean ± SD of three 
rats. 
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Table 7.9. Oral pharmacokinetic parameters of 6.15 
Parameter Unit No.1 No.2 No.3 Mean 
AUC(0-t) µg/L*h 6.24 8.80 19.46 11.50 
AUC(0-∞) µg/L*h 8.48 12.35 20.61 13.82 
λ 1/h 1.50 1.63 1.55 1.56 
C µg/L 3.361 5.78 1.78 3.64 
t1/2 h 0.463 0.43 0.45 0.45 
Tmax h 0.25 0.5 0.5 0.42 
Vd L/kg 1573.7 992.9 628.1 1064.9 
CL L/h/kg 2357.3 1619.9 970.3 1649.1 
Cmax µg/L 10.32 13.23 18.3 13.95 
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